CN110343090A - Quinazoline derivant salt form crystal form and preparation method and application - Google Patents
Quinazoline derivant salt form crystal form and preparation method and application Download PDFInfo
- Publication number
- CN110343090A CN110343090A CN201810423951.8A CN201810423951A CN110343090A CN 110343090 A CN110343090 A CN 110343090A CN 201810423951 A CN201810423951 A CN 201810423951A CN 110343090 A CN110343090 A CN 110343090A
- Authority
- CN
- China
- Prior art keywords
- crystal form
- quinazoline derivant
- formula
- following
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 397
- 241001597008 Nomeidae Species 0.000 title claims abstract description 327
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title claims abstract description 324
- 238000002360 preparation method Methods 0.000 title claims abstract description 107
- 150000003839 salts Chemical group 0.000 title abstract description 56
- 239000003814 drug Substances 0.000 claims abstract description 107
- 239000007787 solid Substances 0.000 claims abstract description 77
- 229940079593 drug Drugs 0.000 claims abstract description 64
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 52
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims abstract description 41
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 36
- 229940077388 benzenesulfonate Drugs 0.000 claims abstract description 36
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims abstract description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 32
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 28
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims abstract description 24
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 22
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229940049920 malate Drugs 0.000 claims abstract description 18
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims abstract description 18
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 16
- 238000012546 transfer Methods 0.000 claims abstract description 15
- 208000003174 Brain Neoplasms Diseases 0.000 claims abstract description 13
- 210000004556 brain Anatomy 0.000 claims abstract description 11
- 201000007983 brain glioma Diseases 0.000 claims abstract description 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 184
- 239000000203 mixture Substances 0.000 claims description 108
- 238000000034 method Methods 0.000 claims description 105
- 239000003960 organic solvent Substances 0.000 claims description 103
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 100
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 75
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 68
- 201000010099 disease Diseases 0.000 claims description 54
- 239000008194 pharmaceutical composition Substances 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- 229910001868 water Inorganic materials 0.000 claims description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 39
- 235000019441 ethanol Nutrition 0.000 claims description 34
- 238000005119 centrifugation Methods 0.000 claims description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 27
- 238000003756 stirring Methods 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- 230000035772 mutation Effects 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 230000003213 activating effect Effects 0.000 claims description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 15
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 14
- 238000001228 spectrum Methods 0.000 claims description 14
- 230000001404 mediated effect Effects 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 10
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 102000001301 EGF receptor Human genes 0.000 claims description 7
- 108060006698 EGF receptor Proteins 0.000 claims description 6
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- 239000001530 fumaric acid Substances 0.000 claims description 6
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
- 239000005711 Benzoic acid Substances 0.000 claims description 5
- 208000006274 Brain Stem Neoplasms Diseases 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 5
- 235000010233 benzoic acid Nutrition 0.000 claims description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- 238000009792 diffusion process Methods 0.000 claims description 4
- 239000011976 maleic acid Substances 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- 102200048928 rs121434568 Human genes 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- KBIWNQVZKHSHTI-UHFFFAOYSA-N 4-n,4-n-dimethylbenzene-1,4-diamine;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)C1=CC=C(N)C=C1 KBIWNQVZKHSHTI-UHFFFAOYSA-N 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 125000005909 ethyl alcohol group Chemical group 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- 150000003891 oxalate salts Chemical class 0.000 claims description 2
- 150000003246 quinazolines Chemical class 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 4
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 46
- 238000011282 treatment Methods 0.000 abstract description 35
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 17
- 229910052731 fluorine Inorganic materials 0.000 abstract description 9
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 abstract description 8
- 210000004072 lung Anatomy 0.000 abstract description 7
- 238000002054 transplantation Methods 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 description 146
- 150000003840 hydrochlorides Chemical group 0.000 description 86
- -1 dysbolism Diseases 0.000 description 66
- 239000000243 solution Substances 0.000 description 66
- 206010028980 Neoplasm Diseases 0.000 description 43
- 239000000843 powder Substances 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 31
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 25
- 229940002612 prodrug Drugs 0.000 description 25
- 239000000651 prodrug Substances 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 229940124597 therapeutic agent Drugs 0.000 description 23
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 22
- 201000011510 cancer Diseases 0.000 description 22
- 230000008859 change Effects 0.000 description 22
- 239000003153 chemical reaction reagent Substances 0.000 description 22
- 229920001223 polyethylene glycol Polymers 0.000 description 22
- 235000014113 dietary fatty acids Nutrition 0.000 description 21
- 229930195729 fatty acid Natural products 0.000 description 21
- 239000000194 fatty acid Substances 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 20
- 239000004094 surface-active agent Substances 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000002202 Polyethylene glycol Substances 0.000 description 18
- 230000008499 blood brain barrier function Effects 0.000 description 18
- 210000001218 blood-brain barrier Anatomy 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 16
- 229940050390 benzoate Drugs 0.000 description 16
- 150000002148 esters Chemical class 0.000 description 16
- 239000003550 marker Substances 0.000 description 16
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 239000000470 constituent Substances 0.000 description 15
- 239000002552 dosage form Substances 0.000 description 15
- 229960004756 ethanol Drugs 0.000 description 15
- 206010018338 Glioma Diseases 0.000 description 14
- 239000003755 preservative agent Substances 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- 208000032612 Glial tumor Diseases 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- 235000011152 sodium sulphate Nutrition 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 229960003742 phenol Drugs 0.000 description 12
- 230000002335 preservative effect Effects 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 239000003513 alkali Substances 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 235000013772 propylene glycol Nutrition 0.000 description 10
- 229960004063 propylene glycol Drugs 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000006072 paste Substances 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 230000019491 signal transduction Effects 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 229960001866 silicon dioxide Drugs 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- HIISVQYDQWJITQ-UHFFFAOYSA-N 1h-pyrrole;quinoline Chemical class C=1C=CNC=1.N1=CC=CC2=CC=CC=C21 HIISVQYDQWJITQ-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000314 lubricant Substances 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 102000001253 Protein Kinase Human genes 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 230000000857 drug effect Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108060006633 protein kinase Proteins 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 235000011054 acetic acid Nutrition 0.000 description 6
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 239000003292 glue Substances 0.000 description 6
- 125000005456 glyceride group Chemical group 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 229940049964 oleate Drugs 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 150000005846 sugar alcohols Polymers 0.000 description 6
- 238000003419 tautomerization reaction Methods 0.000 description 6
- 238000011287 therapeutic dose Methods 0.000 description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 5
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 150000005829 chemical entities Chemical class 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 5
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 5
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 5
- 229940070765 laurate Drugs 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000012265 solid product Substances 0.000 description 5
- 235000010199 sorbic acid Nutrition 0.000 description 5
- 239000004334 sorbic acid Substances 0.000 description 5
- 229940075582 sorbic acid Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 235000019483 Peanut oil Nutrition 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 4
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 4
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 4
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 235000010216 calcium carbonate Nutrition 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- 239000002285 corn oil Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 229960001484 edetic acid Drugs 0.000 description 4
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical group CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000001361 adipic acid Substances 0.000 description 3
- 235000011037 adipic acid Nutrition 0.000 description 3
- 229960000250 adipic acid Drugs 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 238000012054 celltiter-glo Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 239000002385 cottonseed oil Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 229940113088 dimethylacetamide Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002081 enamines Chemical class 0.000 description 3
- 201000003914 endometrial carcinoma Diseases 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 3
- 229940093471 ethyl oleate Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229940116315 oxalic acid Drugs 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229940120982 tarceva Drugs 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 3
- 230000010148 water-pollination Effects 0.000 description 3
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- FCGXLCNBWYIEAA-UHFFFAOYSA-N 1,3-benzothiazol-6-ylmethanamine Chemical compound NCC1=CC=C2N=CSC2=C1 FCGXLCNBWYIEAA-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 2
- MWDRJPWAGWFASY-UHFFFAOYSA-N 2-fluoro-1-methylpiperidine Chemical compound CN1CCCCC1F MWDRJPWAGWFASY-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 2
- 244000147568 Laurus nobilis Species 0.000 description 2
- 235000017858 Laurus nobilis Nutrition 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108060006706 SRC Proteins 0.000 description 2
- 102000001332 SRC Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- OXMGUTQVUIWQEK-UHFFFAOYSA-N [N].CC(=O)N(C)C Chemical compound [N].CC(=O)N(C)C OXMGUTQVUIWQEK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009056 active transport Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000011111 cardboard Substances 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 229960000800 cetrimonium bromide Drugs 0.000 description 2
- 210000003467 cheek Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000006389 diacetylation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960000878 docusate sodium Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002085 enols Chemical class 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229940074046 glyceryl laurate Drugs 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229940071870 hydroiodic acid Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 2
- 229940043349 potassium metabisulfite Drugs 0.000 description 2
- 235000010263 potassium metabisulphite Nutrition 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 229940057950 sodium laureth sulfate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 230000035322 succinylation Effects 0.000 description 2
- 238000010613 succinylation reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- OEZPKXDBWNXBRE-UHFFFAOYSA-N 2,3-bis(2-hydroxyethoxy)propyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(OCCO)COCCO OEZPKXDBWNXBRE-UHFFFAOYSA-N 0.000 description 1
- IYOLBFFHPZOQGW-UHFFFAOYSA-N 2,4-dichloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=C(Cl)C(C)=C1Cl IYOLBFFHPZOQGW-UHFFFAOYSA-N 0.000 description 1
- UGDAWAQEKLURQI-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethanol;hydrate Chemical compound O.OCCOCCO UGDAWAQEKLURQI-UHFFFAOYSA-N 0.000 description 1
- MQFYRUGXOJAUQK-UHFFFAOYSA-N 2-[2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC MQFYRUGXOJAUQK-UHFFFAOYSA-N 0.000 description 1
- JUSXLWAFYVKNLT-UHFFFAOYSA-N 2-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1Br JUSXLWAFYVKNLT-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Chemical class CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- DSRWBPDMEPWZPG-UHFFFAOYSA-N 3,3-difluoro-1-methylpiperidine Chemical compound CN1CCCC(F)(F)C1 DSRWBPDMEPWZPG-UHFFFAOYSA-N 0.000 description 1
- HDZJBTLCBDRDGW-UHFFFAOYSA-N 3,3-diphenylpiperidine Chemical class C1CCNCC1(C=1C=CC=CC=1)C1=CC=CC=C1 HDZJBTLCBDRDGW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AXPZIVKEZRHGAS-UHFFFAOYSA-N 3-benzyl-5-[(2-nitrophenoxy)methyl]oxolan-2-one Chemical compound [O-][N+](=O)C1=CC=CC=C1OCC1OC(=O)C(CC=2C=CC=CC=2)C1 AXPZIVKEZRHGAS-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- OITHRYPVJIVVPG-UHFFFAOYSA-N 4,5-dihydro-1,3-oxazol-4-amine Chemical compound NC1COC=N1 OITHRYPVJIVVPG-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102000000872 ATM Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 101000783817 Agaricus bisporus lectin Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 101100190806 Arabidopsis thaliana PLT3 gene Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- QGRREIPUONUGKZ-UHFFFAOYSA-N C(=O)OC(C)(C)C.FN1CCC(CC1)O Chemical compound C(=O)OC(C)(C)C.FN1CCC(CC1)O QGRREIPUONUGKZ-UHFFFAOYSA-N 0.000 description 1
- WAFOLKGHTYHQGS-UHFFFAOYSA-N C(CCCCCCCC=C/CCCCCCCC)(=O)O.[N+](=O)(O)[O-] Chemical compound C(CCCCCCCC=C/CCCCCCCC)(=O)O.[N+](=O)(O)[O-] WAFOLKGHTYHQGS-UHFFFAOYSA-N 0.000 description 1
- 229940124204 C-kit inhibitor Drugs 0.000 description 1
- ODAIHMZJOZHAFI-UHFFFAOYSA-N COC(N(C)C)OC.[N] Chemical compound COC(N(C)C)OC.[N] ODAIHMZJOZHAFI-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N Caprolactam Natural products O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 108030004793 Dual-specificity kinases Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 229940124009 ErbB-2 tyrosine kinase inhibitor Drugs 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- LHNWMULAKLZVHJ-UHFFFAOYSA-N FBrF Chemical compound FBrF LHNWMULAKLZVHJ-UHFFFAOYSA-N 0.000 description 1
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
- IJMWOMHMDSDKGK-UHFFFAOYSA-N Isopropyl propionate Chemical compound CCC(=O)OC(C)C IJMWOMHMDSDKGK-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000531897 Loma Species 0.000 description 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 1
- 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- UDSJAWNMLSIKNH-UHFFFAOYSA-N NC1=NC2=CC=CC=C2C=C1.N1=CC=CC2=CC=CC=C12 Chemical compound NC1=NC2=CC=CC=C2C=C1.N1=CC=CC2=CC=CC=C12 UDSJAWNMLSIKNH-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- 229940116355 PI3 kinase inhibitor Drugs 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 108030005449 Polo kinases Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229930182475 S-glycoside Natural products 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- JSTADIGKFYFAIY-GJNDDOAHSA-K [2-[bis[[hydroxy(oxido)phosphoryl]methyl]amino]ethyl-(phosphonomethyl)amino]methyl-hydroxyphosphinate;samarium-153(3+) Chemical compound [H+].[H+].[H+].[H+].[H+].[153Sm+3].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O JSTADIGKFYFAIY-GJNDDOAHSA-K 0.000 description 1
- SXWZKIXXIJHINC-UHFFFAOYSA-N [N].C1(=CC=CC=C1)CCCC(=O)O Chemical compound [N].C1(=CC=CC=C1)CCCC(=O)O SXWZKIXXIJHINC-UHFFFAOYSA-N 0.000 description 1
- CUTSCJHLMGPBEJ-UHFFFAOYSA-N [N].CN(C)C=O Chemical compound [N].CN(C)C=O CUTSCJHLMGPBEJ-UHFFFAOYSA-N 0.000 description 1
- AHORCQNZMSFMRH-UHFFFAOYSA-N [N].CNC Chemical compound [N].CNC AHORCQNZMSFMRH-UHFFFAOYSA-N 0.000 description 1
- AHIBWURJLGCHAY-UHFFFAOYSA-N [S].C1=CC=CC=C1 Chemical compound [S].C1=CC=CC=C1 AHIBWURJLGCHAY-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 229910052767 actinium Inorganic materials 0.000 description 1
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001279 adipic acids Chemical class 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-N anhydrous cyanic acid Natural products OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001967 antemetic effect Effects 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003719 aurora kinase inhibitor Substances 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 238000005815 base catalysis Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical group C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229910001423 beryllium ion Inorganic materials 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- IUEWAGVJRJORLA-HZPDHXFCSA-N bmn-673 Chemical compound CN1N=CN=C1[C@H]1C(NNC(=O)C2=CC(F)=C3)=C2C3=N[C@@H]1C1=CC=C(F)C=C1 IUEWAGVJRJORLA-HZPDHXFCSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N caprylic acid monoglyceride Natural products CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000008271 cosmetic emulsion Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 229950010569 dichloroxylenol Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- UYAAVKFHBMJOJZ-UHFFFAOYSA-N diimidazo[1,3-b:1',3'-e]pyrazine-5,10-dione Chemical compound O=C1C2=CN=CN2C(=O)C2=CN=CN12 UYAAVKFHBMJOJZ-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- JBFHTYHTHYHCDJ-UHFFFAOYSA-N gamma-caprolactone Chemical class CCC1CCC(=O)O1 JBFHTYHTHYHCDJ-UHFFFAOYSA-N 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940068939 glyceryl monolaurate Drugs 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- AZMMUMQYPBKXHS-UHFFFAOYSA-N gold sodium Chemical compound [Na].[Au] AZMMUMQYPBKXHS-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 239000002474 gonadorelin antagonist Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 231100000640 hair analysis Toxicity 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229950002248 idoxifene Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- ATYGMDZIBQHJFX-UHFFFAOYSA-N imidazolidine;urea Chemical compound NC(N)=O.C1CNCN1 ATYGMDZIBQHJFX-UHFFFAOYSA-N 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- IQCVSPUMHPGWOM-UHFFFAOYSA-N methyl formate phenol Chemical compound C(=O)OC.OC1=CC=CC=C1 IQCVSPUMHPGWOM-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940087004 mustargen Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 1
- 229950011068 niraparib Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 150000002918 oxazolines Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000011087 paperboard Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940077412 peg-12 laurate Drugs 0.000 description 1
- 229940008456 peg-32 oleate Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000004968 peroxymonosulfuric acids Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical class O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940116423 propylene glycol diacetate Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- UBZJXAQDXUGXIZ-UHFFFAOYSA-N quinazoline;quinoline Chemical compound N1=CC=CC2=CC=CC=C21.N1=CN=CC2=CC=CC=C21 UBZJXAQDXUGXIZ-UHFFFAOYSA-N 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 1
- 229950004707 rucaparib Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 1
- 229950009919 saracatinib Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 1
- 229940006509 strontium-89 Drugs 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229940035023 sucrose monostearate Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000007755 survival signaling Effects 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229950004550 talazoparib Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003569 thioglycosides Chemical class 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000004520 water soluble gel Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses a kind of quinazoline derivant salt form crystal form and preparation method and application;The specially hydrochloride Form A, B, C, D of quinazoline derivant shown in formula (I), F, H, I, sulfate crystal form A, maleate crystal form A, succinate crystal form A, adipate crystal form A, glycollate crystal form A, malate crystal form A, fumarate crystal form A, benzene sulfonate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A and Crystal form of oxalate A.Salt form crystal form provided by the invention is with good stability, can be in treatment brain transplantation of non small cell Lung transfer, meninx transfer is applied in the drug of primary brain cancer or glioma etc., and there is preferable bioavilability, be of great significance to the curative effect for further studying such solid drugs.
Description
Technical field
The present invention relates to a kind of quinazoline derivant salt form and its crystal forms;More particularly to (R) -6- [(fluoro- 1- first of 3,3- bis-
Phenylpiperidines -4- base) oxygroup]-nitrogen-(3- acetenyl -2- fluorophenyl) -7- methoxyquinazoline hydrochloride -4- amine (I) hydrochloride Form A,
B, C, D, F, H, I, sulfate crystal form A, maleate crystal form A, succinate crystal form A, adipate crystal form A, glycollate are brilliant
Type A, malate crystal form A, fumarate crystal form A, benzene sulfonate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A
And Crystal form of oxalate A and its preparation method and application.
Background technique
Biological signal conduction refers to stimulation or signal is inhibited to be sent into the cell, is transmitted by a series of signal, makes cell
Interior generation biological response.Many researchs have been carried out in many signal transduction paths and its biological respinse.In signal transduction pathway
It is cancer the reason of leading to many diseases, including diversified forms, dysbolism, inflammatory disease that the different defects of middle appearance, which have found,
Disease, blood vessel and neuronal disease.These defects often occur to be inserted into gene level, such as DNA, missing or transposition, one
Cell is proliferated uncontrollably in a little cancers.
Signal transduction is often mediated by the certain albumen for being referred to as kinases.Kinases is commonly divided into protein kinase and lipid
Kinases and certain kinases for showing dual specificity.Protein kinase be catalyzed other protein phosphorylation enzyme and/or from
Body phosphorylation, and can be classified based on them to the effect of substrate, such as: tyrosine kinase refers to major phosphate junket ammonia
Sour residue (for example, Kit, EGFR, HER2, VEGFR, PDGFR, SRC and ABL etc.), serine/threonine kinase refers to major phosphate
Change serine and/or threonine residues (for example, mTORC1, mTORC2, ATM, ATR, Akt etc.) and dual-specificity kinase phosphoric acid
Change the tyrosine of substrate, serine and/or threonine residues.
EGF-R ELISA (EGFR) belongs to the transmembrane protein tyrosine kinases of ErbB receptor family, including epidermis life
Growth factor receptor body EGFR/ERBB1, HER2/ERBB2/NEU, HER3/ERBB3 and HER4/ERBB4.With epidermal growth factor
(EGF) ligand binding, the EGFR receptor of induction and another EGFR receptor or another family member, for example, HER2/ERBB2/
NEU, HER3/ERBB3 or HER4/ERBB4 form homopolymer or heterodimer, lead to the activation of EGFR tyrosine kinase activity.
The EGFR of activation then its substrate of phosphorylation, so as to cause multiple downstream passages in the cell, including Pl3K-AKT-mTOR
Approach (activation for participating in cell survival) and RAS-RAF-MEK-ERK approach (being related to cell Proliferation).ErbB receptor signal transduction
And its participation in tumour, see, e.g., Chong et al.Nature Med.2013;19(11):1389-1400);N
Engl J Med.(2008)Vol.358,1160-74and Biochemical and Biophysical Research
Communications(2004)Vol.319,1-11。
Glioma is the most common primary intracranial tumour, accounts for the 40-50% of intracranial tumour.Patients with gliomas is about
60% has the relevant EGFR mutation of tumour.Wherein about 70% mutation is that exon 2-7 lacks EGFRV3 (EGFRVIII).It is this prominent
Become the kinase activity for increasing EGFR, downstream is caused to promote the overactivity of survival signaling pathway.EGFRV3 (EGFRVIII) is
The missing gene of the exon 2-7 of epidermal growth factor EGFR and prevent mutant receptor from any of ligand binding.
EGFRV3 is mutated in the cancer of the brain, glioma, bladder cancer, breast cancer, colorectal cancer, cancer of the esophagus, Head and neck squamous cell carcinoma, lung cancer,
Lung squamous cancer, oophoroma, prostate cancer are expressed in brain stem tumor etc..Referring to Terrance G.Johns etc., FEBS Journal
280(2013)5350–5370。
The derepression of ErbB family signal transduction promotes proliferation, invades, transfer, angiogenesis and tumor cell survival,
And in many human cancers, including lung, head and neck and breast are described, therefore ErbB family represents anticancer drug hair
The small-molecule drug of the logical targets of exhibition, targeting EGFR or ErbB2, including Gefitinib (Iressa IressaTM), Tarceva
(ErlotinibTM), Afatinib, Tai Ruisha and Lapatinib (TYKERBTM, TYVERBTM) non-small cell lung cancer clinically
It gets the Green Light, being specifically used for EGFR mutation is exons 19 (Exon 19del) missing or exon 2 1L858R (Exon
21L858R) it is mutated.Because EGFRVIII be the missing gene of EGFR exon 2-7 and prevent mutant receptor from it is any known
Ligand binding, with exons 19 (Exon 19del) missing or exon 2 1L858R (Exon21L858R) mutation completely not
Together, existing EGFR inhibitor can not effectively inhibit EGFRVIII, be far below outside to EGFR to the bioactivity of EGFRVIII
Aobvious 19 (Exon 19del) of son missing or exon 2 1L858R (Exon 21L858R) mutation, activity usually reduce by 10 times, even
100 times or more, see, e.g., Paul S.Mischel et al, Molecular Cell, 60,307-318,2015.Meanwhile
Because of the presence of blood-brain barrier (BBB), these drugs of existing approved more can not reach effective quantity in encephalic.For brain colloid
Tumor, radiotherapy and surgical operation are aided with the main means that chemotherapeutics (for amine is not frustrated) is still treatment, but therapeutic effect is limited,
Overall survival about 10 months.
Therefore, there is the high bioactivity of EGFRVIII mutation to have simultaneously across blood-brain barrier barrier for treating for research and development
Or the glioma that prevention is mediated for EGFR is particularly useful.
It is well known that the crystal form of the different crystal forms of same drug, salt form and salt, stability, solubility and biological utilisation
Degree etc. may have notable difference, to influence the curative effect of drug.Therefore, research and development are more advantageous to drug processing and drug
The new salt form of quinazoline derivant used in composition and the novel crystal forms of salt mention for the curative effect and safety research of solid drugs
Be for more qualitative, quantitative information it is highly useful, be of great significance.
Summary of the invention
Problem to be solved by this invention is can not effectively to inhibit EGFR Activating mutations for existing EGFR inhibitor
EGFRVIII and effective the problem of reaching effective blood drug concentration across blood-brain barrier to encephalic and quinazoline of the present invention spread out
Biology (R) -6- [(the fluoro- 1- methyl piperidine -4- base of 3,3- bis-) oxygroup]-nitrogen-(3- acetenyl -2- fluorophenyl) -7- methoxyl group quinoline
The property of the free alkali of oxazoline -4- amine (I) is unfavorable for the problem used in drug processing and pharmaceutical composition, provides one kind more
Be conducive to quinazoline derivant salt form crystal form and preparation method and application used in drug processing and pharmaceutical composition, be solid
The curative effect and safety research of drug provide more qualitative, quantitative information.
Quinazoline derivant provided by the invention has the bioactivity for EGFRVIII Activating mutations, effectively passes through blood
Brain barrier.Shown in the quinazoline derivant such as formula (I):
The purpose of the present invention is achieved through the following technical solutions:
A technical solution of the present invention is to provide a kind of chiral novel quinazoline derivant (I) for being R.
Preferably, chiral purity ee > 90%, it is highly preferred that chiral purity ee > 97%.
A technical solution of the present invention is to provide a kind of chiral novel quinazoline derivant (I) tool for being R
There is the bioactivity of EGFRVIII Activating mutations.
A technical solution of the present invention is to provide a kind of chiral novel quinazoline derivant (I) tool for being R
Have the bioactivity of EGFRVIII Activating mutations, at the same have height pass through blood-brain barrier ability.
The present invention also provides a kind of synthetic methods for preparing quinazoline derivant of the present invention (I).
A technical solution of the present invention is to provide the hydrochloride Form A, XRPD of a kind of quinazoline derivant
Map is in 2 θ
Principal character peak: 6.5,13.1,9.4
Secondary feature peak: 7.3,18.2,20.0
Characteristic peak again: 27.5,26.6,21.6
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the hydrochloride Form A of quinazoline derivant (I) provided by the invention is in 2 θ=6.48,
7.31,9.36,10.26,13.12,14.37,14.98,16.06,16.88,17.48,18.25,20.01,20.83,21.55,
22.21,23.35,25.47,26.60,27.46,28.29,29.98,34.07,34.89,36.25,36.47,36.87,37.54
Place has derivative peak, and the error range of above-mentioned 2 θ value is ± 0.2.
Another technical solution of the present invention is to provide the hydrochloride Form B, XRPD of a kind of quinazoline derivant
Map is in 2 θ
Principal character peak: 6.5,17.7,19.8
Secondary feature peak: 7.3,8.2,10.5,13.2
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the hydrochloride Form B of quinazoline derivant (I) provided by the invention is in 2 θ=4.32,
5.98,6.54,7.28,8.17,10.52,13.20,15.99,17.74,18.48,19.32,19.84,22.56,23.88,
There is derivative peak, the error model of above-mentioned 2 θ value at 24.36,24.87,30.47,32.92,33.55,34.60,38.06,38.34
Enclose is ± 0.2.
Another technical solution of the present invention is to provide the hydrochloride Form C, XRPD of a kind of quinazoline derivant
Map is in 2 θ
Principal character peak: 7.2,17.6,22.0
Secondary feature peak: 14.0,13.6,12.8
Characteristic peak again: 24.6,26.2,27.3
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the hydrochloride Form C of quinazoline derivant (I) provided by the invention is in 2 θ=5.66,
7.16,8.32,8.86,9.52,10.98,11.63,12.80,13.57,13.96,14.81,15.14,15.49,16.55,
16.86,17.61,22.04,22.93,24.55,26.19,27.30,28.49,34.12,34.76,35.65,36.68,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 37.31,37.80,38.20,38.53.
Another technical solution of the present invention is to provide the hydrochloride Form D, XRPD of a kind of quinazoline derivant
Map is in 2 θ
Principal character peak: 13.4,7.1,25.4
Secondary feature peak: 6.7,18.0,19.8
Characteristic peak again: 17.2,27.3,24.7
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the hydrochloride Form D of quinazoline derivant (I) provided by the invention is in 2 θ=3.43,
6.72,7.12,8.47,9.32,12.25,13.44,14.07,15.69,16.87,17.22,17.97,19.77,20.73,
22.25,22.82,23.64,24.77,25.40,27.28,28.13,29.69,31.01,33.48,34.87,35.42,38.08
Place has derivative peak, and the error range of above-mentioned 2 θ value is ± 0.2.
Another technical solution of the present invention is to provide the hydrochloride Form F, XRPD of a kind of quinazoline derivant
Map is in 2 θ
Principal character peak: 6.8,20.5,13.6
Secondary feature peak: 14.8,14.3,17.9,11.9
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the hydrochloride Form F of quinazoline derivant (I) provided by the invention is in 2 θ=4.91,
5.67,6.51,6.77,7.44,8.58,9.20,9.73,10.40,10.85,11.86,13.58,14.30,14.78,15.57,
Have at 15.85,16.15,16.41,16.97,17.89,18.96,19.76,20.45,20.79,21.57,22.21,24.17
Derivative peak, the error range of above-mentioned 2 θ value are ± 0.2.
Another technical solution of the present invention is to provide the hydrochloride Form H, XRPD of a kind of quinazoline derivant
Map is in 2 θ
Principal character peak: 7.3,18.0,14.1
Secondary feature peak: 6.4,13.2,15.8
Characteristic peak again: 16.8,14.5,20.3
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the hydrochloride Form H of quinazoline derivant (I) provided by the invention is in 2 θ=5.83,
6.43,7.26,8.10,10.24,11.93,13.22,14.11,14.45,14.88,15.78,16.80,17.95,18.96,
There is derivative peak at 20.25,21.07,21.65,24.16,24.53,25.67,26.37,27.03,27.61, above-mentioned 2 θ value
Error range is ± 0.2.
Another technical solution of the present invention is to provide the hydrochloride Form I, XRPD of a kind of quinazoline derivant
Map is in 2 θ
Principal character peak: 18.6,7.4,6.9
Secondary feature peak: 13.2,25.1,12.3
Characteristic peak again: 14.7,28.1,14.2
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the hydrochloride Form I of quinazoline derivant (I) provided by the invention is in 2 θ=6.88,
7.42,8.20,12.31,13.20,13.88,14.23,14.66,15.69,17.48,17.90,18.64,19.23,20.24,
20.92,21.94,22.88,23.42,23.88,25.12,25.40,25.85,26.64,28.07,28.92,31.19,33.10
Place has derivative peak, and the error range of above-mentioned 2 θ value is ± 0.2.
Another technical solution of the present invention is to provide a kind of fumarate crystal form A of quinazoline derivant,
XRPD map is in 2 θ
Principal character peak: 6.5,17.8,9.4
Secondary feature peak: 13.4,7.5,19.7
Characteristic peak again: 14.6,18.5
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the fumarate crystal form A of quinazoline derivant (I) provided by the invention 2 θ=
6.51,6.74,7.47,9.37,10.82,13.43,13.97,14.61,17.78,18.51,18.80,19.69,20.90,
21.36,21.68,22.63,23.76,24.39,27.09,28.73,29.69,30.52,31.07,35.14,36.12,38.33
Place has derivative peak, and the error range of above-mentioned 2 θ value is ± 0.2.
Another technical solution of the present invention is to provide a kind of succinate crystal form A of quinazoline derivant,
XRPD map is in 2 θ
Principal character peak: 6.6,17.8,7.5
Secondary feature peak: 9.4,20.3,18.5
Characteristic peak again: 21.0,14.5,19.5
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the succinate crystal form A of quinazoline derivant (I) provided by the invention 2 θ=
3.92,4.40,6.56,6.74,7.50,9.42,11.92,12.68,13.53,14.50,14.84,15.22,15.68,
16.25,17.82,18.55,19.48,20.34,20.99,22.08,22.59,24.14,24.52,24.92,28.07,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 30.92,36.11.
Another technical solution of the present invention is to provide a kind of maleate crystal form A of quinazoline derivant,
XRPD map is in 2 θ
Principal character peak: 6.3,18.8,16.7
Secondary feature peak: 25.2,21.2
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the maleate crystal form A of quinazoline derivant provided by the invention is in 2 θ=6.25,
8.44,8.68,9.42,10.41,14.42,14.88,16.65,17.93,18.78,20.58,21.17,22.63,25.16,
There is derivative peak at 31.15,32.40,33.66,34.34,34.52,35.82,36.06,36.35,36.91, above-mentioned 2 θ value
Error range is ± 0.2.
Another technical solution of the present invention is to provide a kind of glycollate crystal form A of quinazoline derivant,
XRPD map is in 2 θ
Principal character peak: 6.6,7.4,17.9
Secondary feature peak: 13.3
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the glycollate crystal form A of quinazoline derivant provided by the invention is in 2 θ=4.53,
5.89,6.59,7.35,10.02,12.54,13.26,15.94,17.93,18.67,19.36,19.84,21.06,24.99,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 31.13,33.48,34.79,35.56,36.17.
Another technical solution of the present invention is to provide sulfate the crystal form A, XRPD of a kind of quinazoline derivant
Map is in 2 θ
Principal character peak: 7.3,18.2,15.0
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the sulfuric acid crystal form A of quinazoline derivant (I) provided by the invention is in 2 θ=7.27,
8.41,11.88,14.96,18.23,19.68,20.64,24.83,25.82,27.10,28.16,29.79,30.71,32.35,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 34.12,35.56,37.56,38.37.
Another technical solution of the present invention is to provide a kind of oxalate crystal form A of quinazoline derivant,
XRPD map is in 2 θ
Principal character peak: 6.9,15.1,13.7
Secondary feature peak: 15.4,9.6,19.0
Characteristic peak again: 20.6,27.3,23.4
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the oxalate crystal form A of quinazoline derivant (I) provided by the invention 2 θ=
5.43,6.88,7.38,9.56,13.68,15.10,15.43,16.32,16.88,17.68,18.60,19.02,20.58,
21.62,22.33,22.70,23.35,25.68,27.29,27.88,28.53,29.37,31.35,34.89,37.11,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 37.78,38.17,38.36,39.65.
Another technical solution of the present invention is to provide a kind of malate crystal form A of quinazoline derivant,
XRPD map is in 2 θ
Principal character peak: 6.5,18.8,19.9
Secondary feature peak: 7.5,8.4,9.2
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
The XRPD map of the malate crystal form A of quinazoline derivant (I) provided by the invention is in 2 θ=5.43, and 6.53,
7.49,8.35,9.17,12.10,13.16,16.17,18.77,19.85,20.79,23.14,23.94,26.66,28.25,
There is derivative peak, the error model of above-mentioned 2 θ value at 29.32,30.38,33.24,33.69,34.80,35.97,36.87,37.88
Enclose is ± 0.2.
Another technical solution of the present invention is to provide a kind of benzene sulfonate crystal form A of quinazoline derivant,
XRPD map is in 2 θ
Principal character peak: 6.6,14.0,15.3
Secondary feature peak: 7.1,5.5,19.7
Characteristic peak again: 17.8,16.9,21.0
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
The XRPD map of the benzene sulfonate crystal form A of quinazoline derivant provided by the invention is in 2 θ=5.48, and 6.56,
7.08,7.65,8.14,8.48,9.71,10.55,11.14,11.77,13.32,13.95,15.32,16.46,16.89,
17.82,19.15,19.70,20.43,21.02,21.98,22.68,23.23,25.26,26.07,26.59,28.63,
Have at 29.09,30.45,31.12,32.09,32.55,33.66,35.76,37.86,38.67,39.11 and derives peak, above-mentioned 2
The error range of θ value is ± 0.2.
Another technical solution of the present invention is to provide a kind of benzene sulfonate crystal form B of quinazoline derivant,
XRPD map is in 2 θ
Principal character peak: 8.5,14.5,23.4
Secondary feature peak: 18.3,19.7
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
The XRPD map of the benzene sulfonate crystal form B of quinazoline derivant provided by the invention is in 2 θ=5.50, and 6.32,
7.28,8.50,9.74,10.79,11.55,13.22,14.49,15.53,16.26,16.97,18.29,19.71,21.36,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 22.21,23.44,24.19,25.34,25.87,27.16.
Another technical solution of the present invention is to provide a kind of benzene sulfonate crystal form C of quinazoline derivant,
XRPD map is in 2 θ
Principal character peak: 14.0,14.7,7.7
Secondary feature peak: 8.3,21.2,19.4,
Characteristic peak again: 27.5,24.7
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the benzene sulfonate crystal form C of quinazoline derivant (I) provided by the invention 2 θ=
4.24,7.07,7.68,8.31,9.92,12.55,14.03,14.74,18.72,19.40,20.36,21.19,24.08,
24.73,26.14,27.49,28.28,31.68,33.90,34.82,35.06,35.78,36.54,37.57,37.89,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 38.36,39.0.
Another technical solution of the present invention is to provide a kind of benzoate crystal form A of quinazoline derivant,
XRPD map is in 2 θ
Principal character peak: 7.3,6.3,16.8
Secondary feature peak: 13.5,18.7,27.0
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
The XRPD map of the benzoate crystal form A of quinazoline derivant (I) provided by the invention is in 2 θ=4.45, and 6.31,
6.65,7.33,7.69,8.01,11.85,13.53,16.02,16.77,18.75,19.95,21.06,21.76,22.56,
23.41,26.94,27.44,27.61,27.98,28.55,29.05,31.92,32.29,32.93,33.72,34.61,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 35.35,35.95,37.08,38.13,39.62.
Another technical solution of the present invention is to provide a kind of hippurate crystal form A of quinazoline derivant,
XRPD map is in 2 θ
Principal character peak: 5.6,6.9,20.0
Secondary feature peak: 16.0,7.7,13.7
Characteristic peak again: 24.3,26.4
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the hippurate crystal form A of quinazoline derivant (I) provided by the invention 2 θ=
4.35,5.59,6.85,7.74,9.17,9.95,13.74,14.73,15.96,16.44,18.10,18.63,19.96,
21.38,24.25,25.37,25.72,26.39,27.23,28.56,30.25,30.82,33.31,34.58,35.29,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 36.39,37.24,37.9.
Another technical solution of the present invention is to provide the Crystal form of oxalate A, XRPD of a kind of quinazoline derivant
Map is in 2 θ
Principal character peak: 6.4,9.1,17.5
Secondary feature peak: 12.9,14.5,26.4
Characteristic peak again: 19.4,18.3,15.9
Place has diffraction maximum, wherein the error range of 2 θ values is ± 0.2.
Preferably, the XRPD map of the Crystal form of oxalate A of quinazoline derivant (I) provided by the invention is in 2 θ=4.11,
6.44,7.15,8.75,9.06,9.88,11.26,11.58,12.92,14.52,15.87,17.47,18.29,19.43,
20.14,20.49,23.70,24.34,26.36,26.92,29.75,31.72,32.67,32.99,34.21,34.52,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 34.86,36.36,36.91,37.91,39.03.
Preferably, there is the hydrochloride Form A of quinazoline derivant of the present invention XRPD substantially as shown in Fig. 1 to scheme
Spectrum.
Preferably, there is the hydrochloride Form B of quinazoline derivant of the present invention XRPD substantially as shown in Fig. 2 to scheme
Spectrum.
Preferably, the hydrochloride Form C of quinazoline derivant of the present invention has XRPD substantially as shown in Fig. 10
Map.
Preferably, the hydrochloride Form D of quinazoline derivant of the present invention has XRPD substantially as shown in Fig. 11
Map.
Preferably, the hydrochloride Form F of quinazoline derivant of the present invention schemes with substantially as of fig. 9 shown XRPD
Spectrum.
Preferably, there is the hydrochloride Form H of quinazoline derivant of the present invention XRPD substantially as shown in Fig. 3 to scheme
Spectrum.
Preferably, there is the hydrochloride Form I of quinazoline derivant of the present invention XRPD substantially as shown in Fig. 4 to scheme
Spectrum.
Preferably, the fumarate crystal form A of quinazoline derivant of the present invention has XRPD substantially as shown in Fig. 5
Map.
Preferably, the succinate crystal form A of quinazoline derivant of the present invention has XRPD substantially as shown in Fig. 6
Map.
Preferably, the maleate crystal form A of quinazoline derivant of the present invention has XRPD substantially as shown in Fig. 7
Map.
Preferably, the glycollate crystal form A of quinazoline derivant of the present invention has XRPD substantially as shown in Fig. 8
Map.
Preferably, the sulfate crystal form A of quinazoline derivant of the present invention has XRPD substantially as shown in Fig. 12
Map.
Preferably, the oxalate crystal form A of quinazoline derivant of the present invention has substantially as shown in Fig. 13
XRPD map.
Preferably, the malate crystal form A of quinazoline derivant of the present invention has substantially as shown in Fig. 14
XRPD map.
Preferably, the benzene sulfonate crystal form A of quinazoline derivant of the present invention has substantially as shown in Fig. 15
XRPD map.
Preferably, the benzene sulfonate crystal form B of quinazoline derivant of the present invention has substantially as shown in Fig. 16
XRPD map.
Preferably, the benzene sulfonate crystal form C of quinazoline derivant of the present invention has substantially as shown in Fig. 17
XRPD map.
Preferably, the benzoate crystal form A of quinazoline derivant of the present invention has substantially as shown in Fig. 18
XRPD map.
Preferably, the hippurate crystal form A of quinazoline derivant of the present invention has substantially as shown in Fig. 19
XRPD map.
Preferably, the Crystal form of oxalate I of quinazoline derivant of the present invention has XRPD substantially as shown in Fig. 20
Map.
The present invention also provides the method for hydrochloride Form A for preparing quinazoline derivant of the present invention (I) a kind of, packets
It includes following steps: quinazoline derivant sample shown in formula (I) is added in organic solvent and 0.8~1.2 equivalent of hydrochloric acid and is taken the photograph in 22-28
Lower layer's solid, which is centrifugated out, after stirring under family name's degree obtains crystal form A;Wherein, quinoline azoles shown in formula (I) is added in every milliliter of organic solvent
10~200 milligrams of quinoline derivant.
The present invention also provides the method for hydrochloride Form B for preparing quinazoline derivant of the present invention (I) a kind of, packets
It includes following steps: quinazoline derivant shown in formula (I) is added in organic solvent, and 0.8~1.2 equivalent is added to the suspension
Hydrochloric acid stirs under 22-28 degrees Celsius, is centrifugated out the wet sample solid of lower layer and obtains crystal form B;Wherein, every milliliter of organic solvent adds
Enter shown in formula (I) 10~200 milligrams of quinazoline derivant.
The present invention also provides the method for hydrochloride Form C for preparing quinazoline derivant of the present invention (I) a kind of, packets
It includes following steps: organic solvent is added in quinazoline derivant sample shown in formula (I) and 2~2.5 equivalent of hydrochloric acid is added in 22-28
The wet sample solid of lower layer, which is centrifugated out, after stirring under degree Celsius obtains dihydrochloride crystal form C;Wherein, it is added in every milliliter of organic solvent
10~200 milligrams of quinazoline derivant shown in formula (I).
The present invention also provides the method for hydrochloride Form D for preparing quinazoline derivant of the present invention (I) a kind of, packets
It includes following steps: being cooled to 22-28 degrees Celsius after hydrochloride Form C sample is heated to high temperature, obtain dihydrochloride crystal form D.
The present invention also provides the method for hydrochloride Form F for preparing quinazoline derivant of the present invention (I) a kind of, packets
It includes following steps: alcohols and based organic solvent will be added in quinazoline derivant hydrochloride Form B shown in formula (I), in 22-28
Degree Celsius lower gas-liquid diffusion, until there is solid that crystal form F is precipitated to obtain;Wherein, hydrochloric acid shown in formula (I) is added in every milliliter of organic solvent
10~200 milligrams of salt crystal form B.
The present invention also provides the method for hydrochloride Form H for preparing quinazoline derivant of the present invention (I) a kind of, packets
It includes following steps: organic solvent being added in hydrochloride Form B, (open quick) volatilizees under 22-28 degrees Celsius after filtering
Crystal form H;Wherein, hydrochloride Form B 10~200 milligram are added shown in formula (I) in every milliliter of organic solvent.
The present invention also provides the method for hydrochloride Form I for preparing quinazoline derivant of the present invention (I) a kind of, packets
It includes following steps: being cooled to 22-28 degrees Celsius after heating hydrochloride Form H sample to high temperature.
The present invention also provides the method for fumarate crystal form A for preparing quinazoline derivant of the present invention (I) a kind of,
The following steps are included: after organic solvent is added in the quinazoline derivant shown in formula (I) and 0.4-0.6 equivalent fumaric acid, in 22-28
It is stirred under degree Celsius, solid is collected by centrifugation;Wherein, in every milliliter of organic solvent be added formula (I) shown in quinazoline derivant 10~
200 milligrams.
The present invention also provides the method for succinate crystal form A for preparing quinazoline derivant of the present invention (I) a kind of,
The following steps are included: after organic solvent is added in the quinazoline derivant shown in formula (I) and 0.8-1.2 equivalent succinic acid, in 22-28
It is stirred under degree Celsius, solid is collected by centrifugation and obtains the crystal form;Wherein, quinazoline shown in formula (I) is added in every milliliter of organic solvent
10~200 milligrams of derivative.
The present invention also provides the method for maleate crystal form A for preparing quinazoline derivant of the present invention (I) a kind of,
The following steps are included: being stirred under 22-28 degrees Celsius after organic solvent is added in the quinazoline derivant shown in formula (I) and maleic acid
It mixes, solid is collected by centrifugation and obtains the crystal form;Wherein, in every milliliter of organic solvent be added formula (I) shown in quinazoline derivant 10~
200 milligrams.
The present invention also provides the method for glycollate crystal form A for preparing quinazoline derivant of the present invention (I) a kind of,
The following steps are included: after organic solvent is added in the quinazoline derivant shown in formula (I) and 0.8-1.2 eq. ethanol acid, in room temperature
Lower stirring, is collected by centrifugation solid.
The present invention also provides the method for sulfate crystal form A for preparing quinazoline derivant of the present invention (I) a kind of, packets
It includes following steps: organic solvent is added in quinazoline derivant sample shown in formula (I) and 0.8-1.2 equiv. sulfuric acid aqueous solution exists
It is stirred under 22-28 degrees Celsius, solid is collected by centrifugation and obtains the crystal form;Wherein, quinoline shown in formula (I) is added in every milliliter of organic solvent
10~200 milligrams of oxazoline derivative.
The present invention also provides the method for oxalate crystal form A for preparing quinazoline derivant of the present invention (I) a kind of,
The following steps are included: organic solvent and 0.8-1.2 equivalent ethanedioic acid is added in 22- in quinazoline derivant sample shown in formula (I)
It is stirred under 28 degrees Celsius, solid is collected by centrifugation and obtains the crystal form;Wherein, quinoline azoles shown in formula (I) is added in every milliliter of organic solvent
10~200 milligrams of quinoline derivant.
The present invention also provides the method for malate crystal form A for preparing quinazoline derivant of the present invention (I) a kind of,
The following steps are included: organic solvent and 0.8-1.2 equivalent malic acid is added in 22- in quinazoline derivant sample shown in formula (I)
It is stirred under 28 degrees Celsius, solid is collected by centrifugation and obtains the crystal form;Wherein, quinoline azoles shown in formula (I) is added in every milliliter of organic solvent
10~200 milligrams of quinoline derivant.
The present invention also provides the method for benzene sulfonate crystal form A for preparing quinazoline derivant of the present invention (I) a kind of,
The following steps are included: organic solvent and 0.8-1.2 equivalent benzene sulfonic acid is added in 22- in quinazoline derivant sample shown in formula (I)
It is stirred under 28 degrees Celsius, solid is collected by centrifugation and obtains the crystal form;Wherein, quinoline azoles shown in formula (I) is added in every milliliter of organic solvent
10~200 milligrams of quinoline derivant.
The present invention also provides the method for benzene sulfonate crystal form B for preparing quinazoline derivant of the present invention (I) a kind of,
The following steps are included: organic solvent and 0.8-1.2 equivalent benzene sulfonic acid is added in 22- in quinazoline derivant sample shown in formula (I)
It is stirred under 28 degrees Celsius, solid is collected by centrifugation and obtains the crystal form;Wherein, quinoline azoles shown in formula (I) is added in every milliliter of organic solvent
10~200 milligrams of quinoline derivant.
The present invention also provides the method for benzene sulfonate crystal form C for preparing quinazoline derivant of the present invention (I) a kind of,
The following steps are included: organic solvent and 0.8-1.2 equivalent benzene sulfonic acid is added in 22- in quinazoline derivant sample shown in formula (I)
It is stirred under 28 degrees Celsius, solid is collected by centrifugation and obtains the crystal form;Wherein, quinoline azoles shown in formula (I) is added in every milliliter of organic solvent
10~200 milligrams of quinoline derivant.
The present invention also provides the method for benzoate crystal form A for preparing quinazoline derivant of the present invention (I) a kind of,
The following steps are included: organic solvent and 0.8-1.2 equivalent benzoic acid is added in 22- in quinazoline derivant sample shown in formula (I)
It is stirred under 28 degrees Celsius, solid is collected by centrifugation and obtains the crystal form;Wherein, quinoline azoles shown in formula (I) is added in every milliliter of organic solvent
10~200 milligrams of quinoline derivant.
The present invention also provides the method for hippurate crystal form A for preparing quinazoline derivant of the present invention (I) a kind of,
The following steps are included: organic solvent and 0.8-1.2 equivalent hippuric acid is added in 22- in quinazoline derivant sample shown in formula (I)
It is stirred under 28 degrees Celsius, solid is collected by centrifugation and obtains the crystal form;Wherein, quinoline azoles shown in formula (I) is added in every milliliter of organic solvent
10~200 milligrams of quinoline derivant.
The present invention also provides the method for Crystal form of oxalate A for preparing quinazoline derivant of the present invention (I) a kind of, packets
It includes following steps: organic solvent and 0.8-1.2 equivalent oxalic acid is added in quinazoline derivant sample shown in formula (I) and is taken the photograph in 22-28
It is stirred under family name's degree, solid is collected by centrifugation and obtains the crystal form;Wherein, quinazoline shown in formula (I) is added in every milliliter of organic solvent to spread out
10~200 milligrams of biology.
In the above-mentioned methods, it is preferred that the organic solvent is alcohols, ethers, esters, fat hydrocarbon, arene have
One or more of solvent.
It is furthermore preferred that the alcohol organic solvent is methanol, in ethyl alcohol, isopropanol, normal propyl alcohol, isobutanol, n-butanol
It is one or more of.
It is furthermore preferred that the ether organic solvent is ether, isopropyl ether or methyl tertiary butyl ether(MTBE).
It is furthermore preferred that the based organic solvent is ethyl acetate, butyl acetate or isopropyl acetate.
It is furthermore preferred that the organic solvent of ketone is acetone, butanone or 4-methyl-2 pentanone.
It is furthermore preferred that the fat hydrocarbon organic solvent is normal heptane or acetonitrile.
It is furthermore preferred that the arene organic solvent is toluene.
It is further preferred that the preparation method of the hydrochloride Form A of the quinazoline derivant (I), preferably organic molten
Agent is methanol.
The preparation method of the hydrochloride Form B of the quinazoline derivant (I), preferably organic solvent are acetonitrile, acetic acid
Ethyl ester or tetrahydrofuran/water (15-20/1, v/v).
The preparation method of the hydrochloride Form C of the quinazoline derivant (I), preferably organic solvent are acetone.
The preparation method of the hydrochloride Form D of the quinazoline derivant (I), preferably the temperature range 120- of high temperature
160 degrees Celsius.
The preparation method of the hydrochloride Form F of the quinazoline derivant (I), preferably alcohols are methanol, and esters are second
Isopropyl propionate.More preferable methanol, ethyl acetate weight ratio be 1:1.
Preferably organic solvent is ethyl alcohol in the preparation method of the hydrochloride Form H of the quinazoline derivant (I).
The preparation method of the hydrochloride Form I of the quinazoline derivant (I), preferably high-temperature temperature are taken the photograph for 120-130
Family name's degree.
The preparation method of the fumarate crystal form A of the quinazoline derivant (I), preferably organic solvent are methanol, third
Ketone, ethyl acetate or volume ratio are tetrahydrofuran/water mixed liquid of 15-20:1.
The preparation method of the succinate crystal form A of the quinazoline derivant (I), preferably organic solvent are methanol or third
Ketone.
The preparation method of the maleate crystal form A of the quinazoline derivant (I), preferably organic solvent are acetone.
The preparation method of the glycollate crystal form A of the quinazoline derivant (I), preferably organic solvent are methanol, second
Nitrile or ethyl acetate.
The preparation method of the sulfate crystal form A of the quinazoline derivant (I), preferably organic solvent be methanol, acetonitrile,
Acetone, ethyl acetate or volume ratio are tetrahydrofuran/water mixed liquid of 15-20:1.
The preparation method of the oxalate crystal form A of the quinazoline derivant (I), preferably organic solvent are methanol or second
Acetoacetic ester.
The preparation method of the malate crystal form A of the quinazoline derivant (I), preferably organic solvent are methanol, second
Tetrahydrofuran/water mixed liquid that acetoacetic ester or volume ratio are 15-20:1.
The preparation method of the benzene sulfonate crystal form A of the quinazoline derivant (I), preferably organic solvent are methanol.
The preparation method of the benzene sulfonate crystal form B of the quinazoline derivant (I), preferably organic solvent are acetonitrile.
The preparation method of the benzene sulfonate crystal form C of the quinazoline derivant (I), preferably organic solvent are tetrahydrofuran
With the mixed solvent (volume ratio 15-20:1, more preferably 19:1) of water.
The preparation method of the benzoate crystal form A of the quinazoline derivant (I), preferably organic solvent are methanol, second
Nitrile, acetone or volume ratio are tetrahydrofuran/water mixed liquid of 15-20:1.
The preparation method of the hippurate crystal form A of the quinazoline derivant (I), preferably organic solvent are methanol.
The preparation method of the Crystal form of oxalate A of the quinazoline derivant (I), preferably organic solvent are methanol.
The present invention also provides a kind of pharmaceutical composition, the composition includes quinazoline derivant shown in formula (I)
Hydrochloride Form A, B, C, D, F, H, I, sulfate crystal form A, maleate crystal form A, succinate crystal form A, adipate crystal form
A, glycollate crystal form A, malate crystal form A, fumarate crystal form A, benzene sulfonate crystal form A, B, C, benzoate crystal form A,
Hippurate crystal form A and Crystal form of oxalate A or their combination and pharmaceutically acceptable auxiliary material or complementary ingredient.
Preferably, the auxiliary material or auxiliary sexual element include carrier, excipient, diluent, medium, adjuvant.
The present invention also provides the hydrochloride Form A, B, C, D, F, H, I of quinazoline derivant shown in a kind of formula (I), sulphur
Hydrochlorate crystal form A, maleate crystal form A, succinate crystal form A, adipate crystal form A, glycollate crystal form A, malate are brilliant
Type A, fumarate crystal form A, benzene sulfonate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A and Crystal form of oxalate A
Or above-mentioned pharmaceutical composition treats or prevents the drug by EGF-R ELISA EGFR protein mediated disease in preparation
In purposes.
Preferably, the drug is that treatment or prevention are protein mediated by EGF-R ELISA EGFR, and are
The drug of disease caused by EGFRVIII Activating mutations.
The drug be treat or prevent it is protein mediated by EGF-R ELISA EGFR, and be EGFR Del19 and/
Or the drug of disease caused by EGFR L858R Activating mutations.
It is furthermore preferred that the drug is that preparation treats or prevents brain transplantation of non small cell Lung transfer, meninx transfer, incidence squama
The drug of shape cell cancer, squamous cell carcinoma, brain stem tumor, primary brain cancer or glioma.
Those of ordinary skill in the art can according to its knowledge and experience, dosage and method to agents useful for same of the present invention into
Row adjustment, including raw material or solvent usage are proportionally zoomed in or out, the scheme of these adjustment is also contained in side of the invention
In method.
Compared with prior art, the invention has the following beneficial effects:
1) quinazoline derivant (I) and its pharmaceutical salts that novel chirality of the invention is R have having beyond expection
Across the ability of blood-brain barrier, and can be as the medicinal property of kinases inhibitor, in particular for passing through epidermal growth factor
The medical conditions that certain activated mutated forms of sub- receptor mediate are (for example, the missing activation of epidermal growth receptor EGFR exon 2-7
Mutant), for example, the glioma with EGFRVIII mutation, and can be used to treat or prevent abnormal protein kinase activity
Relevant disorder, such as cancer, cancer brain metastes, the transfer of cancer meninx and nerve center disease etc..
2) quinazoline derivant of the invention (I) and its pharmaceutical salts have low discharge rate, are not P- glycoprotein outlet enzyme bottoms
Object or breast carcinoma resistance outlet zymolyte can reduce the drug resistance generated by outlet enzyme.
3) quinazoline derivant of the invention and its pharmaceutical salts have good pharmacokinetics and high bioactivity, can drop
The tablet of low patient takes in burden, improves the tablet intake compliance of patient.
4) the hydrochloride Form A, B, C, D, F, H, I of quinazoline derivant of the present invention (I) provided by the invention, sulfate are brilliant
Type A, maleate crystal form A, succinate crystal form A, adipate crystal form A, glycollate crystal form A, malate crystal form A are rich
Horse hydrochlorate crystal form A, benzene sulfonate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A and Crystal form of oxalate A have good
Good stability and water solubility is conducive to process in drug and use in pharmaceutical composition, can treat prominent by EGFR activation
Become the cancer that (for example, EGFRVIII, EGFR del19 or EGFR L858R) is mediated, for example, brain transplantation of non small cell Lung shifts,
The application of meninx transfer, head and neck squamous cell carcinoma, squamous cell carcinoma, brain stem tumor, primary brain cancer or glioma etc., and
And there is preferable bioavilability, while providing the qualitative, quantitative information of efficacy and saferry, it is such solid to further studying
The curative effect of body drug has great importance.
Detailed description of the invention
Upon reading the detailed description of non-limiting embodiments with reference to the following drawings, other feature of the invention,
Objects and advantages will become more apparent upon:
Fig. 1 is the XRPD map of the hydrochloride Form A of quinazoline derivant of the invention;
Fig. 2 is the XRPD map of the hydrochloride Form B of quinazoline derivant of the invention;
Fig. 3 is the XRPD map of the hydrochloride Form H of quinazoline derivant of the invention;
Fig. 4 is the XRPD map of the hydrochloride Form I of quinazoline derivant of the invention;
Fig. 5 is the XRPD map of the fumarate crystal form A of quinazoline derivant of the invention;
Fig. 6 is the XRPD map of the succinate crystal form A of quinazoline derivant of the invention;
Fig. 7 is the XRPD map of the maleate crystal form A of quinazoline derivant of the invention;
Fig. 8 is the XRPD map of the glycollate crystal form A of quinazoline derivant of the invention;
Fig. 9 is the XRPD map of the hydrochloride Form F of quinazoline derivant of the invention;
Figure 10 is the XRPD map of the hydrochloride Form C of quinazoline derivant of the invention;
Figure 11 is the XRPD map of the hydrochloride Form D of quinazoline derivant of the invention;
Figure 12 is the XRPD map of the sulfate crystal form A of quinazoline derivant of the invention;
Figure 13 is the XRPD map of the oxalate crystal form A of quinazoline derivant of the invention;
Figure 14 is the XRPD map of the malate crystal form A of quinazoline derivant of the invention;
Figure 15 is the XRPD map of the benzene sulfonate crystal form A of quinazoline derivant of the invention;
Figure 16 is the XRPD map of the benzene sulfonate crystal form B of quinazoline derivant of the invention;
Figure 17 is the XRPD map of the benzene sulfonate crystal form C of quinazoline derivant of the invention;
Figure 18 is the XRPD map of the benzoate crystal form A of quinazoline derivant of the invention;
Figure 19 is the XRPD map of the hippurate crystal form A of quinazoline derivant of the invention;
Figure 20 is the XRPD map of the Crystal form of oxalate A of quinazoline derivant of the invention;
Figure 21 is the inhibition schematic diagram of quinazoline derivant of the invention to EGFRVIII phosphorylation;
Figure 22 is that quinazoline derivant of the invention is illustrated in the drug efficacy study of humanization glioma mouse subcutaneous model
Figure;
Figure 23 is TGA the and DSC map of quinazoline derivant fumarate of the invention;Wherein, a is TGA map, without bright
Aobvious weightlessness;B is DSC map, and crystal form is stable during heating, and crystal form does not change, and fusing point is 240 degrees Celsius;
Figure 24 is the inhibiting mechanism schematic diagram of quinazoline derivant and EGFR of the invention.
Specific embodiment
Term of the present invention is explained as follows:
Term " improvement " and " treatment " may be used interchangeably, and indicate to reduce, weaken, inhibit, reduce, prevent or stablize disease
The generation or progress (for example, disease described herein or disorder) of disease, refer to a kind of method for obtain include it is beneficial or
It is desired as a result, but being not limited to treatment benefit and/or preventative benefit.
" disease " refer to damage or interfere cell, organ or tissue normal function any illness or disorder.
" marker " refers to any change relevant to disease or disorder.For example, expression water relevant to disease or disorder
Flat or activity has any albumen or multicore acid anhydride acid of change.
Herein, " comprising ", " containing " and " having " and similar terms have the meaning that them are assigned in Patent Law;
"consisting essentially of ..." or " consisting essentially of " equally assign their meaning with Patent Law, and the term is open
Formula, allow the presence of the object other than cited object, as long as the basis for the object that is cited or new feature not because cited object with
The presence of outer object and change, but do not include the embodiment of the prior art.
As used herein term " antagonist " and " inhibitor " are used interchangeably, they refer to compound or reagent tool
There are the ability for the biological function for inhibiting targeting proteins or polypeptide, such as activity or expression by inhibiting protein or polypeptide.
Although some antagonists and specific target protein or polypeptide effect (for example, in conjunction with EGFR) herein, compound by with others
Other members of the signal transduction path of targeting protein or polypeptide interact and inhibit the bioactivity of target protein or polypeptide
Also clearly include in this definition, also include inhibiting and developing, growth, or the tumour of diffusion, or shown in autoimmune disease
Those of undesirable immune response correlation bioactivity.
As used herein term " anticancer agent ", " antitumor agent " or " chemotherapeutics " refers to be had in neoplastic conditions treatment
Any reagent.A kind of anticancer agent includes chemotherapeutics." chemotherapy " refer to one or more chemotherapeutics and/or other reagents with
By various methods, including it is intravenous, it takes orally, it is subcutaneously, intramuscular, in peritonaeum, in bladder, percutaneously, cheek, or the form sucked is to cancer
Disease patient application.
As used herein term " cell Proliferation ", which refers to, to be increased by cell number as fissional result
The phenomenon that, also include and the consistent cell growth (for example, size increase) changed by the cellular morphology of proliferation signal.
As used herein term " co-administration ", refers to and two or more drugs is used alone in the same time,
Be included in the same time using all existing composition of two or more reagents, be also included within the different time be administered alone or
Apply two or more drugs and/or its metabolin.
As used herein term " effective quantity " or " effective therapeutic dose " refer to compound as described herein or medicine group
The amount for closing object is to sufficiently achieve expected application, includes, but are not limited to treat disease.In some embodiments, the amount is
Detect effective for killing or inhibiting growth of cancer cells or diffusion;The size or quantity of tumour;Or the seriousness water of cancer
It is flat, stage and progress.Effective therapeutic dose can change according to scheduled application, such as external or internal, the situation of disease
And severity, subject age, weight or administration mode etc..The term is also applied for dosage for inducing target cell, for example,
Reduce a specific response of cell migration.Specific dosage will depend on, for example, choosing in specific compound, subject
The risk of species and their age/existing health status or health status, administration route, the severity of disease, with it
His medicament combination medicine-feeding, administration time, tissue and drug delivery device for being applied to it etc..
As used herein term " therapeutic effect ", including treatment benefit and/or prevention benefit.Preventive effect includes prolonging
Late or eliminate the appearance of disease or illness, delay or the paresthesia epilepsy for eliminating disease or illness, slow down, stop or reverse disease or
The progress of illness or their any combination.
As used herein term " signal transduction " be during this period, stimulation or inhibit signal be sent into the cell with
Cause the process responded into the cell, " regulator " of signal transduction pathway refers to that compound adjusts one or more cell proteins
Activity pass through signal specific transduction pathway." regulator " can increase (agonist) or inhibit (antagonist) signal transduction molecule
Activity.
As used herein term " selective depression " reduces echo signal conduction with referring to the compound property of can choose
Active ability is compared for signal activity of missing the target, and direct interaction or Indirect Interaction etc. are passed through.For example, a chemical combination
The activity of the EGFR of object selective depression mutation is to be directed at least about 2 times of the activity of Wild type EGFR, about 3 times, about 5 times, and about 10
Times, about 20 times, about 50 times, about 100 times or more.
As used herein term " radiotherapy " refers to that subject is exposed to radiation transmitter, such as, but not limited to,
Alpha particle emits radioactive nucleus element (for example, actinium and thorium radioactive nucleus element), low linear energy transfer (LET) radiation transmitter
(that is, beta emitter), converted electronic emission device (for example, strontium -89 and samarium 153-EDTMP) or high-energy radiation, include, but are not limited to
X-ray, gamma-rays and neutron.
Term " subject " as used herein includes, but are not limited to the mankind (that is, any age group, for example, a size
The sex (for example, baby, children, teenager) of section subject or Adult human subjects are (for example, Young adult, the middle year's harvest
People or advanced adult)) and/or other primates (for example, machin, rhesus macaque);Mammal, including the related food in one's mouth of business
Newborn animal, such as ox, sheep, goat, pig, horse, cat and/or dog;And/or birds, including the relevant birds of business, such as chicken, goose,
Quail, duck and/or turkey.
Term " internal " as used herein refers to the intracorporal activity of body occurred in subject.It is also included within and nibbles in vivo
The event occurred in tooth class animal, such as rat, mouse, cavy and analog.
Term " external " as used herein refers to the event that the place other than body occurs at one.For example, external
Testing inspection includes any detection for occurring to carry out except body.External test includes the cell based on alive or dead cell
Measurement, is also included within without cell-less measurement method used in complete cell.
As used herein term " compound ", is also intended to the salt, prodrug and prodrug of the general formula compound including this paper
Salt.The term further includes any one of aforementioned any solvate, hydrate and polymorph.This hair described in this application
In bright some aspects, the specific of " prodrug ", " prodrug salt ", " solvate ", " hydrate " or " polymorph " is quoted not
Should be interpreted using term " compound " without quote these other forms other aspects of the present invention in, it is intended that
Exclude these forms.
The salt of the compound of the present invention is in the sour basic group with compound, such as is formed between amido functional group.According to
Another preferred embodiment, the compound are pharmaceutically acceptable acid-addition salts.
The salt of the compound of the present invention such as is formed in the acidic-group of alkali and compound between carboxyl functional group.According to
Another preferred embodiment, the compound are pharmaceutically acceptable base addition salts.
As used herein and unless otherwise specified, term " prodrug " refers to the derivative of compound, can be in biology
It hydrolyzed under condition (in vitro or in vivo), aoxidize or otherwise react to provide the compound of the present invention.Prodrug can be only
Become active after such reaction under biological condition, or can be active under its unreacted form.Of the invention
The example of prodrug includes, but are not limited to the analog or derivative of the compound of any one general formula disclosed herein, also includes
The hydrolyzable part of biology, such as amide and ester analogs.
Prodrug salt is the basic group of acid with prodrug, such as the acidic-group of amido functional group or alkali and prodrug, such as carboxylic
The compound formed between base functional group.In one embodiment, prodrug salt is pharmaceutically acceptable salt.
Particularly preferred prodrug and prodrug salt are when such compound is for increasing change of the invention when mammal or people
It closes the bioavilability (for example, by making the compound of oral administration be easier to be absorbed) of object or promotes relative to parent species
Compound is delivered to those of biological compartment (for example, brain or central nervous system).Preferred prodrug includes that will wherein increase water
Dissolubility increases derivative of the group addition for passing through the active transport of goldbeater's skin on general formula structure as described herein.Referring to example
Such as, Design of Prodrugs, edited by H.Bundgaard, (Elsevier, 1985) and Methods in
Enzymology,Vol.42,p.309-396,edited by K.Widder,et al.(Academic Press,1985);A
Textbook of Drug Design and Development,edited by Krogsgaard-Larsen and
H.Bundgaard, Chapter 5 " Design and Application of Prodrugs ", by H.Bundgaard
p.113-191(1991);H.Bundgaard,Advanced Drug Delivery Reviews,8,1-38(1992);
H.Bundgaard,et al.,Journal of Pharmaceutical Sciences,77,285(1988);and
N.Kakeya, et al., Chem Pharm Bull, 32,692 (1984) are described.
Term " pharmaceutically acceptable " as used herein refers within the scope of reasonable medicine, is suitable for and people and other
The tissue of mammal contacts without excessive toxicity, irritates, allergic reaction etc., and has the group of reasonable interests/Hazard ratio
Point." pharmaceutically acceptable salt " refers to any avirulent salt, after being applied to receptor, can directly or indirectly provide this
The compound of invention or the prodrug of compound.
The acid for being commonly used to form pharmaceutically acceptable salt includes inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, hydroiodic acid
And phosphoric acid and organic acid, such as trifluoroacetic acid, citric acid, maleic acid, oxalic acid, picric acid, acetic acid, adipic acid, alginic acid, day
Aspartic acid, sulfuric acid, boric acid, butyric acid, valeric acid, camphoric acid, thiocyanic acid camphorsulfonic acid, didextrose acid, dodecyl sulphate, new penta
Acid, formic acid, enanthic acid, fumaric acid, hydroiodic acid, benzoic acid, 2- hydroxy-ethanesulfonic acid, fumaric acid, stearic acid lactobionic acid, propionic acid laurel
Acid, oleic acid nitric acid niacin, lactic acid cinnamic acid, succinic acid, mandelic acid, malic acid, tartaric acid, two tartaric acid, lactic acid, pyruvic acid,
Pectic acid, methanesulfonic acid flutter acid, benzene sulfonic acid, persulfuric acid, palmitinic acid, malonic acid phosphoglycerol, 2- naphthalene sulfonic acids, p-methyl benzenesulfonic acid, water
Poplar acid, ascorbic acid, 3- phenylpropionic acid, gluconic acid, glucuronic acid, phosphoric acid, glutamic acid, ethanesulfonic acid, to bromo-benzene sulfonic acid and
Carbonic acid and relevant inorganic and organic acid.The alkali for being commonly used to form pharmaceutically acceptable salt includes alkali metal, alkaline earth gold
Belong to, ammonium salt, N+(C1-4 alkyl)4Salt and relevant inorganic and organic base.Representative alkali and alkaline earth metal ions such as sodium,
The salt that lithium, potassium, calcium, magnesium, iron, copper, manganese, zinc, aluminium etc. and organic base are formed, including, for example, primary, secondary and tertiary aminess replace amine,
Including naturally occurring substitution amine, cyclammonium, deacidite and analog, such as isopropylamine, trimethylamine, diethylamine, three
Ethamine, tripropyl amine (TPA) and ethanol amine.In some embodiments, pharmaceutically acceptable base addition salts can be from ammonium, potassium, sodium, calcium
It is selected with magnesium salts.See, e.g. Berge et al.J.Pharmaceutical Sciences (1977) 66:1-19.
As used herein term " hydrate " refers to including stoichiometry or non-stoichiometric passes through non-covalent bond
The compound for the water that intermolecular force combines.As used herein term " solvate " refers to including stoichiometry or non-
The compound for the solvent of stoichiometry combined by active force between Non-covalent molecular, the solvent such as water, methylene chloride, 2-
Propyl alcohol, acetone, methanol, ethyl alcohol or the like.Pharmaceutically acceptable solvate and hydrate are compounds, for example, can be with
Including 1 to about 100 or 1 to about 10 or 1 to about 4, about 3 or about 2, solvent or hydrone.It should be understood that as used herein
Term " compound " include the compound and compound solvate, hydrate and their mixture.
As used herein term " polymorph " refers to compound or the solid crystallization way of its compound.Mutually assimilate
The different polymorphs for closing object can show different physics, chemistry and/or spectral property.Different physical properties include, but
It is not limited to stability (for example, to heat, light or moisture), density, hygroscopicity, soluble, compressibility and rate of dissolution.
Term " isomers " as used herein is the different compounds with identical molecular formula." stereoisomer " is only
In the different isomers of the space arrangement mode of atom." isomers " word includes any and all several as used herein
What isomers and stereoisomer.For example, " isomers " includes the cis and trans isomer of geometry double bond, also referred to as E- and Z-
Isomers;R- and S- enantiomer;Diastereomer, (D) isomers and (L) isomers, racemic mixture and they its
Its mixture, it is disclosed herein.
Be designated as around carbon-to-carbon substituent group double bond in " Z " or " E " configuration, wherein term " Z " and " E " according to IUPAC
Standard uses.Unless otherwise specified, structure delineation double bond both included " E " and " Z " isomers.
Interchangeable substituent group around carbon-to-carbon double bond can be referred to as " cis- " or " trans- ", take wherein " cis- " refers to
For Dai Ji in the same side of double bond, " trans- " represents substituent group in the two sides of double bond.The arrangement of surrounding's carbocyclic ring of substituent group can also be with
It is designated as " cis- " or " trans- "." cis- " the same side substituent group indicated in plane of a loop of term, " trans- " the expression ring of term
The two sides substituent group of plane.Wherein the mixture of compound of the substituent group in the identical and opposite side of the plane of two rings indicates
For " cis/trans ".
It is each other the stereoisomer of non-superimposable mirror image that term " enantiomer " as used herein, which is a pair of,.A pair with
The mixture of the enantiomer of any ratio is referred to alternatively as " racemic " mixture.Term " (±) " is used in appropriate specified racemic
Mixture." diastereo-isomerism " refers to at least two asymmetric atoms, but its stereoisomer is mutual mirror image
Picture.Absolute stereochemistry is specified according to Cahn-lngold-Prelog R-S system.When compound is enantiomer, in each chiral carbon
Spatial chemistry can be by being appointed as R or S.The compound of fractionation, absolute configuration are unknown, it is possible to specify (+) or
(-), this depends on them in the direction (dextrorotation or left-handed) of the wavelength Plane of rotation polarised light of sodium D-line.
Refer to the compound in compound or (S)-that each asymmetric atom is (R)-, pharmaceutical composition for absolute stereo
Object and method include all these possible isomers, including racemic mixture, optical voidness form and intermediate mixture.Light
It learns active (R)-and (S)-Chiral Synthesis also can be used or prepared by chiral reagent, or torn open using routine techniques
Point.
The composition of term " enantiomeric excess " or " % enantiomeric excess " is usable as follows as used herein
Formula calculate.In example shown in below, composition contains a kind of 90% enantiomer, for example, S enantiomer, and
Containing 10% another enantiomer, for example, R enantiomer.
Ee value=(90-10)/100=80%.
Therefore, the composition for being 10% containing a kind of 90% enantiomer and another enantiomer is said to be with enantiomer mistake
Amount 80%.Some compositions as described herein contain at least about 50% enantiomeric excess, about 75%, about 90%, about 95%, or
About the 99% of S enantiomer.In other words, the composition includes the S enantiomer of enantiomeric excess in R enantiomer.In other implementations
In scheme, some compositions as described herein contain at least about 50% enantiomeric excess, about 75%, about 90%, about 95%, or
About the 99% of R enantiomer.In other words, the composition includes the R enantiomer of enantiomeric excess in S enantiomer.For example, one different
Structure body/enantiomter can be in some embodiments, it is possible to provide the ee value of corresponding enantiomter, and can also be by
Referred to as " optically enriched ", " enantiomer enrichment ", " enantiomer-pure " and " non-raceme ", as interchangeably used herein.These
Term refers to that the weight percent of one of enantiomer is control of the composition than the racemic composition in a kind of enantiomer
The amount of mixture is bigger (for example, the weight ratio for being greater than 1:1).For example, the enantiomer of S enantiomer is enriched with the S enantiomer of (weight)
Relative to R enantiomer, the method for such as by weight at least about 75% compound with greater than about 50%, also as at least
About 80% (weight).In some embodiments, enrichment is greater than by weight about 80%, provides " substantially enantiomer enrichment
", the preparation of " substantially enantiomer-pure " or " substantially non-racemic ", this refers to that the enantiomer of its weight is right relative to other
The composition that one of isomers has at least 85%, such as by weight at least about 90% preparation are reflected, and further, such as
By weight at least about 95%.In certain embodiments, compound provided herein can be by a kind of mapping of at least weight
About the 90% of isomers.In other embodiments, the compound can by least about 95%, about 98% or weight one
About the 99% of kind enantiomter.In some embodiments, the compound is (S)-and (R)-racemic mixture.At it
In his embodiment, there is provided herein a kind of methods, and wherein the single compound (S)-of mixture is mainly existing compound
Mixture or (R)-mixture of compound for being primarily present.For example, (S)-enantiomer that the compound mixture has
Excessive greater than about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about
96%, about 97%, about 98%, about 99%, about 99.5%, or more.In other embodiments, the mixture of compound has
(S)-enantiomeric excess be greater than about 55% to about 99.5%, greater than about 60% to about 99.5%, greater than about 65% to about
99.5%, greater than about 70% to about 99.5%, greater than about 75% to about 99.5%, greater than about 80% to about 99.5%, greater than about
85% to about 99.5%, greater than about 90% to about 99.5%, greater than about 95% to about 99.5%, greater than about 96% to about
99.5%, greater than about 97% to about 99.5%, greater than about 98% to greater than about 99.5%, greater than about 99% to about 99.5%, or
It is higher.In other embodiments, compound mixture (R)-enantiomeric purity has greater than about 55%, about 60%, about 65%,
About 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about
99.5% or more.In some other embodiment, there is the mixture of compound (R)-enantiomeric excess to be greater than about 55%
To about 99.5%, greater than about 60% to about 99.5%, greater than about 65% to about 99.5%, greater than about 70% to about 99.5%, greatly
In about 75% to about 99.5%, greater than about 80% to about 99.5%, greater than about 85% to about 99.5%, greater than about 90%
To about 99.5%, it is greater than 95% to about 99.5%, greater than about 96% to about 99.5%, greater than about 97% to about 99.5%, is greater than
About 98% to greater than about 99.5%, greater than about 99% to about 99.5% or more.
In other embodiments, which includes, in addition to their stereochemical orientation, i.e., (S)-or
(R)-identical chemical entities.For example, if disclosing in compound here has-CH (R)-unit, and R is not hydrogen, that
- CH (R)-is the orientation in the identical chemical entities of each of (S)-or (R)-spatial chemistry.In some embodiments, exist
(S)-isomers in the mixture of identical chemical entities is present in (S)-enantiomeric excess and is greater than about 55% to about
99.5%, greater than about 60% to about 99.5%, greater than about 65% to about 99.5%, greater than about 70% to about 99.5%, greater than about
75% to about 99.5%, greater than about 80% to about 99.5%, greater than about 85% to about 99.5%, greater than about 90% to about
99.5%, greater than about 95% to about 99.5%, greater than about 96% to about 99.5%, greater than about 97% to about 99.5%, greater than about
98% to greater than about 99.5%, greater than about 99% to about 99.5% or more.
In another embodiment, (R)-isomers is in the mixture of identical chemical entities (in addition to its spatial chemistry takes
To) relative to (S)-isomers, it is about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about
90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5% or higher.In some embodiments, (R)-
In mixture (in addition to its stereochemical orientation) isomers of identical chemical entities, it is present in (R)-enantiomeric excess and is greater than about
55% to about 99.5%, greater than about 60% to about 99.5%, it is greater than 65% to about 99.5%, greater than about 70% to about
99.5%, greater than about 75% to about 99.5%, greater than about 80% to about 99.5%, greater than about 85% to about 99.5%, greater than about
90% to about 99.5%, greater than about 95% to about 99.5%, greater than about 96% to about 99.5%, greater than about 97% to about
99.5%, greater than about 98% to greater than about 99.5%, greater than about 99% to about 99.5%, or more.
Enantiomter can pass through any method of known those skilled in the art, including chirality from racemic mixture
High performance liquid chromatography (HPLC), the formation and crystallization of chiral salt or asymmetric synthesis are separated.See, e.g.,
Enantiomers,Racemates and Resolutions(Jacques,Ed.,Wiley lnterscience,New
York,1981);Wilen et al.,Tetrahedron 33:2725(1977);Stereochemistry of Carbon
Compounds(E.L.Eliel,Ed.,McGraw-Hill,NY,1962);and Tables of Resolving Agents
And Optical Resolutions p.268 (E.L.EIM, Et al., Univ.of Notre Dame Press, Notre
Dame,Ind.1972).
Optical isomer can also be obtained with optically active acid or alkali according to a conventional method by resolving racemic mixtures, example
Such as, by forming diastereomeric salt.The example of suitable acid includes, but are not limited to tartaric acid, diacetyl, dibenzoyl,
Ditoluoyltartaric and camphorsulfonic acid.Diastereomer crystallization then obtains from the mixture of optically active alkali of these salt different
The separation of structure body.Another method passes through the optically pure acid or optically pure isocyanic acid of disclosed compound and activated form
Ester reaction is related to the synthesis of covalent diastereo-isomerism molecule.Synthesizing enantiomter can steam by conventional method such as chromatography
It evaporates, crystallizes or distil, then hydrolyze to provide enantiomer enriched compound and be separated.Optically active compound can also pass through
It is obtained using activated feedstock.In some embodiments, these isomers can be with free acid, free alkali, the shape of ester or salt
Formula.
In certain embodiments, pharmaceutically acceptable form is a tautomer.Terms used herein " interconversion
Isomers " is a type of isomers comprising two or more compounds mutually converted are from hydrogen atom and covalently
The migration of at least one form of key and change gained (for example, singly-bound is to double bond, three keys to singly-bound, or vice versa)." interconversion
Isomery " includes proton or proton transfer tautomerism, is considered the subset of Acid-Base chemistry." proton transfer tautomerism " or
" proton translocation tautomerism " is related to the proton transfer changed with bond order.The definite ratio of tautomer depend on it is several because
Element, including temperature, solvent and pH value.Wherein, tautomerism is possible (for example, in the solution), the chemistry of tautomer
Balance is i.e. reachable.Tautomerization (that is, providing the reaction of tautomer pair) can be by sour or base catalysis or no external
The effect or presence of agent can occur.Such as tautomerization includes, but are not limited to ketone to enol;Amide is to acid imide;Interior acyl
Amine is to lactim;Enamine is to imines;With a form of enamine to different enamines.Ketone to enol tautomeric specific reality
Example is pentane -2,4- diketone and the amyl- 3- alkene -2- keto tautomer of 4- hydroxyl.Tautomeric another example is that phenol and ketone are mutual
Make a variation structure.Phenol and the tautomeric specific example of ketone are pyridine 4- phenol and pyridine -4 (1H) -one tautomer.
Unless otherwise indicated, also mean that structure as described herein includes compound, only in one or more isotope enrichments
The presence of atom.For example, compound has this structure for replacing a hydrogen by deuterium or tritium, or in the range of replacement the displosure
What carbon 13 or carbon 14 were enriched with.
The disclosure also includes those " derivatives of isotope labelling ", is those identical compounds enumerated herein
Pharmaceutically acceptable form, the difference is that one or more atoms are had originals different from what is be generally found in nature
The atom of protonatomic mass or mass number is replaced.The example for the isotope that can be incorporated into disclosed compound includes hydrogen, carbon, nitrogen,
The isotope of oxygen, phosphorus, fluorine and chlorine, such as2H,3H,13C,14C,15N,18O,17O,18F, and36Cl.Certain isotope labellings it is disclosed
Compound is (for example, those are indicated3H and14C measurement compound and/or substrate tissue distribution) be can be used for.Tritium is (i.e.3) and carbon H
14 (i.e.14C) isotope can be readily made and detect.In addition, with heavier isotope such as deuterium (that is,2H or D) replace can provide
The certain treatment advantages (for example, increasing half-life period in vivo or reduced dose requirements) generated by larger metabolic stability.
The disclosed compound of isotope labelling can usually pass through the examination to a kind of isotope-labeled reagent substitution isotope labelling
It is prepared by agent.In some embodiments, it provided herein is can also contain one or more non-natural atom isotope groups
At this compound.All isotopic variations of compound as disclosed are used herein, regardless of whether being radioactivity, all
In range disclosed herein.In some embodiments, radiolabeled compound can be used for studying metabolism and
Compound Tissue distribution is to change metabolic pathway or rate or other biological functions.
Term " CDCl3" refer to deuterated chloroform.
Term " DMSO-d6 " refers to deuterated dimethyl sulfoxide
Term " LC-MS:(ESI) " refer to electrospray ionisation liquid chromatography mass
Albumen " change " is defined as used herein, the term, changes relative to normal physiological condition.Show
The change of example property includes mutation, missing and other protein fusions, overexpression or low expression.
The compound of the present invention:
On the one hand, the present invention provides the compound of formula (I):
Or its salt;Or the salt of its prodrug or its prodrug;Or its hydrate, solvate or polymorph.
The synthesis of the chiral novel quinazoline quinoline derivant (I) for being R of the present invention can be easily by commonly synthesizing chemistry
Technical staff realizes.For example, correlation technique disclosed herein and intermediate.Each patent being mentioned above, patent Shen
Please and publication be integrally incorporated herein by reference regardless of it can be obtained in traditional magazine or only by internet.
The other modes for synthesizing compound described herein (I) can easily be changed from references cited herein
It is dynamic.The version of these programs and its optimization are in the limit of power of those of ordinary skill.
The present invention also provides compositions comprising a effective amount of compound as described herein, or if applicable, the chemical combination
Pharmaceutically acceptable salt, solvate, hydrate, polymorph or the prodrug of object;And acceptable carrier.Preferably, originally
The composition of invention prepares (" pharmaceutical composition ") for pharmaceutical usage, wherein the carrier is pharmaceutically acceptable carrier.It examines
Consider compatible with preparation other compositions, and in the case where pharmaceutically acceptable carrier, the carrier must be " acceptable
", do not damage its recipient under the amount being typically used in drug.
" pharmaceutically acceptable carrier " or " pharmaceutically acceptable excipient " includes any and all solvents, and dispersion is situated between
Matter, coating, antibacterial agent and antifungal agent, wait and blend absorption delaying agent and the like.Pharmaceutically acceptable carrier or figuration
Agent does not destroy the pharmacological activity of disclosed compound, is nontoxic when being applied with the dosage for being enough the therapeutic dose of the compound delivered
's.It is well known in the art for pharmaceutically active substances using such medium and reagent.Unless any conventional media
Or reagent is incompatible with active constituent, it is expected in the use of therapeutic combination as disclosed herein.It is pharmaceutically acceptable
Carrier example and excipient include but is not limited to: sugar, for example, lactose, sucrose and glucose;Starch, for example, potato is formed sediment
Powder and cornstarch;Cellulose and its derivates, such as sodium carboxymethylcellulose, cellulose acetate and ethyl cellulose;Gelatin;
Tragacanth gum powder;Talcum;Malt;Cocoa butter and suppository wax;Oil, for example, peanut oil, safflower oil, cottonseed oil, olive oil, sesame
Oil, corn oil and soybean oil;Glycol, such as polyethylene glycol and propylene glycol;Ester, for example, ethyl oleate and ethyl laurate;Fine jade
Rouge;Buffer, for example, magnesium hydroxide and aluminium hydroxide;Alginic acid;Ringer's solution;Isotonic saline solution;Ethyl alcohol;Phosphate buffer;
The lubricant of non-toxic compatible, for example, NaLS and magnesium stearate;Colorant;Coating agent;Releasing agent;Sweetener, seasoning
Agent and aromatic;Antioxidant;Preservative;Ion exchange;Aluminium oxide;Lecithin;Aluminum stearate;Self-emulsifying drug delivery systems
(SEDDS) such as TPGS 1000;For the surfactant of pharmaceutical dosage form, for example, Tweens or its
Its similar polymeric delivery matrices;Haemocyanin, for example, human serum albumins;Glycine;Sorbic acid;Potassium sorbate;It is full
With the partial glyceride mixture of vegetable fatty acid;Water, salt or electrolyte, for example, protamine sulfate, potassium hydrogen phosphate, phosphoric acid hydrogen
Disodium, sodium chloride and zinc salt;Colloidal silicon dioxide;Magnesium trisilicate;Polyvinylpyrrolidone;Substance based on cellulose;Poly- third
Olefin(e) acid ester;Wax;With polyethylene-polyoxypropylene-block polymer.Cyclodextrin, for example, alpha, beta and gamma- cyclodextrin,
Or the derivative of chemical modification, for example, hydroxyalkylcyclodextrins, including 2- and 3- hydroxy propyl cyclodextrin or other for improving
The derivative of the solubilising of the delivering of compound as described herein.
Pharmaceutical composition of the invention can be in solid or liquid form for being administered, comprising: oral administration, for example,
It gavages agent (aqueous or non-aqueous solution or suspension), tablet (for example, those are directed to oral cavity, sublingual and systemic Absorption), firmly
Or soft capsule, pill, syrup, powder, granule, paste are applied to tongue, intraduodenal route;Parenteral administration, including vein
Interior, intra-arterial is subcutaneously, intramuscular, and intraocularly, lung is intravascular, in peritonaeum or is infused, for example, sterile solution or suspension, or continue
Delivery formulations;Local use, such as emulsifiable paste, ointment, gelling agent, aqueous or oily solution or suspension, or it is suitable for skin
The control-released plaster of skin is spraying;In intravaginal or rectum, such as vaginal suppository, emulsifiable paste, bracket or foam;Sublingual administration;
It is locally transmitted by conduit or bracket;Intrathecal or nose is used by being blown into use (such as attritive powder) or pass through sucking
(such as attritive powder or Liquid Aerosol).
Suitable aqueous and non-aqueous carrier example includes water in pharmaceutical composition, ethyl alcohol, polyalcohol (such as glycerol,
Propylene glycol, polyethylene glycol, etc.) and its suitable mixture, the organic ester of vegetable oil, such as olive oil and injectable, such as oil
Acetoacetic ester.By using coating material, for example, lecithin, by the dispersion of the granular size needed for maintaining, and by using
Surfactant keeps mobility appropriate.These compositions can also contain adjuvant, such as preservative, wetting agent, and emulsifier divides
Powder, lubricant and/or antioxidant.The effect of the pre- preventing microorganism of compound as described herein can be by the inclusion of different
Antibacterial agent and antifungal agent ensure, for example, p-hydroxybenzoate, methaform, phenol sorbic acid and analog.It can also be with
Being includes isotonic agent, such as sugar, in the composition of sodium chloride etc..In addition, absorb can be by the inclusion of for the extension of injectable drug form
Delayed absorber, such as aluminum monostearate and gelatin.
The method for preparing these preparations or composition include compound as described herein and/or with chemotherapy carrier and appoint
The step of association of one or more auxiliary elements of choosing.In general, preparation be by equably with chemical combination disclosed herein
Object and liquid-carrier or subdivided solids carrier or both closely combine, then if it is necessary, making product shaping.Preparation is in this way
Pharmaceutical composition be well known in the art.See, e.g., Anderson, Philip O.;Knoben,James E.;
Troutman,William G,eds.,Handbook of Clinical Drug Data,Tenth Edition,McGraw-
Hill,2002;Pratt and Taylor,eds.,Principles of Drug Action,Third Edition,
Churchill Livingston,New York,1990;Katzung,ed.,Basic and Clinical
Pharmacology,Ninth Edition,McGraw Hill,2003;Goodman and Gilman,eds.,The
Pharmacological Basis of Therapeutics,Tenth Edition,McGraw Hill,2001;The g's of Rem
N's Pharmaceutical Sciences, 20th Edition, Lippincott Williams&Wilkins., 2000;
Martindale,TheExtra Pharmacopoeia,Thirty-Second Edition(ThePharmaceutical
Press,London,1999);These bibliography are integrally incorporated herein by reference.Unless any conventional excipients are situated between
Matter is incompatible with compound provided herein, such as passes through any other component phase interaction with pharmaceutically acceptable composition
With generating any undesirable biological effect or with harmful effect, the use of excipient be also covered by the scope of the present disclosure it
It is interior.
In some embodiments, the concentration that pharmaceutical composition provides compound disclosed in one or more can be small
In about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 19%, about
18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about
7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, about
0.1%, about 0.09%, about 0.08%, about 0.07%, about 0.06%, about 0.05%, about 0.04%, about 0.03%, about
0.02%, about 0.01%, about 0.009%, about 0.008%, about 0.007%, about 0.006%, about 0.005%, about 0.004%,
About 0.003%, about 0.002%, about 0.001%, about 0.0009%, about 0.0008%, about 0.0007%, about 0.0006%, about
0.0005%, about 0.0004%0.0003%0.0002% or about 0.0001% weight/weight ratio, weight/volume or body
Product/volume ratio.
In some embodiments, the concentration of one or more compounds as disclosed herein can be greater than about 90% with
On, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 19.75%, about 19.50%, about
19.25% about 19%, about 18.75%, about 18.50%, about 18.25%, about 18%, about 17.75%, about 17.50%, about
17.25%, about 17%, about 16.75%, about 16.50%, about 16.25%, about 16%, about 15.75%, about 15.50%, about
15.25%, about 15%, about 14.75%, about 14.50%, about 14.25%, about 14%, about 13.75%, about 13.50%, about
13.25%, about 13%, about 12.75%, about 12.50%, about 12.25%, about 12%, about 11.75%, about 11.50%, about
11.25%, about 11%, about 10.75%, about 10.50%, about 10.25%, about 10%, about 9.75%, about 9.50%, about
9.25%, about 9%, about 8.75%, about 8.50%, about 8.25%, about 8%, about 7.75%, about 7.50%, about 7.25%, about
7%, about 6.75%, about 6.50%, about 6.25%, about 6%, about 5.75%, about 5.50%, about 5.25%, about 5%, about
4.75%, about 4.50%, about 4.25%, about 4%, about 3.75%, about 3.50%, about 3.25%, about 3%, about 2.75%, about
2.50%, about 2.25%, about 2%, about 1.75%, about 1.50%, about 1.25%, about 1%, about 0.5%, about 0.4%, about
0.3%, about 0.2%, about 0.1%, about 0.09%, about 0.08%, about 0.07%, about 0.06%, about 0.05%, about 0.04%,
About 0.03%, about 0.02%, about 0.01%, about 0.009%, about 0.008%, about 0.007%, about 0.006%, about 0.005%,
About 0.004%, about 0.003%, about 0.002%, about 0.001%, about 0.0009%, about 0.0008%, about 0.0007%, about
0.0006%, about 0.0005%, about 0.0004%, about 0.0003%, about 0.0002%, or about 0.0001% weight/weight ratio,
Weight/volume or volume/volume ratio.In some embodiments, the concentration of one or more compounds disclosed herein,
Can range from about 0.0001% to about 50%, about 0.001% to about 40%, about 0.01% to about 30%, about 0.02% to
About 29%, about 0.03% to about 28%, about 0.04% to about 27%, about 0.05% to about 26%, about 0.06% to about 25%, about
0.07% to about 24%, about 0.08% to about 23%, about 0.09% to about 22%, about 0.1% to about 21%, about 0.2% to about
20%, about 0.3% to about 19%, about 0.4% to about 18%, about 0.5% to about 17%, about 0.6% to about 16%, about 0.7%
To about 15%, about 0.8% to about 14%, about 0.9% to about 12%, about 1% to about 10% weight/weight ratio, weight/volume
Or volume/volume ratio.In some embodiments, the concentration of one or more compounds can be in range as disclosed herein
From about 0.001% to about 10%, about 0.01% to about 5%, about 0.02% to about 4.5%, about 0.03% to about 4%, about
0.04% to about 3.5%, about 0.05% to about 3%, about 0.06% to about 2.5%, about 0.07% to about 2%, about 0.08% to
About 1.5%, about 0.09% to about 1%, about 0.1% to about 0.9% weight/weight ratio, weight/volume or volume/volume ratio.
In some embodiments, the amount of one or more compounds as disclosed herein, which can be, is equal to or less than
About 10g, about 9.5 grams, about 9.0 grams, about 8.5 grams, about 8.0 grams, about 7.5 grams, about 7.0 grams, about 6.5 grams, about 6.0 grams, about 5.5
Gram, 5.0 grams, about 4.5 grams, about 4.0 grams, 3.5 grams, about 3.0 grams, about 2.5 grams, about 2.0 grams, about 1.5 grams, about 1.0 grams, about 0.95
Gram, about 0.9 gram, about 0.85 gram, about 0.8 gram, about 0.75 gram, about 0.7 gram, about 0.65 gram, about 0.6 gram, about 0.55 gram, about
0.5g, about 0.45 gram, about 0.4 gram, about 0.35 gram, about 0.3 gram, about 0.25 gram, about 0.2 gram, about 0.15 gram, about 0.1 gram, about
0.09 gram, about 0.08 gram, about 0.07 gram, about 0.06 gram, about 0.05g, about 0.04 gram, about 0.03 gram, about 0.02 gram, about 0.01
Gram, 0.009 gram, about 0.008 gram, about 0.007 gram, about 0.006 gram, about 0.005 gram, about 0.004 gram, about 0.003 gram, about
0.002g, about 0.001 gram, about 0.0009 gram, 0.0008g, about 0.0007 gram, about 0.0006 gram, about 0.0005 gram, about
0.0004 gram, 0.0003 gram, 0.0002 gram, or about 0.0001 gram.In some embodiments, disclosed herein a kind of or more
The amount of kind compound can be more than about 0.0001 gram, about 0.0002 gram, 0.0003 gram, about 0.0004 gram, about 0.0005g, about
0.0006 gram, about 0.0007 gram, about 0.0008g, about 0.0009 gram, about 0.001 gram, 0.0015 gram, about 0.002 gram, 0.0025
Gram, about 0.003 gram, about 0.0035 gram.About 0.004 gram, about 0.0045 gram, about 0.005 gram, about 0.0055 gram, about 0.006 gram,
About 0.0065 gram, about 0.007 gram, about 0.0075 gram, about 0.008 gram, about 0.0085 gram, 0.009g, about 0.0095 gram, about 0.01
Gram, about 0.015 gram, about 0.02 gram, about 0.025 gram, about 0.03 gram, about 0.035 gram, about 0.04 gram, about 0.045 gram, about 0.05
Gram, about 0.055 gram, about 0.06 gram, about 0.065 gram, about 0.07 gram, about 0.075 gram, about 0.08 gram, about 0.085 gram, about 0.09
Gram, about 0.095 gram, about 0.1g, about 0.15 gram, about 0.2 gram, about 0.25 gram, about 0.3 gram, about 0.35 gram, about 0.4 gram, about 0.45
Gram, about 0.5g, about 0.55 gram, about 0.6 gram, about 0.6 gram, about 0.7 gram, about 0.75 gram, about 0.8 gram, about 0.85 gram, about 0.9 gram,
About 0.95 gram, about 1 gram, about 1.5 grams, about 2 grams, about 2.5, about 3 grams, about 3.5, about 4 grams, about 4.5 grams, about 5 grams, about 5.5 grams, about
6 grams, about 6.5 grams, about 7 grams, about 7.5 grams, about 8 grams, about 8.5 grams, about 9 grams, about 9.5 grams, or about 10g.
In some embodiments, the range of the amount of one or more compounds disclosed herein can be at about 0.0001 gram
To about 10 grams, about 0.0005 gram to about 9 grams, about 0.001 gram to about 0.5 gram, about 0.001 gram to about 2 grams, about 0.001 gram to about 8
Gram, about 0.005 gram to about 2 grams, about 0.005 gram to about 7 grams, about 0.01 gram to about 6 grams, about 0.05 gram to about 5 grams, about 0.1 gram
To about 4 grams, about 0.5 gram to about 4 grams, or about 1 gram to about 3 grams.
In certain preferred aspects, containing compound as disclosed herein be administered orally, and suitable for take orally to
The pharmaceutical composition of the drug excipient of medicine.In some embodiments, provided herein is the pharmaceutical compositions of oral administration: (1)
Optional a effective amount of disclosed compound;(2) a effective amount of one or more second reagents;(3) it is suitable for oral administration
One or more pharmaceutical excipients.In some embodiments, pharmaceutical composition further includes: (4) a effective amount of third examination
Agent.
In some embodiments, pharmaceutical composition can be suitable for oral composition of liquid medicine.Suitable for oral
The pharmaceutical composition of administration can be used as discrete dosage form, such as the glue of the predetermined amounts of active ingredients each containing powder or particle
Capsule, cachet or tablet or liquid, solution aerosol spray or suspension are in aqueous or non-aqueous liquid, and oil is in water
Lotion or water liquid emulsion in the oil.Such dosage form can be prepared by any method of pharmacy, but all methods include
By the way that active constituent and liquid-carrier, liposome or finely divided solid carrier or both progress equably and are closely associated
Come the step of preparing composition.Under normal circumstances, pharmaceutical composition be by by active constituent equably and closely with liquid
Body carrier or solid carrier fine crushing or both mixing, if it is necessary, product is made to be configured to required form.For example, tablet can
Be will choose any one kind of them or Multiple components compacting or molding.Tabletting can be by by free-flowing form such as powder or particle
Active constituent, optionally with excipient, such as, but not limited to, adhesive, lubricant, inert diluent and/or surfactant
Or dispersant, it is suppressed in suitable machine.Molded tablet can by suitable machine by inert liquid diluent
The mixture of the powder compound of wetting moulds to prepare.Tablet is optionally uncoated, is coated or indentation, and can be formulated
To provide the slow or controlled release of wherein active constituent, so that the continuous action of longer term is provided, the delay that can be used
Material, such as glycerin monostearate or bi-tristearin.Formulations for oral use can also be hard gelatin capsule,
Wherein active constituent can be mixed with inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft bright
Glue capsule, wherein active constituent can be with water or oil medium, for example, peanut oil, atoleine or olive oil mixing.
Active component can closely be combined with pharmaceutical carrier by conventional medicine hybrid technology.The carrier can be adopted
Diversified forms are taken, this depends on the form that required preparation is administered.When preparing pharmaceutical composition for peroral dosage form, Ren Hechang
Drug media is used as carrier, for example, water, glycol, oil, ethyl alcohol, flavoring agent, preservative, colorant and liquid oral
Preparation (for example, suspension, solution and elixir) or aerosol or carrier, for example, starch, sugar, microcrystalline cellulose, diluent,
Granulating agent, lubricant, adhesive and disintegrating agent can use in the case where oral solid formulation, not make in some embodiments
Use lactose.In some embodiments, compound can be with lactose, sucrose, starch powder, the cellulose esters of alkanoic acid, fiber
Plain Arrcostab, talcum, stearic acid, magnesium stearate, magnesia, calcium phosphate, sodium phosphate, calcium sulfate, sodium sulphate, gelatin are Arabic
Glue, mosanom, polyvinylpyrrolidone and/or polyvinyl alcohol are used for further preparation.For example, the system of solid orally ingestible
Standby, suitable carrier further includes powder, capsule and tablet.In some embodiments, tablet can be by standard aqueous or non-
Aqueous technology is coated.
Suitable for the coating of pharmaceutical composition and dosage form, include, but are not limited to cornstarch, potato starch or other
Starch, gelatin, natural glue and paragutta such as Arabic gum, mosanom, alginic acid, other alginates, powdered Huang alpine yarrow
Glue, guar gum, cellulose and its derivates are (for example, ethyl cellulose, cellulose acetate, calcium carboxymethylcellulose, carboxymethyl are fine
Tie up plain sodium), polyvinylpyrrolidone, methylcellulose, pregelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and
Their mixture.
Include, but are not limited to slide there is disclosed herein the example for the suitable filler in pharmaceutical composition and dosage form
Stone, calcium carbonate (for example, particle or powder), microcrystalline cellulose, cellulose powder, dextrates, kaolin, mannitol,
Silicic acid, sorbierite, starch, pregelatinized starch and their mixture.
Disintegrating agent can be collapsed with providing when being exposed to water environment in pharmaceutical composition using as provided herein
The tablet of solution.Too many disintegrating agent can cause tablet to be disintegrated in bottle.It may be not enough to be disintegrated generation very little, and therefore can be with
Change the rate of release and degree of the active constituent of dosage form.Therefore, disintegrating agent should sufficient amount, it is neither very little also not many and have
Change the release of active constituent harmfully.The amount of disintegrating agent depends on formula and administration mode, and can be and be easy to by this field
In those of ordinary skill realize.The disintegrating agent of about 0.5 to about 15 weight %, or the disintegrating agent of about 1 to about 5 weight %, can be with
It is used in pharmaceutical composition.It can be used to form the disintegrating agent of pharmaceutical composition and dosage form, including but not limited to, agar, seaweed
Acid, calcium carbonate, microcrystalline cellulose, cross-linked carboxymethyl sodium, Crospovidone, polacrilin potassium, primojel, potato or wood
Sweet potato starch, other starch, pre- gelatine starch, clay, other phycocolloid, other celluloses, or mixtures thereof natural gum.
Lubricant can be used for being formed pharmaceutical composition and dosage form, include, but are not limited to calcium stearate, magnesium stearate,
Mineral oil, light mineral oil, glycerol, sorbierite, mannitol, polyethylene glycol, other glycol, stearic acid, NaLS are sliding
Stone, hydrogenated vegetable oil (for example, peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil) are stearic
Sour zinc, ethyl oleate, ethyl laurate, agar or their mixture.Lubricant further includes that, for example, silica gel, solidified gas is molten
Or mixtures thereof glue,.Lubricant is optionally added with the amount of the pharmaceutical composition less than about 1 weight %.
When aqueous suspension and/or elixir are for when being administered orally, active constituent can with various sweeteners or flavoring agent,
Colorant or dyestuff, and for example, emulsifier and/or suspending agent, diluent are combined together, for example, water, ethyl alcohol, propylene glycol are sweet
Oil and their various combinations.
The surfactant that can be used for being formed pharmaceutical composition and dosage form includes, but are not limited to hydrophilic surfactant
Agent, lipophilic surfactant and their mixture.Suitable hydrophilic surfactant usually can have at least about 10
HLB value, and suitable lipophilic surfactant can generally have the HLB value less than about 10.It is relatively close for what is characterized
Aqueous and hydrophobic empirical parameter is hydrophilic lipophilic balance HLB (" HLB " value).The surfactant of lower HLB value is
More lipophilic is hydrophobic, and has biggish solubility in the oil, and having compared with the activating agent of high hlb is more hydrophilic property, and
And there is bigger solubility in aqueous solution.Hydrophilic surfactant active, which is generally considered to be, is greater than about 10 with HLB value
Those compounds, however, anion, cation or zwitterionic compound, HLB scale are usually not applicable.Similarly, lipophilicity
(that is, hydrophobicity) surfactant is to be equal to or less than about 10 with HLB value.However, the HLB value of surfactant is only one
As for industry, the rough guide of drug and cosmetic emulsions.
Hydrophilic surfactant active can be ion or non-ionic.Suitable ionic surface active agent includes, but unlimited
In alkylammonium salt;Fusidic Acid salt;The derivative of fatty acid of amino acid, oligopeptides and polypeptide;Amino acid, oligopeptides and polypeptide it is sweet
The derivative of grease;Lecithin and hydrolecithin;Lysolecithin and hydrogenated lyso lecithin;Phosphatide and its derivative;It is molten
Blood phospholipid and its derivative;Carnitine fatty acid ester salt;Alkyl sulfate;Fatty acid salt;Docusate sodium;Acyl-lactate;It is mono- and
The tartrate of the list of diacetylation and two glyceride;Succinylation list and two glyceride;The citric acid of mono-and diglycerides
Ester;With their mixture.Ionic surfactant includes, but are not limited to for example, lecithin, lysolecithin, phosphatide,
Lysophosphatide and its derivative;Carnitine fatty acid ester salt;Alkyl sulfate;Fatty acid salt;Docusate sodium;Acyl-lactate;It is mono-
With the diacetylation tartrate of mono-and diglycerides;Succinylation list and two glyceride;The lemon of mono-and diglycerides
Acid esters;With their mixture.Hydrophilic nonionic surfactant includes, but are not limited to alkyl glycosides;Alkyl maltose;Alkane
Base thio glycoside;Lauroyl LABRAFIL M 1944CS;Polyoxyalkylene alkyl, for example, polyethylene glycol alkyl ether;Polyoxyalkylene alkane
Base phenol, for example, polyalkylene glycol alkyl phenol;Polyoxyalkylene alkylphenol aliphatic ester, for example, polyethylene glycol fatty acid monoesters and poly-
Glycol fatty acid diester;Polyethylene glycol glycerol aliphatic ester;Polyglyceryl fatty acid ester;Polyoxyalkylene sorbitan polyol fatty acid
Ester, for example, polyethylene glycol sorbitan fatty acid ester;With glyceride, vegetable oil, hydrogenated vegetable oil, in fatty acid and sterol
The hydrophily transesterification product of at least one polyalcohol;Polyoxyethylene sterol, derivative, and the like;It is polyoxyethylated
Vitamin and its derivative;Polyox-yethylene-polyoxypropylene block copolymer;With their mixture;Polyethylene glycol anhydrosorbitol
The hydrophily transesterification product of the polyalcohol of alcohol fatty acid ester and at least one triglycerides, vegetable oil and hydrogenated vegetable oil.It should
Polyalcohol can be glycerol, ethylene glycol, polyethylene glycol, sorbierite, propylene glycol, pentaerythrite or carbohydrate.Other hydrophilies it is non-from
Sub- surfactant includes, but are not limited to PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32
Laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate.PEG-20 oleate, bis- oleic acid of PEG-20
Ester, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate,
PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glycerol trioleate, bis- oil of PEG-32
Acid esters, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20glyce kowtow my stearate, PEG-20
Olein, PEG-30 olein, PEG-30glyce kowtow my laurate, PEG-40 glyceryl laurate, PEG-
40 palm-kernel oils, PEG-50 rilanit special, PEG-40 castor oil, Cremophor ELP, PEG-60 castor oil, PEG-40 hydrogenation
Castor oil, PEG-60 rilanit special, PEG-60 corn oil, the PEG-6 last of the ten Heavenly stems/glycerol caprylate, PEG-8 decylate/cap are kowtowed late sweet
Grease, polyglyce kowtow 1-10 laurate, PEG-30 cholesterol, PEG-25 phytosterol, PEG-30 sojasterol, PEG-
20 trioleates, PEG-40 Oleate, PEG-80 sorbitan laurate, polysorbate 20, poly- sorb
Alcohol ester 80, POE-9 lauryl ether, POE-23 laurel ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether,
PEG-100 tocopherol succinate, PEG-24 cholesterol, Tween 40, Tween 60, sucrose monostearate, sucrose Dan Yue
Cinnamic acid ester, sucrose palmitic acid ester, PEG 10-100 nonylphenol series, PEG 15-100 octyl phenol series and poloxamer.It closes
Suitable lipophilic surfactants include, but are not limited to for example, fatty alcohol;Fatty acid glyceride;Acetylated glycerol fatty acid esters;
Lower alcohol fatty acid esters;Methyl glycol fatty acid ester;Sorbitan fatty acid ester;Polyethylene glycol fatty acid esters of sorbitan;Gu
Pure and mild steroid derivatives;Polyoxyethylated sterol and sterol derivative;Polyethylene glycol alkyl ether;Sugar ester;Sugar ether;Single and two glycerol
The lactic acid derivative of ester.
Pharmaceutical composition may include solubilizer to ensure good solubilising and/or the dissolution of compound, and reduce chemical combination to the greatest extent
The precipitating of object.This can be for non-oral use, for example, the pharmaceutical composition of the pharmaceutical composition for injection is especially heavy
It wants.Solubilizer can also be added, to increase hydrophilic medicament and/or other components, such as the solubility of surfactant, or maintenance
Pharmaceutical composition as stable or uniform solution or dispersion.The example of suitable solubilizer includes, but are not limited to example
Such as, pure and mild polyalcohol, for example, ethyl alcohol, isopropanol, butanol, benzylalcohol, ethylene glycol, propylene glycol, butanediol and its isomers, glycerol,
Pentaerythrite, sorbierite, mannitol, Isosorbide dimethyl ether, polyethylene glycol, polypropylene glycol, polyvinyl alcohol and other fibers
Plain derivative, cyclodextrin and cyclodextrine derivatives;The ether of polyethylene glycol has molecular weight about 200 to about 6000, such as tetrahydro chaff
Alcohol PEG ether (Tetrahydrofurfuryl polyethylene glycol ether) or methoxyl group PEG;Amide and other nitrogenous compounds, such as 2-Pyrrolidone, 2-
Piperidones, epsilon-caprolactams, N- alkyl pyrrolidone, N- hydroxyalkylpyrrolidone, N- Alkylpiperidine, N- alkyl caprolactam,
Dimethyl acetamide and polyvinylpyrrolidone;Ester, for example, ethyl propionate, tributyl citrate, acetyl triethyl citrate,
Acetyl tributyl citrate, triethyl citrate, ethyl oleate, ethyl caprilate, ethyl butyrate, glycerol triacetate, the third two
Alcohol monoacetate, propylene-glycol diacetate, the isomers of 6-caprolactone and they, delta- valerolactone and its isomers, in fourth
Ester and its isomers;With other known solubilizer, such as dimethyl acetamide, Isosorbide dimethyl ether, N-Methyl pyrrolidone,
Diethylene glycol monoethyl ether and water.Also the mixture of solubilizer can be used.
The amount of given solubilizer can be limited in a biological acceptable amount, can pass through those skilled in the art
It is readily determined.Solubilizer can be about 10%, about 25%, about 50%, about 100% weight ratio, or at most by weight
About 200%, based on the total weight of drug and other auxiliary materials.If necessary, a small amount of solubilizer can also be used, for example, about
5%, 2%, 1% or even less.Typically, solubilizer can reside in about 1% to about 100%, and typically about 5% to about
25% (weight).
The pharmaceutical composition can also include one or more pharmaceutically acceptable additives and excipient.In this way
Additive and excipient includes, but are not limited to for example, antitack agent, anti-foaming agent, buffer, polymer, antioxidant is prevented
Rotten agent, chelating agent, flavoring agent, colorant, essential oil, fragrance, opacifier, suspending agent, adhesive, filler, plasticizer, lubrication
Agent and their mixture.Preservative may include, but be not limited to, for example, antioxidant, chelating agent, antimicrobial anti-corrosion
Agent, antifungal preservative, alcohol preservative, acidic preservative and other preservatives.Antioxidant includes, but are not limited to α-fertility
Phenol, ascorbic acid, butylated hydroxyanisol, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, gallate third
Ester, sodium ascorbate, sodium hydrogensulfite and sodium sulfite.Chelating agent includes, but are not limited to for example, ethylenediamine tetra-acetic acid
(EDTA), citric acid monohydrate closes object, disodium ethylene diamine tetraacetate, dipotassium edetate, edetic acid(EDTA), fumaric acid, apple
Acid, phosphoric acid, edetate sodium, tartaric acid and citric acid triethylenediamine tetrem.Anti-microbial preservative includes, but are not limited to example
Such as, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimonium bromide, cetylpyridinium chloride, dichloroxylenol, first
Phenol, ethyl alcohol, glycerol, Hexetidine, imidazolidine urea, phenol, phenoxetol, benzyl carbinol, phenylmercuric nitrate and propylene glycol.It is anti-true
Microbial inoculum includes, but are not limited to for example, butyl p-hydroxybenzoate, methyl p-hydroxybenzoate, ethyl-para-hydroxybenzoate are right
Nipasol, benzoic acid, hydroxybenzoic acid, Potassium Benzoate, potassium sorbate, sodium benzoate, sodium propionate and sorbic acid.It is anti-
Rotten agent includes, but are not limited to for example, ethyl alcohol, polyethylene glycol, phenol, phenolic compounds, bis-phenol, methaform, hydroxybenzoate,
And benzyl carbinol.Acidic preservative includes, but are not limited to for example, vitamin A, vitamin C, vitamin E, beta carotene, lemon
Acid, acetic acid, dehydroactic acid, ascorbic acid, sorbic acid and phytic acid.Other preservatives include, but are not limited to for example, tocopherol vinegar
Acid esters, cetrimonium bromide, butylated hydroxyanisol (BHA), butylated hydroxytoluene (BHT), ethylenediamine, NaLS
(SLS), sodium laureth sulfate (SLES), hydrogen sulfate sodium salt, sodium pyrosulfite, potassium sulfite, potassium metabisulfite, para hydroxybenzene
Methyl formate.In certain embodiments, preservative can be a kind of antioxidant.In other embodiments, preservative can
To be chelating agent.In some embodiments, it provided herein is the pharmaceutical compositions contained for parenteral: (1) one
The effective quantity of a disclosed compound;A effective amount of one or more second reagents in optional (2);(3) it is suitable for parenteral to apply
One or more drug excipients and (4) a effective amount of third reagent.
Wherein pharmaceutical composition can include aqueous by way of drug administration by injection or oily suspensions or emulsion, sesame oil,
Corn oil, cotton seed oil or peanut oil and elixir, mannitol, dextrose or aseptic aqueous solution and similar drug carry
Body.Physiological saline aqueous solution is also commonly used for injecting.Ethyl alcohol, glycerol, propylene glycol, liquid macrogol, benzylalcohol, wait (and its close
They suitable mixture), cyclodextrine derivatives, sodium chloride, bassora gum, buffer and vegetable oil can also use.It is appropriate
Mobility can be by using coating, for example, lecithin, or keeps institute by using surfactant in the case of a dispersion
The granular size needed is kept.The prevention of microbial action can be by various antibacterial agents and antifungal agent, for example, para hydroxybenzene first
Esters of gallic acid, methaform, phenol, sorbic acid acid, thimerosal etc..Pharmaceutical composition can also be injected by suitable carrier, including
Salt water, glucose or water, or with cyclodextrin, cosolvent (for example, propylene glycol) or Micellar Solubilization (for example, Tween80).
Aseptic injectable solution can pass through the conjunction of the desired amount of compounds as disclosed herein and various above-mentioned other ingredients
It is prepared by suitable solvent, filtration sterilization.In general, dispersion is situated between by being incorporated into the active constituent of various sterilizings containing basic dispersion
It the sterile carrier of matter and prepares from other components appropriate those of listed above.Sterile note is being prepared with aseptic powdery
Penetrate liquid, certain methods of preparation are that active constituent and any other above-mentioned sterile is generated with vacuum drying and Freeze Drying Technique
The ingredient of filtering.Sterile injectable preparation can also pass through the suspension in the nontoxic acceptable diluent of parenteral or solvent
Liquid, for example, prepared by solution or aseptic injectable solution in 1,3-BDO.In the acceptable carrier and solvent that can be used
Include, but are not limited to for example, water, Ringer's solution and isotonic sodium chlorrde solution.In addition, sterile, fixed oil is typically used as
Solvent or suspension media include, but are not limited to list or two glyceride for example, synthesizing.In addition, fatty acid, for example, oleic acid
It can be used in the preparation of injection using.Injectable formulation can keep filter filtering before use by, for example, bacterium,
Or the bactericidal agent that can be dissolved or dispersed in the incorporation aseptic solid composite of sterile water or other sterile injectable mediums is added
It sterilizes.Injectable composition can be in the compound disclosed herein of about 0.1 to about 5% weight ratio.
In some embodiments, it provided herein is containing as disclosed herein, contain one kind suitable for local administration
Or the compound or pharmaceutical composition of (for example, percutaneous) of a variety of drug excipients.In some embodiments, provided herein
It is the composition containing drug for local administration: (1) effective quantity of a disclosed compound;Optional (2) effective quantity
One or more second reagents;(3) it is suitable for the one or more drug excipients and (4) a effective amount of third of local administration
Medicament.
Pharmaceutical composition provided herein can be configured to be suitable for the solid of local or local application, semisolid or liquid
Form, such as gelling agent, water soluble gel, liniment, creme, lotion, suspension, foaming agent, pulvis, paste preparation agent are soft
Paste, solution is oily, paste, suppository, spray, emulsion, saline solution, the solution based on dimethyl sulfoxide (DMSO).One
As in the case of, the carrier with higher density is capable of providing with being exposed to the region of active constituent for a long time.On the contrary, pharmaceutical solutions
The more direct contact in the selected region of the active constituent can be provided.For example, ointment formulation can have paraffin or water mixed
Dissolubility.Alternatively, active constituent can be configured to emulsifiable paste together with the emulsifiable paste matrix of oil in water.The water phase of emulsifiable paste matrix can
Polyalcohol including for example, at least about 30% weight ratio, for example, propylene glycol, butane -1,3- glycol, mannitol, sorbierite are sweet
Oil, the mixture of polyethylene glycol and they.The pharmaceutical composition also may include suitable solid or gel phase carriers or tax
Shape agent, they can increase infiltration, or the stratum corneum penetration barrier for assisting delivering compound to pass through skin.Such carrier and tax
The example of shape agent includes, but are not limited to for example, wetting agent (for example, urea), glycol (for example, propylene glycol), alcohol is (for example, second
Alcohol), fatty acid (for example, oleic acid), surfactant (for example, isopropyl myristate and fine gold sodium kowtow my sodium sulphate), pyrrolidines
Ketone, glyceryl monolaurate, sulfoxide, terpene (for example, menthol), amine, amide, alkane, alkanol, water, calcium carbonate, calcium phosphate, respectively
Kind sugar, starch, cellulose derivative, the polymer of gelatin and such as polyethylene glycol.
Another exemplary formulation used in the disclosed methods uses percutaneous dosing (" patch ").Such transdermal patch
Agent can be used for continuously or discontinuously providing the pharmaceutical composition of control amount.If activating agent by skin absorb, activating agent by
Control and predetermined amount of flow can be administered to subject.In the case where microcapsules, encapsulation agent is also used as film.For transdermal patch
Use be as known in the art.See, e.g., U.S. Patent number 5,023,252,4992445 and 5,001,139.
Pharmaceutical composition of the invention can be applied with the suppository form of rectally.These compositions can be by incite somebody to action this
The compound of invention mixes to prepare with suitable nonirritant excipient, and the excipient is solid but in rectum at room temperature
At a temperature of be liquid, to will melt in the rectum and release active component.This material includes, but are not limited to for example, poly-
Ethylene glycol, beeswax and cocoa butter.
Pharmaceutical composition of the invention can be administered by nasal aerosol or inhalant.According to known to field of pharmaceutical preparations
Technology prepare this composition, and the solution of salt water can be prepared as, and can be used benzyl alcohol or other be suitble to
Preservative, improve the sorbefacient of bioavilability, other known solubilizer of fluorocarbons and this field or dispersion
Agent.
Particularly advantageous derivative and prodrug is that change of the invention is improved when this compound is administered to mammal
It closes those of bioavilability of object (for example, by allowing the compound being administered orally more easily to be absorbed), or relative to
Parent species can enhance delivering those of of the compound to maternal biological chamber (for example, brain or central nervous system).Preferably
Prodrug includes wherein enhancing group that is water-soluble or wearing goldbeater's skin active transport to be affixed to spreading out on general formula structure as described herein
Biology.See, e.g., Alexander et al., Journal of Medicinal Chemistry l988,31,318-
322;Bundgaard et al., Design of Prodrugs, Elsevier:Amsterdam, 1985,1-92;
Bundgaard et al.,Journal of Medicinal Chemistry l987,30,451-454;Bundgaard et
Al., Textbook of Drug Design and Development, Harwood Academic Publ.:
Switzerland,1991,113-191;Digenis et al.Handbook of Experimental Pharmacology,
1975,28,86-112。
Subject agent application can be it is local, to be applied in target site.Various technologies can be used in target
Provider's composition at position, such as inject, use conduit, gel, bracket, trocar, propellant, sustained drug release polymerization
The equipment that object or other offers are used for internal path.
According to another embodiment, the present invention provides a kind of implantable medical supply, and it includes have change of the invention
Object or the composition including the compound of the present invention are closed, so that the compound has therapeutic activity.
According to another embodiment, the present invention provides a kind of method of drug release device that injection is implantable, including
The step of drug release device and the compound of the present invention or composition are contacted.Implantable drug release device packet
It includes, but is not limited to, biodegradable polymer capsule or pill are nondegradable, diffusible polymer capsule and Ke Sheng
The polymer flake of object degradation.
In another embodiment, composition of the invention further includes second therapeutic agent.Second therapeutic agent includes any
Compound or therapeutic agent, when being administered alone or being administered together with any general formula compound herein, oneself knows have or prove for they
Favorable property.It can include other kinase inhibitors with the drug that these compounds usefully combine, and/or be used for treatment or more
The disease of discussion and other chemotherapeutants of disorder.Such reagent is described in detail in this field.Preferably, it second controls
Treating agent is the reagent that can be used for the treatment or prevention of disease or illness selected from cancer.
In another embodiment, the present invention provides the only of the compound of the present invention and second therapeutic agent associated each other
Vertical dosage form.Term " associating each other " as used herein refers to that the separate dosage forms are packaged together or with other side
Formula is connected to each other, thus the separate dosage forms it is expected sold or be administered together (be less than within 24 hours each other, continuously or
Simultaneously).
In pharmaceutical composition of the invention, the compound of the present invention exists with effective quantity.Term as used herein " has
Effect amount " refers to that the amount reduces enough or improve the severity of disorder to be treated when with the application of suitable dosage regimen, continues
Time or development prevent the progress of disorder to be treated, cause the recession of disorder to be treated, or enhancing or another treatment of improvement
The prevention or therapeutic effect of method.
Dosage is described in Freireich et al., (1966) Cancer Chemother Rep 50:219 to dynamic
The correlation of object and people (according to every square metre of body surface area of milligram).Body surface area can be big according to the height and weight of patient
Ground is caused to determine.See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, N.Y., 1970,
537.The effective quantity of the compound of the present invention can be from about 0.001-lmg/kg to about 500mg/kg, and about 0.01mg/kg is to about
50mg/kg, about 0.lmg/kg are to about 2.5mg/kg.Effective dosage can also change, as understood by those skilled in the art,
Depending on the disease treated, the severity of disease, administration route, the age of patient, gender and general health, excipient
The judgement of usage, a possibility that (such as using other reagents) being used in conjunction with other treatment method and treating physician.
For the pharmaceutical composition including second therapeutic agent, the effective quantity of second therapeutic agent is in the list that the reagent is used only
Between about 20% to the 100% of the dosage usually utilized in therapeutic scheme.Preferably, effective quantity is in normal single therapeutic dose
Between about 70% and 100%.Normal single therapeutic dose of these second therapeutic agents is well known in the art.See, e.g.,
Wells et al., Pharmacotherapy Handbook, Appleton and Lange, Stamford, Conn.
(2000);PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Tarascon
Publishing, Loma Linda, Calif. (2000), these bibliography are integrally incorporated herein by reference.
It is synergistically acted on it is expected that the certain second therapeutic agents being mentioned herein will have with the compound of the present invention.When this happens,
It will allow for the effective dose of second therapeutic agent and/or the compound of the present invention less than dosage needed for single treatment.This has
The advantages of be: make the toxic side effect of second therapeutic agent or the compound of the present invention minimize, improve effect, improve administration or use
Convenience, and/or reduce the overall cost of compound preparations or preparation.
Treatment method is as follows:
According to another embodiment, disease or disorder or its symptom (example are suffered from or are susceptible to the present invention provides treatment
Such as, those of be described herein) subject method, including to the subject with a effective amount of the compound of the present invention or group
Close the step of object is administered.These diseases are it is known in the art that also disclosed herein.
Treatment method is related to by the treatment of the protein kinase such as EGFR disorder mediated.
On the other hand, the present invention provides the method that disease is treated in subject, including to subject's application comprising appointing
The composition of the compound of what this paper general formula.
In some embodiments, disease is kinase mediated by EGFR.
In another embodiment, disease is cancer or hyperplasia.
In another embodiment, the inhibitor as the activated mutant body lacked for EGFR exon 2-7, formula (I)
Compound and pharmaceutically acceptable salt, it is expected to be the activity by EGFRVIII mutant individually or part mediate, example
If the treatment of Cancerous disease or medical conditions is useful.This cancer types that the compound of formula (I) may be used to treat or medicine
Acceptable salt on, including but not limited to, oophoroma, cervix cancer, colorectal cancer, breast cancer, cancer of pancreas, neuroglia
Tumor, glioblastoma, melanoma, prostate cancer, leukaemia, lymthoma, non-Hodgkin lymphoma, gastric cancer, lung cancer, liver cancer,
Osteocarcinoma, gastrointestinal stromal tumor (GIST), thyroid cancer, cholangiocarcinoma, carcinoma of endometrium, kidney, primary cutaneous type are anxious
Property myelomatosis (AML), Huppert's disease, melanoma, celiothelioma, the cancer of the brain, film gland cancer, cutaneum carcinoma or incidence squamous
Cell cancer.
In another embodiment, activated mutant is lacked as EGFR Exon 21L858R mutant and Exon19
The inhibitor of body, the compound and pharmaceutically acceptable salt of formula (I), it is expected to be by EGFR mutant activity individually or
Part mediate, such as the treatment of Cancerous disease or medical conditions is useful.This may use the compound of formula (I) to treat
Cancer types or pharmaceutically acceptable salt, including but not limited to, oophoroma, cervix cancer, colorectal cancer, breast cancer, pancreas
Gland cancer, glioma, glioblastoma, melanoma, prostate cancer, leukaemia, lymthoma, non-Hodgkin lymphoma, stomach
Cancer, lung cancer, liver cancer, osteocarcinoma, gastrointestinal stromal tumor (GIST), thyroid cancer, cholangiocarcinoma, carcinoma of endometrium, kidney, denaturation are big
Cell lymphoma, acute myelogenous leukemia (AML), Huppert's disease, melanoma, celiothelioma, the cancer of the brain, film gland cancer, skin
Cancer or head and neck squamous cell carcinoma.
In another embodiment, disease is glioma.
In another embodiment, disease is the non-small cell lung cancer (NSCLC) shifted with brain.
In another embodiment, disease is nerve center disease.
In one embodiment, method of the invention is for treating the subject for suffering from or being susceptible to disease or symptom.
These diseases, disorder or its symptom include, for example, by those of protein kinase (for example, EGFR protein kinase) regulation.Disease or
Disease symptoms can be, for example, cancer or hyperplasia or disorder.The disease or disease symptoms can be oophoroma, uterus
Neck cancer, colorectal cancer, breast cancer, cancer of pancreas, glioma, glioblastoma, melanoma, prostate cancer, leukaemia,
Lymthoma, non-Hodgkin lymphoma, gastric cancer, lung cancer, liver cancer, osteocarcinoma, gastrointestinal stromal tumor (GIST), thyroid cancer, cholangiocarcinoma,
Carcinoma of endometrium, kidney, primary cutaneous type, acute myelogenous leukemia (AML), Huppert's disease, melanoma,
Celiothelioma, the cancer of the brain, film gland cancer, cutaneum carcinoma or head and neck squamous cell carcinoma.The method described herein is reflected including wherein subject
Those of the treatment that Wei do not need to illustrate subject.Identifying subject needs this treatment can be in subject or care specialists
Judgement within, and can be subjective (for example, opinion) or objectively (for example, can measure by test or diagnostic method
).
In another embodiment, this paper compound (and combinations thereof) can be used to treat with disease or disorder
And oneself through with other therapeutic agents (for example, anticancer agent, neurological disease agent, mental disease agent, cardiovascular disease act on
Agent, anti-fat or diabetes agent) treat and formed the subject of resistance.On the one hand, methods herein includes wherein to controlling
The subject for treating resistant (or be accredited as oneself and formed the resistance treated for Buddhist nun, Tarceva non-for lattice) is administered with this
Those of literary general formula compound (or combinations thereof object) method.In other aspects, therefore subject has response to the treatment, thus phase
For with before the treatment of this paper general formula compound, disorder is adjusted or improves.
In another embodiment, the present invention provides the protein kinase in adjusting cell (for example, protease propylhomoserin swashs
Enzyme, kinases exemplified here) active method, including the compound of cell and one or more any this paper general formulas is carried out
Contact.
Anti-cancer therapies described above can use the compound of the present invention as monotherapy or and the compound of the present invention
Routine operation or radiotherapy or chemotherapy or immunotherapy are applied together.Such chemotherapy can be common with the compound of the present invention, together
When, it is sequential or apply respectively, and can include but is not limited to following classification antitumor agent it is one or more: for example, anti-
Proliferation/antineoplastic, alkylating agent (such as cis-platinum, oxaliplatin, carboplatin, cyclophosphamide, mustargen, melphalan, benzenebutanoic acid nitrogen
Mustard, busulfan, Temozolomide and nitroso ureas), antimetabolite (such as gemcitabine and anti-folic acid as 5 FU 5 fluorouracil and
Tegafur, Raltitrexed, methotrexate (MTX), cytarabine and hydroxycarbamide);Antitumor antibiotics (such as anthracene nucleus medicament such as Ah mould
Element, bleomycin, adriamycin, daunorubicin, Epi-ADM, idarubicin, mitomycin C, dactinomycin D and mithramycin);
Antimitotic agent (such as vinca alkaloids such as vincristine, vincaleukoblastinum, eldisine and vinorelbine and taxanes
Close object such as taxol and taxotere and polokinase inhibitor);With topoisomerase enzyme inhibitor (such as epipodophyllotoxin class according to
Support pool glycosides and Teniposide, amsacrine, Hycamtin and camptothecine);Cytostatic agent such as antiestrogenic (effect) medicine (example
Such as tamoxifen, fulvestrant, Toremifene, Raloxifene, Droloxifene and idoxifene), antiandrogen (effect) medicine (example
Such as, Bicalutamide, Flutamide, acetic acid Nilutamide and acetic acid cyclopropyl), lhrh antagonist or LHRH agonist (such as Ge Sherui
Woods, Leuprorelin and Buserelin, progestational hormone (such as megestrol acetate, aromatase inhibitor (such as such as Anastrozole, come
Bent azoles, Vorozole and Exemestane) and 5 alpha-reductases such as Finasteride inhibitor;Anti-invasion agent is (for example, c-Src kinases man
Group inhibitor, such as saracatinib;Dasatinib and posupini and posupini and metal protease inhibitors such as Ma Masi
He, the inhibitor or antibody heparanase of urokinase plasminogen activator function of receptors.The inhibitor of growth factor function: example
If such inhibitor includes growth factor antibodies and the growth factor receptor antibody (such as antibody trastuzumab [He Sai of anti-erbB 2
Spit of flandTM], anti-egfr antibodies Victibix, anti-ErbB antibody cetuximab (Erbitux, C225) and by Stem et
Any growth disclosed in al.Critical reviews in oncology/haematology, 2005, Vol.54, l1-29
The antibody of the factor or growth factor receptors.Such inhibitor further includes tyrosine kinase inhibitor, such as epidermal growth factor
Family's group inhibitor (such as EGFR family tyrosine kinase inhibitors such as Gefitinib, Tarceva, Kai Meina and tower gires, erbB2
Tyrosine kinase inhibitor, such as Lapatinib, linatinib);The inhibitor of hepatocyte growth factor family;Insulin is raw
The inhibitor of long factor family;The inhibitor of platelet-derived growth factor family, such as Imatinib and/or nilotinib;
(such as RAS/RAF signal inhibitor such as farnesyl transferase inhibitor, such as rope are drawn the inhibitor of serine/threonine kinase
Non- Buddhist nun, tipifamib and lonafamib, by MEK and/or AKT kinases cell signal inhibitor, c-kit inhibitor, abl melts
Kinase inhibitor is closed, PI3 kinase inhibitor, PLT3 kinase inhibitor, CSF-1R kinase inhibitor, (Insulin-Like is raw for IGF receptor
The long factor) kinase inhibitor;Aurora kinase inhibitors and cell cycle protein dependent kinase inhibitor such as CDK2 and/or CDK4
Inhibitor;Anti-angiogenic agent, such as the influence of those inhibition vascular endothelial growth factor, such as anti-vascular endothelial cell growth
Factor antibody bevacizumab (AvastinTM) and such as vegf receptor tyrosine kinase inhibitor such as Vande Thani, vatalanib,
Sutent, Axitinib, pazopanib and Si Dinibu pass through the compounds of other mechanism works (such as tricarboxylic amino quinoline
Quinoline, the depressant of functions and angiogenic inhibitor of integin αV 3);Antisense (nucleic acid) therapy gene therapy, such as on those
The target that face is listed, such as ISIS 2503, antisense (nucleic acid) therapy of anti-ras gene;Gene therapy method, including for example replace
Aberrant gene such as abnormal p53 or abnormal BRCA1 or BRCA2 (for example, olaparib, Niraparib, Rucaparib,
Talazoparib), the method for GDEPT (gene-directed enzyme prodrug therapy) is for example using cytosine deaminase, thymidine kinase or thin
The enzyme of bacterium nitroreductase and those to improve patient tolerance's chemotherapy or radiotherapy such as multidrug resistance gene therapy immunotherapy method,
Immunogenicity including for example increasing the tumour cell of patient, such as with cell factor such as interleukin-22, IL-4 or granulocyte-
Macrophage stimulation factor transfection immunogenicity, the method to reduce T cell anergy, using transfection immunocyte such as
The method of the Dendritic Cells of cytokine transfection, the method for the tumor cell line of cytokine transfection are anti-using antiidiotype
The method of body, to reduce the function of immunosuppressant cell, such as regulatory T cells, marrow source inhibits cell or IDO, TDO, and makes
With by coming from tumor associated antigen such as NY-ES0-1, the cancer epidemic disease of the derivative protein or peptide of MAGE-3, WTI or HER2/neu
Seedling.Or any other reagent of basic medicament or adjuvant application is typically used as in modality of cancer treatment (for example, antemetic, anti-
Anaemia agent etc.).
Terms used herein " co-administration " refer to second therapeutic agent can together with the compound of the present invention, as
The part of single formulation (e.g., including the present composition of the compound of the present invention and second therapeutic agent as described above) or
It is applied as independent, multiple dose form.Alternatively, before the compound of the present invention application or successively or its it
Afterwards, other reagent can be applied.In such combination therapy, the compound of the present invention and second therapeutic agent pass through routine side
Method is applied.Administration of the composition of the invention including the compound of the present invention and second therapeutic agent to subject, however not excluded that
Same therapeutic agent, the other times of any other second therapeutic agent or any compound of the invention over the course for the treatment of are to described
The separate administrable of subject.Wherein continuous or isolated application, or delay are applied the second component and should not be lost from using group
The advantages of effect caused by closing.
The effective quantity of second therapeutic agent is well known to those skilled in the art, see, e.g., Wells et al.,
Pharmacotherapy Handbook,Appleton and Lange,Stamford,Conn.(2000);PDR
Pharmacopoeia,Tarascon Pocket Pharmacopoeia 2000,Tarascon Publishing,Loma
In Linda, Calif. (2000) and other medical text books.However, determining the best available amount range of the second therapeutic agent
Within the ability of those skilled in the art.
In an embodiment of the invention, when second therapeutic agent is administered to subject, the compound of the present invention
Effective quantity be lower than when not applying second therapeutic agent its effective quantity.In another embodiment, second therapeutic agent is effective
Amount is lower than its effective quantity when not applying the compound of the present invention.In this way, any reagent to high dose is relevant undesirable
Side effect can be minimized.For those skilled in the art, potential advantage will be apparent (including, but are not limited to
For example, improving dosage regimen and/or reducing drug cost).
In yet another aspect, the present invention provide the compound of any general formula herein individually or with it is described herein a kind of or
A variety of second therapeutic agents application in manufacture drug together, as single composition or as independent dosage form, the drug
For treating or preventing disease enumerated herein, disorder or symptom in subject.Another aspect of the present invention is that use is led to herein
The compound of formula treats or prevents disease described herein, disorder or symptom in subject.
In other respects, methods herein includes further comprising monitoring subject to those of reaction of therapeutic administratp side
Method.Such monitoring may include subject's tissue of the marker or indicant as therapeutic scheme, body fluid, cerebrospinal fluid, sample
This, cell, protein, chemical marker, the periodic sampling of inhereditary material etc..In other methods, pass through the related mark of assessment
To the adaptability of such treatment, subject, which is screened or is accredited as in advance, needs such treatment for will object or indicant.
In one embodiment, the present invention provides a kind of method for monitoring therapeutic advance.The method includes measurements to suffer from
Have or is susceptible in the subject of disorder described herein or its symptom diagnosis marker (marker) (for example, by the change of this paper
Close any target described herein or cell type that object is adjusted) or diagnostic measurement value (for example, screening, measurement) horizontal step
Suddenly, wherein the subject oneself applied and be enough to treat the compound of this paper of therapeutic dose of the disease or its symptom.?
The marker measured in the method it is horizontal can with the marker in the normal control of health or in other afflicted patients oneself
Know that level compares, to establish the disease condition of subject.In a preferred embodiment, be later than measurement first level when
Between marker in point measurement subject it is second horizontal, and compare two levels to monitor the process of disease or the function of therapy
Effect.In some preferred embodiments, the marker levels before treating in subject are starting treatment according to the present invention
It is preceding measured;The preceding level of the treatment of this marker can start the marker levels in rear subject with treatment and be compared,
To determine the effect for the treatment of.
Marker or marker active horizontal measured at least one in certain method implementations, in subject
It is secondary.Marker levels and the marker levels for example obtained previously or then from same patient, another patient or normal subjects
Another measured value be compared, can be used for determining whether therapy according to the present invention has desired effect, and thus
Allow optionally to adjust dosage level.It is known or described herein any suitable that the measurement of marker levels can use this field
The sampling of conjunction/expression measuring method carries out.Preferably, tissue or fluid sample are taken out from subject first.Suitable sample
Example include blood, urine, cerebrospinal fluid, tissue, mouth or cheek cell and the hair sample containing root.Other suitable samples
Product are that those skilled in the art is known.Protein level in sample, ctDNA, cfDNA and/or mRNA level in-site are (for example, mark
Will object is horizontal) measurement can use the known any suitable technology in this field, including but not limited to, enzyme immunoassay (EIA),
ELISA, radioactive label determination techniques, trace/chemiluminescence method, real-time PCR, electrochemical signals etc. carry out.
The present invention also provides a kind of reagents for treating including disease those of described herein, disorder or its symptom
Box.These kits include: 1) include this paper any general formula compound or its salt;Or the salt of its prodrug or prodrug;Or its
The pharmaceutical composition of hydrate, solvate or polymorph, wherein described pharmaceutical composition is in container;And it 2) describes
The specification of the method including disease described herein, disorder or its symptom is treated using described pharmaceutical composition.The appearance
Device can be any container that can accommodate described pharmaceutical composition or other sealings or sealable equipment.Example includes bottle
Son, separated or multicell reservoir bottle, wherein each subregion or compartment include the single dose of the composition;The foil packet of separation
Dress, wherein each subregion includes the composition of single dose;Or distributor, distribute the composition of single dose.It is described
Container can be this field known any conventional shape or form, be made of pharmaceutically acceptable material, for example, paper or
Cardboard case, glass or plastic bottle or tank, resealable sack (for example, to accommodate " the recharging object " of tablet for putting
Set in different vessels) or blister package with single dosage for being squeezed out from the package according to treatment schedule.It uses
Container can depend on related definite dosage form, for example, conventional cardboard case will generally be not used in receiving liquid suspension.It can
It is capable, more than one container can be used together in individual packaging by the single formulation marketization.For example, tablet can hold
It is contained in bottle, bottle is then contained in box.Preferably, container is blister package.
Kit can also comprise the information and/or specification of doctor, pharmacists or subject.These memory aids
Including the number being printed upon on each compartment containing medicament or subregion, the side that should be taken in specified tablet or capsule
The number of days of case is consistent, or the number of days weekly being printed upon on each compartment or subregion, or the card comprising same type information.
It is of the present invention with EGFRV3 Activating mutations use on the way, quinazoline derivant (I) of the present invention
Enantiomeric purity has greater than about 55% to about 99.5%, greater than about 60% to about 99.5%, greater than about 65% to about 99.5%,
Greater than about 70% to about 99.5%, greater than about 75% to about 99.5%, greater than about 80% to about 99.5%, greater than about 85% to about
99.5%, greater than about 90% to about 99.5%, greater than about 95% to about 99.5%, greater than about 96% to about 99.5%, greater than about
97% to about 99.5%, greater than about 98% to greater than about 99.5%, greater than about 99% to about 99.5%, or higher.
Known scheme in this field can be used in the compound described herein, including, for example, that described herein
A bit, their bioactivity is evaluated.Certain compounds of this paper demonstrate unexpected excellent attribute (for example, metabolism
Stability, highly selective, low discharge rate, high permeability, non-P glycoprotein outlet substrate etc.) so that they become potential treatment agent
Excellent candidate.
All references cited herein, either with electronics, printing, computer-readable preservation medium or its
His form, is all clearly incorporated herein entirety for reference, includes, but are not limited to abstract, article, periodical, publication, religion section
Book, paper, technical data sheet, internet site, database, patent, patent application and patent publications.
The following describes the present invention in detail with reference to examples.Following embodiment will be helpful to those skilled in the art
The present invention is further understood, but the invention is not limited in any way.It should be pointed out that those skilled in the art
For, without departing from the inventive concept of the premise, it can also make certain adjustments and improvements.These belong to guarantor of the invention
Protect range.
The preparation of 1. quinazoline derivant of embodiment (I)
The 1.1 intermediate 5- bromo- 5- of fluoro- 4- methoxyl group -2- nitrobenzonitrile A6 and 1- fluoro- 4- (deuterated methoxyl group) -2- nitro
The synthesis of benzene C1
Synthetic route is as follows:
Step 1: in the methylene chloride (10 milliliters) of A1 (2.0 grams, 10.5mmol) and triethylamine (1.3 grams, 12.6mmol)
Ethyl chloroformate (1.4 grams, 12.6mmol) solution in methylene chloride (3 milliliters) is added dropwise for 0 DEG C in solution.Reaction is mixed
Object stirs 1 hour under 0 degree Celsius, and reaches room temperature.Then reaction mixture is washed twice with water.By organic layer sulphur
Sour magnesium is dry and is evaporated in vacuo, and obtains the product A2 (2.7 grams, yield 100%) for colorless oil.
Step 2: hair is added dropwise for 10 degrees Celsius in the solution of the concentrated sulfuric acid (4.6mL) to A2 (2.7 grams, 10.3mmol)
Cigarette nitric acid (0.73 milliliter, 15.5mmol).After 1 hour, reaction mixture is poured into ice/water, and is extracted with ethyl acetate two
It is secondary.By combined organic layer water, sodium bicarbonate and salt water washing are dried over sodium sulfate and are evaporated in vacuo, obtain residue, will
Its with silicagel column (n-hexane/ethyl acetate=20/1) purify, obtain for yellow oil product A3 (3.0 grams, yield
94.6%).
Step 3: A3 (3.0 grams, 9.8mmol) be added in the solution in methanol (17 milliliters) sodium bicarbonate (1.6 grams,
19.6mmol).Reaction mixture is stirred at 60 c 3 hours.Methanol evaporates under vacuum.Water (15 milliliters) is added to
In residue, water layer is acidified to pH=5 by the way that the solution of 5 moles of hydrogen chloride is added.Water layer is extracted with ethyl acetate twice.Merge
Organic layer it is dry with magnesium sulfate, and be evaporated in vacuo, obtain the product A4 (2.3 grams, yield 100%) for yellow solid.
Step 4: carbon is added in the nitrogen of A4 (2.31 grams, 9.8mmol), nitrogen-dimethylformamide (18.5 milliliters) solution
Sour potassium (2.7 grams, 19.6mmol) and methyl iodide (1.22 milliliters, 19.6mmol).Reaction mixture is stirred 3 at 60 c
Hour.Gained mixture is separated between water and ethyl acetate.Organic layer is dried over sodium sulfate and is evaporated in vacuo, obtain for
The product A5 (2.35 grams, yield 97%) of yellow solid.
Step 5: in the nitrogen of A5 (5.17 grams, 20.7mmol) and the mixture of zinc cyanide (1.46 grams, 12.4mmol), nitrogen-
It is stirred in dimethyl acetamide (104 milliliters) solution, and with after nitrogen discharge air, palladium catalyst, Pd is added2(dba)3(1.90
Gram, 2.07mmol) and ligand, 2- dicyclohexylphosphino -2'- (nitrogen, nitrogen-dimethylamine)-biphenyl (815 milligrams, 2.07mmol), and
The reaction mixture is stirred 5 hours at 110 degrees Celsius.It is then cooled to room temperature, is diluted in ethyl acetate, silicon is passed through
Diatomaceous earth filtering.Organics washed with brine is dried over sodium sulfate, be concentrated in a vacuum and by silicagel column (ethyl acetate/just oneself
Alkane: 1:50 to 1:10) purifying obtains as product as light yellow solid A6 (3.47 grams, yield 85.7%).1HNMR:(400MHz,
DMSO-d6) δ ppm:8.28 (d, J=10.7Hz, 1H), 8.13 (d, J=7.5Hz, 1H), 4.08 (s, 1H) .LC-MS:(ESI)
M/z=197 (M+H)+。
1.2 intermediate tert-butyl 3,3-, the bis- fluoro- 1- methyl piperazine of fluoro- 4- hydroxy piperidine -1- t-butyl formate B8 and 3,3- bis-
The synthesis of pyridine -4- alcohol C2
Synthetic route is as follows:
Step 1: B1 (81.7 is added in methanol (300 milliliters) solution to benzotriazole (47 grams, 394.5mmol)
Gram, 394.5mmol) and 37% formaldehyde (37.9 milliliters, 512.9mmol), obtained mixture be stirred at room temperature 16 hours.
Mixture is removed under vacuum, residue is poured into water (500 milliliters), is extracted with ethyl acetate (500 milliliters × 3), is passed through
Sodium sulphate is dried, filtered and concentrated, and is obtained as yellow oil product B2 (132 grams, yield 98.8%).
Step 2: at room temperature, to what is be added in the tetrahydrofuran of zinc powder (56 grams, 862mmol) (500 milliliters) solution
Trimethyl silicane chlorine (49 grams, 452mmol).Then difluoro bromine second is added dropwise in the stirring of gained suspension at room temperature after 15 minutes
Acetoacetic ester (96 grams, 474mmol), stirs the mixture for 15 minutes.Then B2 (146 grams, 431mmol) are added at room temperature in tetrahydro
Solution in furans (500 milliliters), and be stirred overnight.The mixture pours into the saturated aqueous solution of sodium bicarbonate (2.5 liters), uses second
(500 milliliters) of acetoacetic ester extractions, are filtered with diatomite, are separated, and organic phase is dried over sodium sulfate, filters and be concentrated, obtain remnants
It is used silica gel column purification (ethyl acetate/n-hexane=1/50 to 1/20), obtains the product B3 (90 for yellow oil by object
Gram, yield 60.8%).
Step 3: it is taken the photograph into tetrahydrofuran (500 milliliters) solution of diisopropylamine (63.0 grams, 629mmol) subzero 70
N-BuLi (2.5M hexane, 231.5 milliliters, 576mmol) solution is added dropwise in family name's degree, and it is Celsius that gained mixture is warming up to subzero 10
Degree reaction 30 minutes.Then system is cooled to the tetrahydro furan that B3 (90 grams, 262mmol) are added dropwise after subzero 70 degrees Celsius
It mutters solution (500 liters).Stirring 30 minutes, and be gradually heated to room temperature and be stirred for 1 hour.Mixture is poured into saturated ammonium chloride
It in aqueous solution (500 milliliters), is extracted with ethyl acetate (500 liters × 3), organic phase is dried over sodium sulfate, filters and be concentrated, obtain
For yellow oil product B4 (90.7 grams).Crude product is directly used in next step without further purification.
Step 4: (90 grams, 302mmol) addition 6 mole hydrochlorides (900 milliliters) aqueous solutions of B4 heat the mixture to back
Stream 3 hours.After being cooled to room temperature, mixture is poured slowly into 8 molar sodium hydroxides (1 liter), (1 liter) three is extracted with ethyl acetate
Secondary, organic phase is concentrated into 4-5 liter, is added n-hexane (600 milliliters), stirs the mixture for 1 hour and filter, and obtains as white admittedly
Body product B5 (34 grams, two step yields 46.5%).
Step 5: boron hydrogen is added portionwise at 0-5 degrees Celsius into methanol (730 milliliters) solution of B5 (34 grams, 139mmol)
Change sodium (7.9 grams, 209mmol).Sodium bicarbonate aqueous solution (0.1 is added after mixture is stirred for 15 minutes under 0-5 degrees Celsius
Mole, 54 milliliters), and stir the mixture for 5 minutes, mixture is dry with sodium sulphate, concentration, and pass through silica gel column purification
(ethyl acetate/n-hexane=1/20 to 1/10) obtains colorless oil as product B6 (30 grams, yield 97.1%).
Step 6: catalyst palladium dydroxide/activity is added into ethyl alcohol (600 milliliters) solution of B6 (30 grams, 134mmol)
Charcoal (10%, 3.0 grams) stirs mixture 4 hours under hydrogen balloon.It filters the mixture and is concentrated, obtain as white solid
Product B7 (15.8 grams, yield 85.8%).1HNMR:(400MHz, DMSO-d6) δ ppm:5.43 (d, J=5.1Hz, 1H), 3.71
(m,1H,),2.98(m,1H),2.84–2.57(m,2H),2.23(s,1H),1.85–1.64(m,1H),1.60–1.34(m,
1H).LC-MS:(ESI) m/z=138.0 (M+H)+
Step 7: at room temperature, until 88% formic acid solution (941 milligrams, 18.0mmol) of B7 (500 milligrams, 3.6mmol)
Middle additionFormaldehyde (584 milligrams, 7.2mmol) solution.Solution is stirred 30 minutes under 78 degrees Celsius.The mixing
Object with sodium hydrate aqueous solution wash adjust pH toMixture (30 milliliters × 3) are extracted with ethyl acetate.By organic phase
It is dried and concentrated, is obtained as white solid product B8 (340 milligrams, yield 62.5%) with sodium sulphate.1H NMR(400MHz,
DMSO-d6) δ 5.48 (d, J=5.4Hz, 1H), 3.79-3.48 (m, 1H), 2.74 (dd, J=22.1,12.2Hz, 1H), 2.46-
2.34(m,1H),2.20(s,4H),1.90–1.69(m,1H),1.69–1.47(m,1H).LC-MS:(ESI) m/z=152 [M+
H]+。
1.3 intermediates (Z)-nitrogen '-{ 2- cyano -4- [(the fluoro- 1- methyl piperidine -4- base of 3,3- bis-) oxygroup] -5- methoxyl group
Phenyl }-nitrogen, the synthesis of -2 methylrnethwirnidamide A9 of nitrogen
Synthetic route is as follows:
Step 1: to the nitrogen of sodium hydride (4.85 grams, 102mmol), 50 in nitrogen-dimethyl acetamide (10 milliliters) solution
The nitrogen of A6 (10 grams, 51mmol) and B8 (7.71 grams, 51mmol), nitrogen-dimethyl acetamide (30 are added dropwise under degree Celsius nitrogen protection
Milliliter) solution.It is stirred 1 hour under 0 degree Celsius.The saturated solution of ammonium chloride is poured the mixture into, and is extracted with ethyl acetate.
Organic phase is washed with brine, is dried over sodium sulfate, be concentrated in a vacuum and passes through silica gel column purification (ethyl acetate/n-hexane
=1:3 to 1:1) obtains as yellow solid product A7 (12 grams, yield 71%).1HNMR:(400MHz,CDCl3-d6)δppm:
7.85 (s, 1H), 7.39 (s, 1H), 4.56 (td, J=9.7,4.9Hz, 1H), 4.06 (s, 3H), 2.96-2.86 (m, 1H),
2.79 (dd, J=19.9,12.3Hz, 1H), 2.57 (dd, J=29.0,23.4Hz, 2H), 2.43 (s, 3H), 2.18 (dd, J=
8.1,3.9Hz, 2H) .LC-MS:(ESI) m/z=328 (M+H)+
Step 2: in acetic acid (250 milliliters) solution of A7 (5 grams, 15.28mmol) be added zinc powder (9.93 grams,
In 152.8mmol).Mixture stirs 0.5 hour at 30-40 degrees Celsius.Reaction solution pours into ethyl acetate (200mL) and water
It is to 7. separation organic phases and dry with sodium sulphate that sodium bicarbonate adjusting pH value is added in (400mL).It is dense to filter the mixture vacuum
Contracting filtrate obtains being directly used in for yellow oil product A8 (4.4 grams, yield 88.0%) in next step.LC-MS:(ESI)m/z
=298 (M+H)+
Step 3: A8 (4.4 grams, 14.8mmol) and nitrogen, nitrogen-dimethylformamide dimethyl acetal (8.8 grams, 74mmol)
Toluene (50 milliliters) solution in mixture 100 degrees Celsius under nitrogen protection stir 20 hours.It is concentrated in vacuo the mixing
Object obtains residue, it is used silica gel column purification (methylene chloride/methanol=100:1), is obtained as yellow oil product A9
(3.4 grams, 63%).1HNMR:(400MHz,DMSO)δppm:7.58(s,1H),7.17(s,1H),6.47(s,1H),4.20
(tt, J=10.1,5.1Hz, 1H), 3.88 (s, 3H), 3.08 (s, 6H), 2.90 (ddd, J=18.4,11.8,4.4Hz, 1H),
2.69 (dt, J=30.2,9.6Hz, 2H), 2.46 (dd, J=15.2,8.9Hz, 1H), 2.39 (s, 3H), 2.08 (s, 2H) .LC-
MS:(ESI) m/z=353 (M+H)+。
The synthesis of 1.4 quinazoline derivants (I)
Synthetic route is as follows:
Step 1: A9 (3.4 grams, 9.65mmol) and the fluoro- 3- of 2- ((trimethyl silicane methyl) acetenyl) aniline (4 grams,
19.3mmol) in the mixture of acetic acid (90 milliliters), 80 degrees Celsius stirred under nitrogen atmosphere 16 hours.After cooling, carbonic acid is used
Hydrogen sodium saturated solution is handled to pH=8, and is extracted with dichloromethane.Organic phase sodium sulphate is dry and vacuum concentration obtains remnants
Object, by its use silica gel column purification (methylene chloride/methanol=100:1), obtain for white solid product A10 (2.4 grams, yield
48%).LC-MS:(ESI) m/z=515 (M+H)+
Step 2: TBAF (1M tetrahydro furan is added in the solution of tetrahydrofuran (10 milliliters) in A10 (1 gram, 1.94mmol)
It mutters solution, 1.94 milliliters, 1.94mmol), it is stirred at room temperature 0.5 hour.It is used silica gel column purification (dichloro by vacuum concentration
Methane/methanol=200:1 to 100:1) obtains as yellow solid product A11 (800 milligrams, yield 93%).1HNMR:
(400MHz,CDCl3- d6) δ ppm:8.74 (s, 1H), 8.63 (td, J=8.0,1.7Hz, 1H), 7.42 (s, 1H), 7.35 (d, J
=8.5Hz, 2H), 7.28-7.18 (m, 2H), 4.50 (dd, J=9.5,4.9Hz, 1H), 4.05 (s, 3H), 3.38 (s, 1H),
3.07–2.91(m,1H),2.88–2.69(m,2H),2.56(s,1H),2.45(s,3H),2.30–2.13(m,2H)。LC-MS:
(ESI) m/z=443 (M+H)+
Step 3: racemic mixture A11 (1.03 grams) makes through efficient liquid phase chiral separation column OJ-H (4.6*100*5um)
With methanol (0.2% methanol ammonia) cross column obtain enantiomer-pure (R)/(-) free alkali cpd (I) (480 milligrams, ee% > 99%,
LC-MS:(ESI) m/z=443 (M+H)+)。
The above method is hydrate, has hygroscopicity, crystal form conversion occurs in heating process.Due to moisture absorption and thermally labile
It is difficult to that solid pharmaceutical preparation is made under drug processing conditions.Therefore, it is necessary to further prepare with superior physicochemical properties
The preferred salt form of quinazoline derivant and the crystal form of salt advantageous can use in drug processing and pharmaceutical composition.
The preparation of the hydrochloride Form A of 2. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant shown in about 20 milligrams of formula (I) is weighed (that is, (R) -6- [(3,3- bis- fluoro- 1- methyl piperidine -4-
Base) oxygroup]-nitrogen-(3- acetenyl -2- fluorophenyl) -7- methoxyquinazoline hydrochloride -4- amine (I)) sample in 1.5 milliliters of bottles, adds
Enter 0.6 ml methanol and 46 microlitres of hydrochloric acid (1mol/L), be stirred at room temperature about two days later, it is solid to be centrifugated out the wet sample of lower layer
Body.It is detected through XRPD, which is hydrochloride Form A.
The preparation of the hydrochloride Form B of 3. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant sample shown in about 160 milligrams of formula (I) is weighed, 5 milliliters of tetrahydrofuran/water (19/1, v/ are added
V), 0.37 milliliter of hydrochloric acid (1mol/L) and into the suspension is added, is stirred at room temperature about two days, is centrifugated out lower layer
Wet sample solid.It is detected through XRPD, which is hydrochloride Form B.
The preparation of the hydrochloride Form H of 4. quinazoline derivant of the present invention (I) of embodiment
In 3 milliliters of bottles 2 milliliters of ethyl alcohol are added, in room temperature after filtering in the hydrochloride Form B sample for weighing about 10 milligrams
Lower open mouth quickly volatilizees.It is detected through XRPD, obtained solid is hydrochloride Form H.
The preparation of the hydrochloride Form I of 5. quinazoline derivant of the present invention (I) of embodiment
The hydrochloride Form H sample for weighing about 10 milligrams, is cooled to room after being heated to 125 DEG C using DSC Q2000
Temperature obtains hydrochloride Form I.
The preparation of the fumarate crystal form A of 6. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant shown in about 160 milligrams of formulas (I) and 45 milligrams of fumaric acid samples are weighed in 20 milliliters of vials,
After 5 ml methanols are added, it is stirred at room temperature about two days, solid is collected by centrifugation.It is detected through XRPD, which is that fumarate is brilliant
Type A.
The preparation of the succinate crystal form A of 7. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant shown in about 160 milligrams of formulas (I) and 43 milligrams of succinic acid samples are weighed in 20 milliliters of vials,
After 5 milliliters of acetone are added, it is stirred at room temperature about two days, solid is collected by centrifugation.It is detected through XRPD, which is that succinate is brilliant
Type A.
The preparation of the maleate crystal form A of 8. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant shown in about 10 milligrams of formulas (I) and 2.6 milligrams of maleic acid samples are weighed in 1.5 milliliters of vials
In, 0.3 milliliter of acetone is added, is stirred at room temperature about two days, solid is collected by centrifugation.It is detected through XRPD, which is maleic acid
Salt crystal form A.
The preparation of the glycollate crystal form A of 9. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant shown in about 150 milligrams of formulas (I) and 27 milligrams of glycolic samples are weighed in 1.5 milliliters of vials
In, 5 milliliters of ethyl acetate are added, is stirred at room temperature about two days, solid is collected by centrifugation.It is detected through XRPD, which is ethyl alcohol
Hydrochlorate crystal form A.
The preparation of the hydrochloride Form F of 10. quinazoline derivant of the present invention (I) of embodiment
The hydrochloride sample for weighing about 5 milligrams is added 0.1 ml methanol and makes it dissolve in 3 milliliters of vials.By institute
It obtains clear solution to be placed in 20 milliliters of vials for filling 5 milliliters of isopropyl acetates, gas-liquid is spread at room temperature, until there is solid
It is precipitated.It is detected through XRPD, obtained solid is hydrochloride Form F.
The preparation of the hydrochloride Form C of 11. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant sample shown in about 10 milligrams of formula (I) is weighed, is added 0.3 milliliter of acetonitrile, and to the suspension
The middle hydrochloric acid (1mol/L) for being added 46 microlitres, is stirred at room temperature and is about centrifugated out the wet sample solid of lower layer two days later.Through XRPD
Detection, is accredited as dihydrochloride crystal form C.
The preparation of the hydrochloride Form D of 12. quinazoline derivant of the present invention (I) of embodiment
The hydrochloride Form C sample for weighing about 2 milligrams, is cooled to room after being heated to 140 degree using DSC Q2000
Temperature obtains dihydrochloride crystal form D.
The preparation of the sulfate crystal form A of 13. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant sample shown in about 10 milligrams of formulas (I) is weighed in 1.5 milliliters of vials, 0.3 milliliter of first is added
Alcohol and 23 microlitres of aqueous sulfuric acids (1mol/L), are stirred at room temperature about two days, solid are collected by centrifugation.It is detected through XRPD, this is solid
Body is sulfate crystal form A.
The preparation of the oxalate crystal form A of 14. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant shown in about 10 milligrams of formulas (I) and 3.7 milligrams of adipic acid samples are weighed in 1.5 milliliters of vials
In, 0.3 ml methanol is added, is stirred at room temperature about two days, solid is collected by centrifugation.It is detected through XRPD, which is adipic acid
Salt crystal form A (the complete adipic acid containing a small amount of unreacted, characteristic peak are as follows: 21.6,25.7).
The preparation of the malate crystal form A of 15. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant shown in about 10 milligrams of formulas (I) and 2.9 milligrams of malic acid samples are weighed in 1.5 milliliters of vials
In, after 0.3 ml methanol is added, it is stirred at room temperature about two days, solid is collected by centrifugation.It is detected through XRPD, which is apple
Hydrochlorate crystal form A.
The preparation of the benzene sulfonate crystal form A of 16. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant shown in about 10 milligrams of formulas (I) and 3.7 milligrams of benzene sulfonic acid samples are weighed in 1.5 milliliters of vials
In, 0.3 ml methanol is added, is stirred at room temperature about two days, solid is collected by centrifugation.It is detected through XRPD, which is benzene sulfonic acid
Salt crystal form A.
The preparation of the benzene sulfonate crystal form B of 17. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant shown in about 10 milligrams of formulas (I) and 3.5 milligrams of benzene sulfonic acid samples are weighed in 1.5 milliliters of vials
In, 0.3 milliliter of acetonitrile is added, is stirred at room temperature about two days, solid is collected by centrifugation.It is detected through XRPD, which is benzene sulfonic acid
Salt crystal form B.
The preparation of the benzene sulfonate crystal form C of 18. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant shown in about 10 milligrams of formulas (I) and 3.9 milligrams of benzene sulfonic acid samples are weighed in 1.5 milliliters of vials
In, the mixed solvent (19:1, v/v) of 0.3 milliliter of tetrahydrofuran and water is added, is stirred at room temperature about two days, is collected by centrifugation solid
Body.It is detected through XRPD, which is benzene sulfonate crystal form C.
The preparation of the benzoate crystal form A of 19. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant shown in about 10 milligrams of formulas (I) and 3.0 milligrams of benzoic acid samples are weighed in 1.5 milliliters of vials
In, after 0.3 ml methanol is added, it is stirred at room temperature about two days, solid is collected by centrifugation.It is detected through XRPD, which is benzene first
Hydrochlorate crystal form A.
The preparation of the hippurate crystal form A of 20. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant shown in about 10 milligrams of formulas (I) and 4.2 milligrams of hippuric acid samples are weighed in 1.5 milliliters of vials
In, after 0.3 ml methanol is added, it is stirred at room temperature about two days, solid is collected by centrifugation.It is detected through XRPD, which is horse urine
Hydrochlorate crystal form A.
The preparation of the Crystal form of oxalate A of 21. quinazoline derivant of the present invention (I) of embodiment
Quinazoline derivant shown in about 10 milligrams of formulas (I) and 2.0 milligrams of oxalic acid samples are weighed in 1.5 milliliters of vials,
After 0.3 ml methanol is added, it is stirred at room temperature about two days, solid is collected by centrifugation.It is detected through XRPD, which is that oxalates is brilliant
Type A.
Embodiment 22. characterizes the crystal form of the salt of quinazoline derivant of the invention (I) by XRPD figure
XRPD device information is as follows:
XRPD map acquires on the X-ray powder diffraction analyzer of Bruker, and XRPD parameter is as shown in table 1.
1 XRPD test parameter of table
According to hydrochloride Form A, XRPD (the X-ray powder of the quinazoline derivant (I) of the present embodiment the method preparation
Last diffraction) map is as shown in Fig. 1, embodiments such as the following table 2:
Table 2
According to hydrochloride Form B, the XRPD (x-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Diffraction) map is as shown in Fig. 2, embodiments such as the following table 3:
Table 3
According to hydrochloride Form H, the XRPD (x-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Diffraction) map is as shown in Fig. 3, embodiments such as the following table 4:
Table 4
According to hydrochloride Form I, the XRPD (x-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Diffraction) map is as shown in Fig. 4, embodiments such as the following table 5:
Table 5
According to fumarate crystal form A, XRPD (the X-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Last diffraction) map is as shown in Fig. 5, embodiments such as the following table 6:
Table 6
According to succinate crystal form A, XRPD (the X-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Last diffraction) map is as shown in Fig. 6, embodiments such as the following table 7:
Table 7
According to maleate crystal form A, XRPD (the X-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Last diffraction) map is as shown in Fig. 7, embodiments such as the following table 8:
Table 8
According to glycollate crystal form A, XRPD (the X-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Last diffraction) map is as shown in Fig. 8, embodiments such as the following table 9:
Table 9
According to hydrochloride Form F, the XRPD (x-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Diffraction) map is as shown in Fig. 9, embodiments such as the following table 10:
Table 10
According to hydrochloride Form C, the XRPD (x-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Diffraction) map is as shown in Fig. 10, embodiments such as the following table 11:
Table 11
According to hydrochloride Form D, the XRPD (x-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Diffraction) map is as shown in Fig. 11, embodiments such as the following table 12:
Table 12
According to sulfate crystal form A, the XRPD (x-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Diffraction) map is as shown in Fig. 12, embodiments such as the following table 13:
Table 13
According to oxalate crystal form A, XRPD (the X-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Last diffraction) map is as shown in Fig. 13, embodiments such as the following table 14:
Table 14
According to malate crystal form A, XRPD (the X-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Last diffraction) map is as shown in Fig. 14, embodiments such as the following table 15:
Table 15
According to benzene sulfonate crystal form A, XRPD (the X-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Last diffraction) map is as shown in Fig. 15, embodiments such as the following table 16:
Table 16
According to benzene sulfonate crystal form B, XRPD (the X-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Last diffraction) map is as shown in Fig. 16, embodiments such as the following table 17:
Table 17
According to benzene sulfonate crystal form C, XRPD (the X-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Last diffraction) map is as shown in Fig. 17, embodiments such as the following table 18:
Table 18
According to benzoate crystal form A, XRPD (the X-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Last diffraction) map is as shown in Fig. 18, embodiments such as the following table 19:
Table 19
According to hippurate crystal form A, XRPD (the X-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Last diffraction) map is as shown in Fig. 19, embodiments such as the following table 20:
Table 20
According to Crystal form of oxalate A, the XRPD (x-ray powder of the quinazoline derivant (I) of embodiment the method preparation
Diffraction) map is as shown in Fig. 20, embodiments such as the following table 21:
Table 21
D is the interplanar distance of two neighboring crystal face in crystal lattices, by angstrom as unit of, I% is intensity.
As shown in Figure 1, the XRPD map of the hydrochloride Form A of quinazoline derivant (I) provided by the invention 2 θ=
6.48,7.31,9.36,10.26,13.12,14.37,14.98,16.06,16.88,17.48,18.25,20.01,20.83,
21.55,22.21,23.35,25.47,26.60,27.46,28.29,29.98,34.07,34.89,36.25,36.47,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 36.87,37.54.
As shown in Figure 2, the XRPD map of the hydrochloride Form B of quinazoline derivant (I) provided by the invention 2 θ=
4.32,5.98,6.54,7.28,8.17,10.52,13.20,15.99,17.74,18.48,19.32,19.84,22.56,
There is derivative peak at 23.88,24.36,24.87,30.47,32.92,33.55,34.60,38.06,38.34, above-mentioned 2 θ value
Error range is ± 0.2.
From the figure 3, it may be seen that the XRPD map of the hydrochloride Form H of quinazoline derivant (I) provided by the invention 2 θ=
5.83,6.43,7.26,8.10,10.24,11.93,13.22,14.11,14.45,14.88,15.78,16.80,17.95,
Have at 18.96,20.25,21.07,21.65,24.16,24.53,25.67,26.37,27.03,27.61 and derives peak, above-mentioned 2
The error range of θ value is ± 0.2.
As shown in Figure 4, the XRPD map of the hydrochloride Form I of quinazoline derivant (I) provided by the invention 2 θ=
6.88,7.42,8.20,12.31,13.20,13.88,14.23,14.66,15.69,17.48,17.90,18.64,19.23,
20.24,20.92,21.94,22.88,23.42,23.88,25.12,25.40,25.85,26.64,28.07,28.92,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 31.19,33.10.
As shown in Figure 5, the XRPD map of the fumarate crystal form A of quinazoline derivant (I) provided by the invention 2 θ=
6.51,6.74,7.47,9.37,10.82,13.43,13.97,14.61,17.78,18.51,18.80,19.69,20.90,
21.36,21.68,22.63,23.76,24.39,27.09,28.73,29.69,30.52,31.07,35.14,36.12,38.33
Place has derivative peak, and the error range of above-mentioned 2 θ value is ± 0.2.
It will be appreciated from fig. 6 that the XRPD map of the succinate crystal form A of quinazoline derivant (I) provided by the invention 2 θ=
3.92,4.40,6.56,6.74,7.50,9.42,11.92,12.68,13.53,14.50,14.84,15.22,15.68,
16.25,17.82,18.55,19.48,20.34,20.99,22.08,22.59,24.14,24.52,24.92,28.07,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 30.92,36.11.
As shown in Figure 7, the XRPD map of the maleate crystal form A of quinazoline derivant provided by the invention 2 θ=
6.25,8.44,8.68,9.42,10.41,14.42,14.88,16.65,17.93,18.78,20.58,21.17,22.63,
Have at 25.16,31.15,32.40,33.66,34.34,34.52,35.82,36.06,36.35,36.91 and derives peak, above-mentioned 2
The error range of θ value is ± 0.2.
As shown in Figure 8, the XRPD map of the glycollate crystal form A of quinazoline derivant provided by the invention 2 θ=
4.53,5.89,6.59,7.35,10.02,12.54,13.26,15.94,17.93,18.67,19.36,19.84,21.06,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 24.99,31.13,33.48,34.79,35.56,36.17.
As shown in Figure 9, the XRPD map of the hydrochloride Form F of quinazoline derivant (I) provided by the invention 2 θ=
4.91,5.67,6.51,6.77,7.44,8.58,9.20,9.73,10.40,10.85,11.86,13.58,14.30,14.78,
15.57,15.85,16.15,16.41,16.97,17.89,18.96,19.76,20.45,20.79,21.57,22.21,24.17
Place has derivative peak, and the error range of above-mentioned 2 θ value is ± 0.2.
As shown in Figure 10, the XRPD map of the hydrochloride Form C of quinazoline derivant (I) provided by the invention 2 θ=
5.66,7.16,8.32,8.86,9.52,10.98,11.63,12.80,13.57,13.96,14.81,15.14,15.49,
16.55,16.86,17.61,22.04,22.93,24.55,26.19,27.30,28.49,34.12,34.76,35.65,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 36.68,37.31,37.80,38.20,38.53.
As shown in Figure 11, the XRPD map of the hydrochloride Form D of quinazoline derivant (I) provided by the invention 2 θ=
3.43,6.72,7.12,8.47,9.32,12.25,13.44,14.07,15.69,16.87,17.22,17.97,19.77,
20.73,22.25,22.82,23.64,24.77,25.40,27.28,28.13,29.69,31.01,33.48,34.87,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 35.42,38.08.
As shown in Figure 12, the XRPD map of the sulfuric acid crystal form A of quinazoline derivant (I) provided by the invention 2 θ=
7.27,8.41,11.88,14.96,18.23,19.68,20.64,24.83,25.82,27.10,28.16,29.79,30.71,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 32.35,34.12,35.56,37.56,38.37.
As shown in Figure 13, the XRPD map of the oxalate crystal form A of quinazoline derivant (I) provided by the invention 2 θ=
5.43,6.88,7.38,9.56,13.68,15.10,15.43,16.32,16.88,17.68,18.60,19.02,20.58,
21.62,22.33,22.70,23.35,25.68,27.29,27.88,28.53,29.37,31.35,34.89,37.11,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 37.78,38.17,38.36,39.65.
As shown in Figure 14, the XRPD map of the malate crystal form A of quinazoline derivant (I) provided by the invention 2 θ=
5.43,6.53,7.49,8.35,9.17,12.10,13.16,16.17,18.77,19.85,20.79,23.14,23.94,
Have at 26.66,28.25,29.32,30.38,33.24,33.69,34.80,35.97,36.87,37.88 and derives peak, above-mentioned 2
The error range of θ value is ± 0.2.
As shown in Figure 15, the XRPD map of the benzene sulfonate crystal form A of quinazoline derivant provided by the invention 2 θ=
5.48,6.56,7.08,7.65,8.14,8.48,9.71,10.55,11.14,11.77,13.32,13.95,15.32,16.46,
16.89,17.82,19.15,19.70,20.43,21.02,21.98,22.68,23.23,25.26,26.07,26.59,
Have at 28.63,29.09,30.45,31.12,32.09,32.55,33.66,35.76,37.86,38.67,39.11 and derives
Peak, the error range of above-mentioned 2 θ value are ± 0.2.
As shown in Figure 16, the XRPD map of the benzene sulfonate crystal form B of quinazoline derivant provided by the invention 2 θ=
5.50,6.32,7.28,8.50,9.74,10.79,11.55,13.22,14.49,15.53,16.26,16.97,18.29,
There is derivative peak, the error model of above-mentioned 2 θ value at 19.71,21.36,22.21,23.44,24.19,25.34,25.87,27.16
Enclose is ± 0.2.
As shown in Figure 17, the XRPD map of the benzene sulfonate crystal form C of quinazoline derivant (I) provided by the invention 2 θ=
4.24,7.07,7.68,8.31,9.92,12.55,14.03,14.74,18.72,19.40,20.36,21.19,24.08,
24.73,26.14,27.49,28.28,31.68,33.90,34.82,35.06,35.78,36.54,37.57,37.89,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 38.36,39.0.
As shown in Figure 18, the XRPD map of the benzoate crystal form A of quinazoline derivant (I) provided by the invention 2 θ=
4.45,6.31,6.65,7.33,7.69,8.01,11.85,13.53,16.02,16.77,18.75,19.95,21.06,
21.76,22.56,23.41,26.94,27.44,27.61,27.98,28.55,29.05,31.92,32.29,32.93,
There is derivative peak at 33.72,34.61,35.35,35.95,37.08,38.13,39.62, the error range of above-mentioned 2 θ value is ±
0.2。
It appears from figure 19 that the XRPD map of the hippurate crystal form A of quinazoline derivant (I) provided by the invention 2 θ=
4.35,5.59,6.85,7.74,9.17,9.95,13.74,14.73,15.96,16.44,18.10,18.63,19.96,
21.38,24.25,25.37,25.72,26.39,27.23,28.56,30.25,30.82,33.31,34.58,35.29,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 36.39,37.24,37.9.
As shown in Figure 20, the XRPD map of the Crystal form of oxalate A of quinazoline derivant (I) provided by the invention 2 θ=
4.11,6.44,7.15,8.75,9.06,9.88,11.26,11.58,12.92,14.52,15.87,17.47,18.29,
19.43,20.14,20.49,23.70,24.34,26.36,26.92,29.75,31.72,32.67,32.99,34.21,
There is derivative peak, the error range of above-mentioned 2 θ value is ± 0.2 at 34.52,34.86,36.36,36.91,37.91,39.03.
After tested, the error range of 2 θ values be also possible to ± 0.2. it will be understood by those skilled in the art that these diffraction maximums not
Represent the hydrochloride Form A, B, C, D, F, H, I of quinazoline derivant (I), sulfate crystal form A, maleate crystal form A, succinic acid
Salt crystal form A, adipate crystal form A, glycollate crystal form A, malate crystal form A, fumarate crystal form A, benzene sulfonate crystal form
A, B, C, the detailed situation of diffraction maximum shown by benzoate crystal form A, hippurate crystal form A and Crystal form of oxalate A.X-ray powder
2 θ values of last diffraction pattern are slight change can to occur with changing between the variation and batch in machine and sample preparation, institute
The value of reference is not intended as absolute value.It will also be appreciated that the absolute intensity at peak may also become with orientation effect, therefore, this
Intensity shown in inventing is exemplary, and is not used to absolutely relatively.
The bioactivity of 23. quinazoline derivant of embodiment (I)
Tumour cell and glioma with EGFR Activating mutations (exons 19 lack Exon 19Del) albumen it is thin
Born of the same parents' viability examination uses CellTiter-Glo (CTG) assay;For about 5000 cell kinds in 96 orifice plates of each blank, 16 is small
Diluted compound in proportion is added in Shi Hou, after drug adds 72 hours, at equilibrium at room temperature 30 minutes.It is added in every hole
100 microlitres of CellTiter-Glo reagents are mixed with inducing cell lysis for orbital shaker 2 minutes.The plate is incubated at room temperature 10 points
Clock is with stabilized illumination signal.In TECAN Infinite M1000Pro instrument record luminous signal.
Inhibition (the IC of table 22. non-small cell lung cancer PC-9 tumour cell and glioma growth of tumour cell5oUnit be
nM)
As shown in Table 22, the quinazoline derivant (I) of the present invention for being configured as R is prominent with unexpected EGFRVIII
The activity of change is higher than enantiomter activity > 100 times.With the bioactivity similar with EGFR Del19 Activating mutations.
As shown in figure 21, in protein immunoblot (western blot) experiment, the phosphorylation of EGFRV3 is spread out by quinazoline
Biological (I) inhibits, and display quinazoline derivant (I) has good bioactivity, and special is situated between for EGFRV3 phosphorylation
The cancer led.
24. quinazoline derivant of embodiment (I) passes through blood-brain barrier rate
To determine whether quinazoline derivant (I) can pass through blood-brain barrier (BBB), rat is carried out with test compound
Administration.After 4 hours are administered, rat is killed, collects blood and brain tissue, analysis test compound concentration.Brain infiltration is defined as
The ratio between the concentration in compound concentration and blood plasma in brain tissue.Across the free concentration of drug that blood-brain barrier rate is in brain tissue
With the ratio between the free concentration of drug in blood plasma.P- glycoprotein is blood-brain barrier efflux protein, and cranium will be discharged outside P- glycoprotein substrate
It is interior.Breast drug-resistance protein is blood-brain barrier efflux protein, and encephalic will be discharged outside breast drug-resistance protein.
23. quinazoline derivant of table (I) passes through blood-brain barrier ability
Pass through blood-brain barrier rate detection in, compound free concentration of the compound of the present invention (I) in brain tissue with
The ratio between free concentration in blood plasma is higher than 50%, and not P- glycoprotein substrate or breast drug-resistance protein outlet substrate, energy
Across blood-brain barrier, therefore they are with the potentiality of effective blood drug concentration are reached in encephalic, for treating glioma or treatment
With pre- anti-cancer brain metastes, meninx transfer, the cancer of the brain and other central nervous diseases, and reduce occur outside cranium it is dose-limiting
The risk of toxicity.
25. quinazoline derivant of embodiment (I) is to the brain tumor being mutated with EGFRV3 in mouse subcutaneous patient's Primary Tumor
The drug effect of the tumour transplatation animal model of tissue
Patient's Primary Tumor tissue (brain tumor) is planted subcutaneous into mouse, is started medication, is controlled after long to about 150 cubic millimeters of tumour
It treats three weeks.
The brain tumor being mutated with EGFRV3 mouse subcutaneous patient's Primary Tumor tissue tumour transplatation animal model medicine
In effect experiment, first group is control group, is free of any drug.The single medicine of second group of quinazoline derivant (I), 3 mgs/kg, mouth
Clothes, twice a day, third group quinazoline derivant (I) list medicine, take orally by 10 mgs/kg, twice a day, the 4th group of quinazoline
Derivative (I) list medicine, takes orally, twice a day by 20 mgs/kg.As shown in figure 22, medication group (second, three, four groups) comparison the
One group (control group) shows the good inhibition increased to tumour, and the drug effect with statistical significance is shown in animal model
Dose dependent drug effect, the 4th group of cause tumour reduce, and show good drug effect.And the drug effect difference with statistical significance.It is swollen
The mutation of the RNA sequencing display EGFRV3 of tumor, display quinazoline derivant (I) have the good biological for EGFRV3 mutation living
Property and drug effect.
The equilbrium solubility of 26. quinazoline derivant of embodiment (I) and its salt crystal form in water
Experimental method: weighing the solid sample (free alkali and each salt form and crystal form) of about 10mg, 1.5mL water is added, in room
Temperature balance takes out the turbid solution of 0.3mL respectively after 24 hours, be centrifugated lower layer's solid and supernatant liquor.Supernatant liquor passes through
After 0.45 μm of (PTFE) filter filtering, the concentration of free alkali is tested respectively.
Table 23
As shown in Table 23, each salt form crystal form of quinazoline derivant (I) of the present invention is molten with good balance in water
Xie Du, it is preferable that the hydrochloride Form A, B, H, I and fumarate crystal form A of quinazoline derivant (I) of the present invention are in water
Equilbrium solubility > 500ug/mL.This absorption of drugs is highly beneficial.
27. stability experiment of embodiment
The salt form of one week physical and chemical stability quinazoline derivant (I) of the present invention and crystal form in 25 DEG C/60%RH and
One week physicochemical properties is stored under 40 DEG C/75%RH to stablize.TGA map shows each in embodiment 2-21 during heating
Crystal form has no significant change, and particularly, DSC map shows that fumarate crystal form A shows good stability.As shown in figure 23,
Fumarate crystal form A is during heating without obvious weightlessness, and fusing point is at about 240 degrees Celsius.Such property is to be conducive to prepare
It is processed into tablet.
28. quinazoline derivant of the present invention (I) of embodiment has good bioavilability
In pharmacokinetics in rats research, one group rat (three) are injected intravenously 1-2 mgs/kg, second group of rat
(three) 2-40 mgs/kg oral, and it is of the present invention that 7 time points (0.25,0.5,1,2,4,8,16 small time point) take blood to survey
Concentration of the quinazoline derivant (I) in blood calculates peak area and half-life period.The calculation of bioavilability are as follows: (drug port
Take peak area/oral dose)/(medical intravenous injects peak area/intravenous injection dosage) x100%.Quinazoline of the present invention spreads out
Each salt form and crystal form of biological (I) have good bioavilability, are all larger than > 35%.
Preferably: hydrochloride Form B, H, I (bioavilability > 60%) and fumarate crystal form A (bioavilability
80%);
More preferably: fumarate crystal form A (bioavilability 80%, 7.4 hours half-life period).
The mechanism of action of 29. quinazoline derivant of the present invention (I) of embodiment
In the experiment that quinazoline derivant of the present invention (I) inhibits the mechanism of action of EGFR, from 0.4nM equal proportion (2
EGFR enzyme is added in the solution of PolyE4Y1 to 0.0125nM and 384 orifice plates of 0 concentration in diluted 6 concentration again), hatches 15 points
Clock is added from the ATP of diluted 7 concentration of 600uM equal proportion (2 times) reaction after sixty minutes, and ADP-Glo reagent and detection is added
40 minutes survey RLU signals of reagent.As shown in figure 24, quinazoline derivant (I) of the present invention shows unexpected non-
ATP Competition mechanism.The benefit of this mechanism of action is it will be apparent that having at quinazoline derivant of the present invention (I)
There is this mechanism of action to show high activity and highly selective, there is the characteristics of Small side effects, overriding resistance.
In conclusion state quinazoline derivant (I) of the present invention has chiral 6 substitution (3, the 3- bis- fluoro- 1- for being R
Methyl piperidine -4- base) oxygroup, there can be high activity simultaneously, highly selective, the blood-brain barrier of height passes through rate, non-outlet substrate,
Inhibition activity with non ATP competition mechanism, while there is significant drug effect to non-small cell lung cancer and glioma, height
Bioavailability.It is emphasized that quinazoline derivant (I) of the present invention can have simultaneously to non-with unexpected
Small Cell Lung Cancer (is mediated, special EGFR Del19 and/or EGFR L858R Activating mutations by certain EGFR activated form
It is those of caused) and brain colloid (mediated by certain EGFR activated form, caused by special EGFRVIII Activating mutations
Those of) high bioactivity, the selectivity of height, the blood-brain barrier of height passes through the non ATP competitive inhibitor of rate.Especially
, the Noncompetition inhibition characteristic bring high activity and high selection of the chiral quinazoline derivant (I) for being R of the present invention
Property, can particularly have the activity of height to glioma.
The hydrochloride Form A, B, C, D, F, H, I of quinazoline derivant of the present invention, sulfate crystal form A, maleate crystal form
A, succinate crystal form A, adipate crystal form A, glycollate crystal form A, malate crystal form A, fumarate crystal form A, benzene sulphur
Hydrochlorate crystal form A, B, C, the solubility of benzoate crystal form A, hippurate crystal form A and Crystal form of oxalate A in water are all larger than formula
(I) quinazoline derivant shown in has better solubility, transformation of crystal does not occur in heating process, has good stabilization
Property.
The hydrochloride Form A, B, C, D, F, H, I of quinazoline derivant of the present invention, sulfate crystal form A, maleate are brilliant
Type A, succinate crystal form A, adipate crystal form A, glycollate crystal form A, malate crystal form A, fumarate crystal form A, benzene
Sulfonate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A and Crystal form of oxalate A have unexpected superior
Physicochemical properties use conducive in drug processing and pharmaceutical composition.It can be applied to treatment brain transplantation of non small cell Lung transfer,
The drug of meninx transfer, head and neck squamous cell carcinoma, squamous cell carcinoma, brain stem tumor, primary brain cancer or glioma etc., together
When the qualitative, quantitative information of curative effect and safety is provided, there is weight to the curative effect and safety for further studying such solid drugs
The meaning wanted.
Specific embodiments of the present invention are described above.It is to be appreciated that the invention is not limited to above-mentioned
Particular implementation, those skilled in the art can make various deformations or amendments within the scope of the claims, this not shadow
Ring substantive content of the invention.
Claims (41)
1. the crystal form of the hydrochloride of quinazoline derivant shown in formula (I), wherein the crystal form is crystal form A, crystal form B, crystal form C, crystalline substance
Type D, crystal form F, crystal form H or crystal form I;
Wherein, the XRPD map of the crystal form A is at following 2 θ with principal character peak: 6.5,13.1,9.4;At following 2 θ
With secondary feature peak: 7.3,18.2,20.0;With characteristic peak again at following 2 θ: 27.5,26.6,21.6;
The XRPD map of the crystal form B is at following 2 θ with principal character peak: 6.5,17.7,19.8;Have at following 2 θ
Secondary feature peak: 7.3,8.2,10.5,13.2;
The XRPD map of the crystal form C is at following 2 θ with principal character peak: 7.2,17.6,22.0
Secondary feature peak: 14.0,13.6,12.8
Characteristic peak again: 24.6,26.2,27.3
The XRPD map of the crystal form D is at following 2 θ with principal character peak: 13.4,7.1,25.4;Have at following 2 θ
Secondary feature peak: 6.7,18.0,19.8;With characteristic peak again at following 2 θ: 17.2,27.3,24.7;
The XRPD map of the crystal form F is at following 2 θ with principal character peak: 6.8,20.5,13.6;Have at following 2 θ
Secondary feature peak: 14.8,14.3,17.9,11.9;
The XRPD map of the crystal form H is at following 2 θ with principal character peak: 7.3,18.0,14.1;Have at following 2 θ
Secondary feature peak: 6.4,13.2,15.8;With characteristic peak again at following 2 θ: 16.8,14.5,20.3;
The XRPD map of the crystal form I is at following 2 θ with principal character peak: 18.6,7.4,6.9;Have at following 2 θ secondary
Want characteristic peak: 13.2,25.1,12.3;With characteristic peak again at following 2 θ: 14.7,28.1,14.2;
Wherein the error range of 2 θ values is ± 0.2.
2. crystal form as described in claim 1, which is characterized in that the crystal form A has substantially with XRPD map shown in FIG. 1;
The crystal form B has substantially with XRPD map shown in Fig. 2;
The crystal form C has substantially with XRPD map shown in Fig. 10;
The crystal form D has substantially with XRPD map shown in Figure 11;
The crystal form F has substantially with XRPD map shown in Fig. 9;
The crystal form H has substantially with XRPD map shown in Fig. 3;
The crystal form I has substantially with XRPD map shown in Fig. 4.
3. the preparation method of crystal form as claimed in claim 1 or 2, which is characterized in that
The preparation method of the crystal form A includes the following steps: for organic solvent and 0.8~1.2 equivalent of hydrochloric acid to be added shown in formula (I)
Quinazoline derivant stirs under 22-28 degrees Celsius, is centrifugated out lower layer's solid and obtains crystal form A;Wherein, every milliliter it is organic molten
Quinazoline derivant 10~200 milligram are added shown in formula (I) in agent;The organic solvent is methanol;
The preparation method of the crystal form B includes the following steps: for quinazoline derivant shown in formula (I) to be added in organic solvent, and
0.8~1.2 equivalent hydrochloric acid is added to the suspension to stir under 22-28 degrees Celsius, is centrifugated out the wet sample solid of lower layer and obtains
Crystal form B;Wherein, quinazoline derivant 10~200 milligram are added shown in formula (I) in every milliliter of organic solvent;The organic solvent
Tetrahydrofuran/the aqueous solution for being 15-20:1 for acetonitrile, ethyl acetate or volume ratio.
The preparation method of the crystal form C includes the following steps: that organic solvent for quinazoline derivant shown in formula (I) is added and is added
2~2.5 equivalent of hydrochloric acid stirs under 22-28 degrees Celsius, is centrifugated out the wet sample solid of lower layer and obtains dihydrochloride crystal form C;Wherein,
Every milliliter of organic solvent is added shown in formula (I) 10~200 milligrams of quinazoline derivant;The organic solvent is acetone;
The preparation method of the crystal form D includes the following steps: to add quinazoline derivant hydrochloride Form C sample shown in formula (I)
Heat obtains dihydrochloride crystal form D to being cooled to 22-28 degrees Celsius after 120~160 degrees Celsius;
The preparation method of the crystal form F includes the following steps: the quinazoline derivant hydrochloride Form B shown in formula (I) alcohol is added
Class organic solvent and based organic solvent, in 22-28 degrees Celsius of lower gas-liquid diffusion, until there is solid that crystal form F is precipitated to obtain;Wherein,
Hydrochloride Form B 10~200 milligram are added shown in formula (I) in every milliliter of organic solvent;The alcohol organic solvent is first
Alcohol, the based organic solvent are isopropyl acetate;
The preparation method of the crystal form H includes the following steps: to be added in the quinazoline derivant hydrochloride Form B shown in formula (I)
Organic solvent, volatilize to obtain crystal form H after filtering under 22-28 degrees Celsius;Wherein, it is added shown in formula (I) in every milliliter of organic solvent
10~200 milligrams of hydrochloride Form B;The organic solvent is ethyl alcohol;
The preparation method of the crystal form I includes the following steps: to heat quinazoline derivant hydrochloride Form H sample shown in formula (I)
22-28 degrees Celsius is cooled to after to 120~130 degrees Celsius.
4. the crystal form of the fumarate of quinazoline derivant shown in formula (I), wherein the crystal form is crystal form A;
The XRPD map of the crystal form A is at following 2 θ with principal character peak: 6.5,17.8,9.4;Have at following 2 θ secondary
Want characteristic peak: 13.4,7.5,19.7;With characteristic peak again at following 2 θ: 14.6,18.5;The wherein error range of 2 θ values
It is ± 0.2.
5. crystal form as claimed in claim 4, which is characterized in that the crystal form A has substantially with XRPD map shown in fig. 5.
6. a kind of preparation method of crystal form as described in claim 4 or 5, which is characterized in that the described method includes: at formula (I)
It after organic solvent is added in shown quinazoline derivant and 0.4-0.6 equivalent fumaric acid, is stirred under 22-28 degrees Celsius, centrifugation is received
Collection solid obtains the crystal form;Wherein, quinazoline derivant 10~200 milligram are added shown in formula (I) in every milliliter of organic solvent.
7. the crystal form of the succinate of quinazoline derivant shown in formula (I), wherein the crystal form is crystal form A;
The XRPD map of the crystal form A is at following 2 θ with principal character peak: 6.6,17.8,7.5;Have at following 2 θ secondary
Want characteristic peak: 9.4,20.3,18.5;With characteristic peak again at following 2 θ: 21.0,14.5,19.5;The wherein error of 2 θ values
Range is ± 0.2.
8. crystal form as claimed in claim 7, which is characterized in that the crystal form A has substantially with XRPD map shown in fig. 6.
9. a kind of preparation method of crystal form as claimed in claim 7 or 8, which is characterized in that the described method includes: at formula (I)
It after organic solvent is added in shown quinazoline derivant and 0.8-1.2 equivalent succinic acid, is stirred under 22-28 degrees Celsius, centrifugation is received
Collection solid obtains the crystal form;Wherein, quinazoline derivant 10~200 milligram are added shown in formula (I) in every milliliter of organic solvent.
10. the crystal form of the maleate of quinazoline derivant shown in formula (I), wherein the crystal form is crystal form A;
The XRPD map of the crystal form A is at following 2 θ with principal character peak: 6.3,18.8,16.7;Have at following 2 θ
Secondary feature peak: 25.2,21.2;Wherein the error range of 2 θ values is ± 0.2.
11. crystal form as claimed in claim 10, which is characterized in that the crystal form A has to scheme with XRPD shown in Fig. 7 substantially
Spectrum.
12. a kind of preparation method of crystal form as described in claim 10 or 11, which is characterized in that the described method includes: in formula
(I) it after organic solvent is added in quinazoline derivant shown in and 0.8-1.2 equivalent maleic acid, stirs, is centrifuged under 22-28 degrees Celsius
It collects solid and obtains the crystal form;Wherein, quinazoline derivant 10~200 milligram are added shown in formula (I) in every milliliter of organic solvent.
13. the crystal form of the glycollate of quinazoline derivant shown in formula (I), wherein the crystal form is crystal form A;
The XRPD map of the crystal form A is at following 2 θ with principal character peak: 6.6,7.4,17.9;Have at following 2 θ secondary
Want characteristic peak: 13.3;Wherein the error range of 2 θ values is ± 0.2.
14. crystal form as claimed in claim 13, which is characterized in that the crystal form A has to scheme with XRPD shown in Fig. 8 substantially
Spectrum.
15. a kind of preparation method of crystal form according to claim 13 or 14, which is characterized in that the described method includes: in formula
(I) it after organic solvent is added in quinazoline derivant shown in and 0.8-1.2 eq. ethanol acid, stirs, is centrifuged under 22-28 degrees Celsius
It collects solid and obtains the crystal form;Wherein, quinazoline derivant 10~200 milligram are added shown in formula (I) in every milliliter of organic solvent.
16. the crystal form of the sulfate of quinazoline derivant shown in formula (I), wherein the crystal form is crystal form A;
The XRPD map of the crystal form A is at following 2 θ with principal character peak: 7.3,18.2,15.0;The wherein error of 2 θ values
Range is ± 0.2.
17. crystal form as claimed in claim 16, which is characterized in that the crystal form A has to scheme with XRPD shown in Figure 12 substantially
Spectrum.
18. a kind of preparation method of the crystal form as described in claim 16 or 17, which is characterized in that the described method includes: by formula
(I) organic solvent is added in quinazoline derivant sample shown in and 0.8-1.2 equiv. sulfuric acid aqueous solution stirs under 22-28 degrees Celsius
It mixes, solid is collected by centrifugation and obtains the crystal form;Wherein, in every milliliter of organic solvent be added formula (I) shown in quinazoline derivant 10~
200 milligrams.
19. the crystal form of the oxalate of quinazoline derivant shown in formula (I), wherein the crystal form is crystal form A;
The XRPD map of the crystal form A is at following 2 θ with principal character peak: 6.9,15.1,13.7;Have at following 2 θ
Secondary feature peak: 15.4,9.6,19.0;With characteristic peak again at following 2 θ: 20.6,27.3,23.4;The wherein mistake of 2 θ values
Poor range is ± 0.2.
20. crystal form as claimed in claim 19, which is characterized in that the crystal form A has to scheme with XRPD shown in Figure 13 substantially
Spectrum.
21. a kind of preparation method of the crystal form as described in claim 19 or 20, which is characterized in that the described method includes: by formula
(I) organic solvent is added in quinazoline derivant sample shown in and 0.8-1.2 equivalent ethanedioic acid stirs under 22-28 degrees Celsius, from
The heart collects solid and obtains the crystal form;Wherein, the milli of quinazoline derivant 10~200 shown in formula (I) is added in every milliliter of organic solvent
Gram.
22. the crystal form of the malate of quinazoline derivant shown in formula (I), wherein the crystal form is crystal form A;
The XRPD map of the crystal form A is at following 2 θ with principal character peak: 6.5,18.8,19.9;Have at following 2 θ
Secondary feature peak: 7.5,8.4,9.2;Wherein the error range of 2 θ values is ± 0.2.
23. crystal form as claimed in claim 22, which is characterized in that the crystal form A has to scheme with XRPD shown in Figure 14 substantially
Spectrum.
24. a kind of preparation method of the crystal form as described in claim 22 or 23, which is characterized in that the described method includes: by formula
(I) organic solvent is added in quinazoline derivant sample shown in and 0.8-1.2 equivalent malic acid stirs under 22-28 degrees Celsius, from
The heart collects solid and obtains the crystal form;Wherein, the milli of quinazoline derivant 10~200 shown in formula (I) is added in every milliliter of organic solvent
Gram.
25. the crystal form of the benzene sulfonate of quinazoline derivant shown in formula (I), wherein the crystal form is crystal form A, crystal form B or crystal form
C;
Wherein, the XRPD map of the crystal form A is at following 2 θ with principal character peak: 6.6,14.0,15.3;At following 2 θ
With secondary feature peak: 7.1,5.5,19.7;With characteristic peak again at following 2 θ: 17.8,16.9,21.0;
The XRPD map of the crystal form B is at following 2 θ with principal character peak: 8.5,14.5,23.4;Have at following 2 θ
Secondary feature peak: 18.3,19.7;
The XRPD map of the crystal form C is at following 2 θ with principal character peak: 14.0,14.7,7.7;Have at following 2 θ
Secondary feature peak: 8.3,21.2,19.4;With characteristic peak again at following 2 θ: 27.5,24.7;
Wherein the error range of 2 θ values is ± 0.2.
26. crystal form as claimed in claim 25, which is characterized in that the crystal form A has to scheme with XRPD shown in figure 15 substantially
Spectrum;
The crystal form B has substantially with XRPD map shown in Figure 16;
The crystal form C has substantially with XRPD map shown in Figure 17.
27. a kind of preparation method of the crystal form as described in claim 25 or 26, which is characterized in that the preparation side of the crystal form A
Method includes: that the addition organic solvent of quinazoline derivant sample shown in formula (I) and 0.8-1.2 equivalent benzene sulfonic acid is Celsius in 22-28
The lower stirring of degree, is collected by centrifugation solid and obtains the crystal form A;Wherein, quinazoline derivative shown in formula (I) is added in every milliliter of organic solvent
10~200 milligrams of object;The organic solvent is methanol;
The preparation method of the crystal form B includes: that organic solvent and 0.8-1.2 is added in quinazoline derivant sample shown in formula (I)
Equivalent benzene sulfonic acid stirs under 22-28 degrees Celsius, and solid is collected by centrifugation and obtains the crystal form B;Wherein, add in every milliliter of organic solvent
Enter shown in formula (I) 10~200 milligrams of quinazoline derivant;The organic solvent is acetonitrile;
The preparation method of the crystal form C includes: that organic solvent and 0.8-1.2 is added in quinazoline derivant sample shown in formula (I)
Equivalent benzene sulfonic acid stirs under 22-28 degrees Celsius, and solid is collected by centrifugation and obtains the crystal form C;Wherein, add in every milliliter of organic solvent
Enter shown in formula (I) 10~200 milligrams of quinazoline derivant;The organic solvent be volume ratio be 15-20:1de tetrahydrofuran and
The mixed solvent of water.
28. the crystal form of the benzoate of quinazoline derivant shown in formula (I), wherein the crystal form is crystal form A;
The XRPD map of the crystal form A is at following 2 θ with principal character peak: 7.3,6.3,16.8;Have at following 2 θ secondary
Want characteristic peak: 13.5,18.7,27.0;Wherein the error range of 2 θ values is ± 0.2.
29. crystal form as claimed in claim 28, which is characterized in that the crystal form A has to scheme with XRPD shown in Figure 18 substantially
Spectrum.
30. a kind of preparation method of the crystal form as described in claim 28 or 29, which is characterized in that the described method includes: by formula
(I) organic solvent is added in quinazoline derivant sample shown in and 0.8-1.2 equivalent benzoic acid stirs under 22-28 degrees Celsius, from
The heart collects solid and obtains the crystal form;Wherein, the milli of quinazoline derivant 10~200 shown in formula (I) is added in every milliliter of organic solvent
Gram.
31. the crystal form of the hippurate of quinazoline derivant shown in formula (I), wherein the crystal form is crystal form A;
The XRPD map of the crystal form A is at following 2 θ with principal character peak: 5.6,6.9,20.0;Have at following 2 θ secondary
Want characteristic peak: 16.0,7.7,13.7;With characteristic peak again at following 2 θ: 24.3,26.4;The wherein error range of 2 θ values
It is ± 0.2.
32. crystal form as claimed in claim 31, which is characterized in that the crystal form A has to scheme with XRPD shown in Figure 19 substantially
Spectrum.
33. a kind of preparation method of the crystal form as described in claim 31 or 32, which is characterized in that the described method includes: by formula
(I) organic solvent is added in quinazoline derivant sample shown in and 0.8-1.2 equivalent hippuric acid stirs under 22-28 degrees Celsius, from
The heart collects solid and obtains the crystal form;Wherein, the milli of quinazoline derivant 10~200 shown in formula (I) is added in every milliliter of organic solvent
Gram.
34. the crystal form of the oxalates of quinazoline derivant shown in formula (I), wherein the crystal form is crystal form A;
The XRPD map of the crystal form A is at following 2 θ with principal character peak: 6.4,9.1,17.5;Have at following 2 θ secondary
Want characteristic peak: 12.9,14.5,26.4;With characteristic peak again at following 2 θ: 19.4,18.3,15.9;The wherein mistake of 2 θ values
Poor range is ± 0.2.
35. crystal form as claimed in claim 34, which is characterized in that the crystal form A has to scheme with XRPD shown in Figure 20 substantially
Spectrum.
36. a kind of preparation method of the crystal form as described in claim 34 or 35, which is characterized in that the described method includes: by formula
(I) organic solvent is added in quinazoline derivant sample shown in and 0.8-1.2 equivalent oxalic acid stirs under 22-28 degrees Celsius, is centrifuged
It collects solid and obtains the crystal form;Wherein, quinazoline derivant 10~200 milligram are added shown in formula (I) in every milliliter of organic solvent.
37. a kind of pharmaceutical composition, which is characterized in that the composition include as claim 1,4,7,10,13,16,19,
22, crystal form or their combination described in any one of 25,28,31,34 and pharmaceutically acceptable auxiliary material or it is complementary at
Point.
38. a kind of crystal form or right as described in any one of claim 1,4,7,10,13,16,19,22,25,28,31,34
It is required that pharmaceutical composition described in 37 is treated or prevented in preparation by EGF-R ELISA EGFR protein mediated disease
Purposes in drug.
39. purposes as claimed in claim 38, which is characterized in that the drug is to treat or prevent by epidermal growth factor receptor
Body EGFR is protein mediated, and is the drug of disease caused by EGFRVIII Activating mutations.
40. purposes as claimed in claim 38, which is characterized in that the drug is to treat or prevent by epidermal growth factor receptor
Body EGFR is protein mediated, and is the drug of disease caused by EGFR Del19 and/or EGFR L858R Activating mutations.
41. the purposes as described in claim 38,39 or 40, which is characterized in that the drug is to treat or prevent non-small cell
Brain metastasis, meninx transfer, head and neck squamous cell carcinoma, squamous cell carcinoma, brain stem tumor, primary brain cancer or glioma
Drug.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/625,315 US20240025874A1 (en) | 2018-04-08 | 2019-03-21 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application |
PCT/CN2019/079043 WO2019196619A1 (en) | 2018-04-08 | 2019-03-21 | Quinazoline derivative salt-form crystal form, and preparation method therefor and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810309035 | 2018-04-08 | ||
CN2018103090351 | 2018-04-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110343090A true CN110343090A (en) | 2019-10-18 |
CN110343090B CN110343090B (en) | 2021-06-04 |
Family
ID=68173327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810423951.8A Active CN110343090B (en) | 2018-04-08 | 2018-05-04 | Quinazoline derivative salt crystal form, preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110343090B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110354261A (en) * | 2018-04-09 | 2019-10-22 | 威尚(上海)生物医药有限公司 | The purposes of quinazoline compounds and Arastin in the combination medicine that preparation prevents disease |
CN110354130A (en) * | 2018-04-09 | 2019-10-22 | 威尚(上海)生物医药有限公司 | Purposes of the quinazoline compounds in the cancer drug that treatment has EGFRv3 Activating mutations |
WO2021209039A1 (en) * | 2020-04-17 | 2021-10-21 | 北京赛特明强医药科技有限公司 | Quinazoline compound, preparation method therefor and application thereof |
CN113527215A (en) * | 2020-04-17 | 2021-10-22 | 北京赛特明强医药科技有限公司 | Quinazoline compound, preparation method and application thereof |
CN115998743A (en) * | 2023-01-16 | 2023-04-25 | 威尚(上海)生物医药有限公司 | Application of quinazoline compound in overcoming Oritinib resistance |
WO2024016783A1 (en) * | 2022-07-21 | 2024-01-25 | 威尚(上海)生物医药有限公司 | 6-substituted chirally pure difluoropiperidine quinazoline derivative and preparation method therefor |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003040109A2 (en) * | 2001-11-03 | 2003-05-15 | Astrazeneca Ab | Quinazoline derivatives as antitumor agents |
CN101128456A (en) * | 2005-02-26 | 2008-02-20 | 阿斯利康(瑞典)有限公司 | Quinazoline derivatives as tyrosine kinase inhibitors |
WO2015154725A1 (en) * | 2014-04-11 | 2015-10-15 | 四川海思科制药有限公司 | Quinazoline derivative and preparation method and use in medicine thereof |
CN108069946A (en) * | 2016-11-08 | 2018-05-25 | 威尚(上海)生物医药有限公司 | With the substituted quinazoline compound through blood-brain barrier ability |
-
2018
- 2018-05-04 CN CN201810423951.8A patent/CN110343090B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003040109A2 (en) * | 2001-11-03 | 2003-05-15 | Astrazeneca Ab | Quinazoline derivatives as antitumor agents |
CN101128456A (en) * | 2005-02-26 | 2008-02-20 | 阿斯利康(瑞典)有限公司 | Quinazoline derivatives as tyrosine kinase inhibitors |
WO2015154725A1 (en) * | 2014-04-11 | 2015-10-15 | 四川海思科制药有限公司 | Quinazoline derivative and preparation method and use in medicine thereof |
CN108069946A (en) * | 2016-11-08 | 2018-05-25 | 威尚(上海)生物医药有限公司 | With the substituted quinazoline compound through blood-brain barrier ability |
Non-Patent Citations (1)
Title |
---|
ZENG QINGBEI等: "Discovery and evalution of clinical candidate AZD3759, a potent oral active, central vervous system-penetrant, epidermal growth factor recptor tyrosine kinase inhibitor", 《J.MED.CHEM.》 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110354261A (en) * | 2018-04-09 | 2019-10-22 | 威尚(上海)生物医药有限公司 | The purposes of quinazoline compounds and Arastin in the combination medicine that preparation prevents disease |
CN110354130A (en) * | 2018-04-09 | 2019-10-22 | 威尚(上海)生物医药有限公司 | Purposes of the quinazoline compounds in the cancer drug that treatment has EGFRv3 Activating mutations |
CN110354261B (en) * | 2018-04-09 | 2023-01-24 | 威尚(上海)生物医药有限公司 | Application of quinazoline compound and avastin in preparation of combined medicine for preventing diseases |
CN110354130B (en) * | 2018-04-09 | 2024-08-13 | 上海威道生物医药有限公司 | Application of quinazoline compounds in medicines for treating cancers with EGFRv3 activating mutation |
WO2021209039A1 (en) * | 2020-04-17 | 2021-10-21 | 北京赛特明强医药科技有限公司 | Quinazoline compound, preparation method therefor and application thereof |
CN113527215A (en) * | 2020-04-17 | 2021-10-22 | 北京赛特明强医药科技有限公司 | Quinazoline compound, preparation method and application thereof |
CN113527215B (en) * | 2020-04-17 | 2023-12-05 | 北京赛特明强医药科技有限公司 | Quinazoline compound, preparation method and application thereof |
WO2024016783A1 (en) * | 2022-07-21 | 2024-01-25 | 威尚(上海)生物医药有限公司 | 6-substituted chirally pure difluoropiperidine quinazoline derivative and preparation method therefor |
CN115998743A (en) * | 2023-01-16 | 2023-04-25 | 威尚(上海)生物医药有限公司 | Application of quinazoline compound in overcoming Oritinib resistance |
CN115998743B (en) * | 2023-01-16 | 2024-05-28 | 威尚(上海)生物医药有限公司 | Application of quinazoline compound in overcoming Oritinib resistance |
WO2024153256A1 (en) * | 2023-01-16 | 2024-07-25 | 威尚(上海)生物医药有限公司 | Use of quinazoline compound in overcoming osimertinib drug resistance |
Also Published As
Publication number | Publication date |
---|---|
CN110343090B (en) | 2021-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110343090A (en) | Quinazoline derivant salt form crystal form and preparation method and application | |
CN108069946A (en) | With the substituted quinazoline compound through blood-brain barrier ability | |
TWI623533B (en) | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications | |
CN101687857B (en) | Pyridazinone derivates | |
CN105934435A (en) | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof | |
CN102470127A (en) | Biaryl compounds and methods of use thereof | |
CN105263934A (en) | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease | |
JP2011527291A (en) | Icotinib hydrochloride, compound, crystallographic form, concomitant drug and its use | |
TW201236684A (en) | Pharmaceutically acceptable salts of (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation process and pharmaceutical use there of | |
CN110461853A (en) | Benzothiophene estrogenic agents | |
JP6654197B2 (en) | Indolinone compounds and uses thereof | |
WO2019001379A1 (en) | Indazole compound for use in inhibiting kinase activity, composition and application thereof | |
WO2019154091A1 (en) | Substituted diaminopyrimidine compound | |
KR20210038906A (en) | Methods of treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use therein | |
CN110357858A (en) | With the 5 substitution difluoropiperdin compounds across blood-brain barrier ability | |
TW201249836A (en) | 4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof | |
CN108026046A (en) | The purposes of substituted quinazoline compound and its inhibitor as G12C mutant KRAS, HRAS and/or NRAS protein | |
CN105209454A (en) | 6-[4-(1 H-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity | |
CN110903283B (en) | Substituted quinazoline compound, pharmaceutical composition containing compound and application of compound | |
CN106831614A (en) | Substituted benzodiazepine * heterocycle compound and its production and use | |
CN104230912B (en) | Quinoline, Its Preparation Method And Use | |
WO2021018173A1 (en) | Adenosine receptor antagonist | |
CN107686477A (en) | New compound and its application as CDK4/6 inhibitor | |
WO2019196619A1 (en) | Quinazoline derivative salt-form crystal form, and preparation method therefor and application thereof | |
WO2019196622A1 (en) | 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240704 Address after: 4th Floor, Building 5, No. 33 Leshan Road, Xuhui District, Shanghai, 200030 Patentee after: Shanghai Weidao Biopharmaceutical Co.,Ltd. Country or region after: China Address before: 201108 room E8, 3 / F, building 6, 4299 Jindu Road, Minhang District, Shanghai Patentee before: WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL Co.,Ltd. Country or region before: China |